Clinical Annotation Id,Location,Gene,Level of Evidence,Clinical Annotation Types,Genotype-Phenotype IDs,Annotation Text,Variant Annotations IDs,Variant Annotations,PMIDs,Evidence Count,Related Drugs,Related Diseases,Race
655386801,rs3957357,"GSTA1 (PA29016),GSTA6P (PA29020)",3,Toxicity/ADR,655386802; 655386803; 655386804,AA:Patients with the AA genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.; AG:Patients with the AG genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.; GG:Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.,655386631; 827824914; 827824940,Genotype AA is associated with increased overall survival when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes GG + AG.; Genotypes AA + AG are associated with increased likelihood of Anemia when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype GG.; Genotypes AA + AG are not associated with increased likelihood of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype GG.,19786980; 22188361; 22188361,3,cisplatin;cyclophosphamide,Anemia;Ovarian Neoplasms,
655385969,rs13058338,RAC2 (PA34163),3,Toxicity/ADR,655385970; 655385971; 655385972,"AA:Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the TT genotype. Please note, the risk allele reported in the study has been complemented to the positive chromosomal strand here. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; AT:Patients with the AT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the AA genotype or may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the TT genotype. Please note, the risk allele reported in the study has been complemented to the positive chromosomal strand here. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; TT:Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the AA genotype. Please note, the risk allele reported in the study has been complemented to the positive chromosomal strand here. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.",655385959,"Allele T is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele A.",16330681,1,doxorubicin,"Arrhythmias, Cardiac;Drug Toxicity;Lymphoma, Non-Hodgkin",White
655385973,rs17222723,ABCC2 (PA116),3,Toxicity/ADR,655385974; 655385975; 655385976,"AA:Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; AT:Patients with the AT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; TT:Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.",655385891,"Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele T.",16330681,1,doxorubicin,"Arrhythmias, Cardiac;Drug Toxicity;Lymphoma, Non-Hodgkin",White
655385977,rs1883112,NCF4 (PA31465),3,Toxicity/ADR,655385978; 655385979; 655385980,"AA:Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; AG:Patients with the AG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; GG:Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubcin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.",655385953,"Genotype AA is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to genotypes GG + AG.",16330681,1,doxorubicin,"Arrhythmias, Cardiac;Drug Toxicity;Lymphoma, Non-Hodgkin",White
655385981,rs45511401,ABCC1 (PA244),3,Toxicity/ADR,655385982; 655385983; 655385984,"GG:Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; GT:Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxocity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; TT:Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.",655385947,"Allele T is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.",16330681,1,doxorubicin,"Arrhythmias, Cardiac;Drug Toxicity;Lymphoma, Non-Hodgkin",White
655385985,rs4673,CYBA (PA27075),3,Toxicity/ADR,655385986; 655385987; 655385988,"AA:Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; AG:Patients with the AG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.; GG:Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.",655385965,"Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.",16330681,1,doxorubicin,"Arrhythmias, Cardiac;Drug Toxicity;Lymphoma, Non-Hodgkin",White
655385856,rs2032582,ABCB1 (PA267),3,Efficacy,655385857; 655385858; 655385859,"AA:Patients with the AA genotype may have 1) decreased, but not absent, risk for resistance 2) increased response to taxanes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to taxanes.; AT:Patients with the AA genotype may have 1) decreased, but not absent, risk for resistance 2) increased response to taxanes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to taxanes.; TT:Patients with the TT genotype may have decreased, but not absent, risk for resistance to taxanes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to taxanes.",655387959; 699638624,Genotype AA is associated with increased chance of positive response to paclitaxel when treated with paclitaxel in people with Ovarian Neoplasms as compared to genotype CC.; Genotype CC is associated with increased risk of resistance when treated with paclitaxel in people with Breast Neoplasms as compared to genotype AC.,16467099; 18836089,2,paclitaxel;taxanes,Breast Neoplasms,
655386995,rs2740574,CYP3A4 (PA130),3,Toxicity/ADR,655386996; 655386997; 655386998,CC:Premenopausal patients with the CC genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.; CT:Premenopausal patients with the CT genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.; TT:Premenopausal patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have a shorter period of time before chemotherapy-induced ovarian failure compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.,699642279,Allele C is associated with increased time to chemotherapy-related ovarian failure when treated with cyclophosphamide in people with Breast Neoplasms as compared to genotype TT.,19376514,1,cyclophosphamide,Breast Neoplasms,
655387009,rs1799983,NOS3 (PA254),3,Efficacy,655387010; 655387011; 655387012,"GG:Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.; GT:Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.; TT:Patients with the TT genotype 1) may have shorter disease-free survival when treated with cyclophosphamide-based regimens 2) may have longer disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence disease-free survival.",699638540; 699638544,"Genotypes GG + GT are associated with increased disease free survival when treated with cyclophosphamide, doxorubicin, fluorouracil and methotrexate in people with Breast Neoplasms as compared to genotype TT.; Genotype TT is associated with increased disease free survival in people with Breast Neoplasms as compared to genotypes GG + GT.",19671875; 19671875,2,cyclophosphamide;doxorubicin;fluorouracil;methotrexate,Breast Neoplasms,
655387014,rs2070744,NOS3 (PA254),3,Efficacy,655387015; 655387016; 655387017,CC:Patients with the CC genotype and breast cancer who are not treated with adjuvant cyclophophamide-based regimens may have longer disease-free survival as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence disease-free survival.; CT:Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.; TT:Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.,699638537,Genotype CC is associated with increased disease free survival in people with Breast Neoplasms as compared to genotypes TT + CT.,19671875,1,cyclophosphamide;doxorubicin;fluorouracil;methotrexate,Breast Neoplasms,
655384910,rs4646,CYP19A1 (PA27091),3,Efficacy,655384911; 655384912; 655384913,AA:Patients with the AA genotype who are treated with letrozole may have improved treatment efficacy compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.; AC:Patients with the AC genotype who are treated with letrozole may have improved treatment efficacy compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.; CC:Patients with the CC genotype who are treated with letrozole may have decreased treatment efficacy compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response.,608431153,Allele A is associated with increased treatment efficacy when treated with letrozole in people with Breast Neoplasms as compared to allele C.,18245543,1,letrozole,Breast Neoplasms,
981202356,rs3745274,CYP2B6 (PA123),3,Dosage,981202357; 981202358; 981202359,"GG:Patients with the GG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose requirements.; GT:Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements.; TT:Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements.",827811269,Allele T is associated with decreased likelihood of dose reduction when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele G.,20179710,1,cyclophosphamide;doxorubicin,Breast Neoplasms,
981238025,rs2032582,ABCB1 (PA267),3,Efficacy,981238028; 981238027; 981238026,CC:Patients with the CC genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CT or TT. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.; CT:Patients with the CT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.; TT:Patients with the TT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.,827811288,Genotypes CT + TT are associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes AC + CC.,20179710,1,cyclophosphamide;doxorubicin,Breast Neoplasms,
981238057,rs2032582,ABCB1 (PA267),3,Other,981238058; 981238059; 981238060,AA:Patients with the AA genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin.; AC:Patients with the AC genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin.; CC:Patients with the CC genotype may have increased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of doxorubicin.,769250973,Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype CC.,18377430,1,doxorubicin,Breast Neoplasms,Asian
981204272,rs1045642,ABCB1 (PA267),3,Efficacy,981204273; 981204274; 981204275,"AA:Genotype AA may be associated with decreased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype GG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.; AG:Genotype AG may be associated with decreased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype GG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.; GG:Genotype GG may be associated with increased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype AG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.",655387906; 827778808; 827922851,"Genotype AG is associated with decreased disease control rate and lower overall survival rate when treated with paclitaxel in people with metastatic breast cancer as compared to genotype GG.; Allele A is not associated with overall survival when treated with dexamethasone, diphenhydramine, paclitaxel and ranitidine in people with Head and Neck Neoplasms as compared to allele G.; Genotypes AA + AG are not associated with increased response to paclitaxel in women with Breast Neoplasms as compared to genotype GG.",18836089; 19504558; 22527101,3,paclitaxel,Breast Neoplasms,
655386070,rs9024,CBR1 (PA26121),4,Dosage,655386071; 655386072; 655386073,"AA:In patients with the AA genotype, the levels of clearance and exposure to doxorubicin may be similar to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.; AG:Patients with the AG genotype 1) may have decreased clearance of doxorubicin 2) increased exposure to doxorubicin compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.; GG:Patients with the GG genotype 1) may have increased clearance of doxorubicin 2) decreased exposure to doxorubicin compared to patients with the AG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.",655386059; 655386064; 655386067; 769173407; 769173442,Genotype GG is associated with increased clearance of doxorubicin in people with Breast Neoplasms as compared to genotype AG.; Genotype GG is associated with decreased exposure when treated with doxorubicin in people with Breast Neoplasms as compared to genotype AG.; Genotype GG is associated with decreased plasma concentration of doxorubicinol in people with Breast Neoplasms as compared to genotype AG.; Genotype GG is associated with increased catalytic activity of CBR1 of doxorubicin.; Genotype GG is associated with increased catalytic activity of CBR1 of doxorubicin.,19016765; 19016765; 19016765; 19022938; 19022938,5,doxorubicin,Breast Neoplasms,
655386083,rs714368,SLC22A16 (PA134911502),4,Other,655386084; 655386085; 655386086,CC:Patients with the CC genotype may have increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CT or TT. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.; CT:Patients with the CT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.; TT:Patients with the TT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.,699642282; 699642283,Genotype CC is associated with increased doxorubicin AUC when treated with doxorubicin in people with Breast Neoplasms as compared to genotypes TT + CT.; Genotype CC is associated with increased doxorubicinol AUC when treated with doxorubicin in people with Breast Neoplasms as compared to genotypes TT + CT.,17559346; 17559346,2,doxorubicin;doxorubicinol,Breast Neoplasms,Asian
655386088,rs20572,CBR1 (PA26121),4,Dosage,655386089; 655386090; 655386091,CC:Patients with the CC genotype may have 1) increased clearance of doxorubicin 2) decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the CT genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.; CT:Patients with the CT genotype may have 1) decreased clearance of doxorubicin 2) increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with CC genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.; TT:Patients with the TT genotype 1) may have similar levels of clearance of doxorubicin 2) may have similar exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.,655386045; 655386047; 655386048,Genotype CC is associated with increased clearance of doxorubicin in people with Breast Neoplasms as compared to genotype CT.; Genotype CC is associated with decreased exposure when treated with doxorubicin in people with Breast Neoplasms as compared to genotype CT.; Genotype CC is associated with decreased plasma concentration of doxorubicinol in people with Breast Neoplasms as compared to genotype CT.,19016765; 19016765; 19016765,3,doxorubicin;doxorubicinol,Breast Neoplasms,Asian
619523400,rs9937,RRM1 (PA298),4,Toxicity/ADR,619523401; 619523402; 619523403,"AA:Patients with the AA genotype with advanced breast cancer who are treated with gemcitabine 1) may be more likely to experience toxicity such as neutropenia as compared to a patient with genotype GG or GA and the A allele at rs1042858 2) may have a tendency, though not a statistically significant one, towards better progression-free survival as compared to patients with the GG genotype and the A allele at rs1042858. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.; AG:Patients with the AG genotype and the A allele of rs1042858 with advanced breast cancer who are treated with gemcitabine 1) may be less likely to experience toxicity such as neutropenia 2) may have a tendency, though not a statistically significant one, towards poorer progression-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.; GG:Patients with the GG genotype and the A allele of rs1042858 with advanced breast cancer who are treated with gemcitabine 1) may be less likely to experience toxicity such as neutropenia 2) may have a tendency, though not a statistically significant one, towards poorer progression-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.",655388028; 655388027,Genotype AA is associated with increased likelihood of progression-free survival when treated with gemcitabine in women with Breast Neoplasms as compared to allele G.; Allele G is associated with decreased risk of Neutropenia when treated with gemcitabine in women with Breast Neoplasms as compared to allele A.,17602053; 17602053,2,gemcitabine,Breast Neoplasms,Asian
981202551,rs4244285,CYP2C19 (PA124),4,Efficacy,981202552; 981202553; 981202554,AA:Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.; AG:Patients with the AG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have a decreased risk of poorer outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.; GG:Patients with the AG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have a decreased risk of poorer outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.,827811311,Genotype AA is associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes AG + GG.,20179710,1,cyclophosphamide;doxorubicin,Breast Neoplasms,
655384698,rs3892097,CYP2D6 (PA128),2A,Efficacy;Toxicity/ADR,655384702; 655384701; 655384700,"CC:Patients with the CC genotype who are treated with tamoxifen: 1) may have a decreased, but not absent, risk of relapse as compared to patients with the TT genotype 2) may have an increased severity in hot flashes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of relapse.; CT:Patients with the CT genotype who are treated with tamoxifen: 1) may have a decreased, but not absent, risk of relapse as compared to patients with the TT genotype 2) may have an increased severity in hot flashes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of relapse.; TT:Patients with the TT genotype who are treated with tamoxifen: 1) may have an increased risk of relapse as compared to patients with the CT or CC genotype 2) may have a decreased severity in hot flashes as compared to patients with the CT or CC genotype.",769169314; 769146128; 769146138; 769146179; 769146129; 769146130; 769146131; 769146144; 769146163,Allele C is associated with increased risk of recurrance when treated with tamoxifen in people with Breast Neoplasms as compared to allele T.; Allele T is associated with CYP2D6*4.; Allele T is not associated with decreased overall survival when treated with tamoxifen in people with Breast Neoplasms as compared to allele C.; Allele T is associated with decreased event-free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotype CC.; Genotype TT is associated with decreased relapse free time when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.; Genotype TT is associated with decreased disease free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.; Genotype TT is associated with decreased severity of hot flashes when treated with in people with Breast Neoplasms as compared to genotypes CC + CT.; Genotype TT is associated with increased disease free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.; Genotype TT is associated with decreased progression free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.,18024866; 16361630; 16361630; 19809024; 16361630; 16361630; 16361630; 17244352; 20849243,9,tamoxifen,Breast Neoplasms,
981238323,rs1695,GSTP1 (PA29028),2A,Efficacy;Toxicity/ADR,981238324; 981238325; 981238326,"AA:Patients with the AA genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patient's response to cyclophosphamide, epirubicin and fluorouracil.; AG:Patients with the AG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) increased drug response 2) decreased severity of toxicity as compared to patients with GG genotype. Some patients were additionally treated with fluorouracilOther genetic and clinical factors may influence a patient's response to cyclophosphamide, epirubicin and fluorouracil.; GG:Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patient's response to cyclophosphamide, epirubicin and fluorouracil.",827704813; 827704840; 827704848,"Allele A is associated with increased response to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.; Genotypes AA + AG are associated with increased response to cyclophosphamide and epirubicin in women with Breast Neoplasms as compared to genotype GG.; Genotypes AA + AG are associated with decreased severity of toxicity when treated with cyclophosphamide and epirubicin in women with Breast Neoplasms as compared to genotype GG.",20568049; 21362365; 21362365,3,cyclophosphamide;epirubicin,Breast Neoplasms,
655384534,rs4880,SOD2 (PA36017),2B,Efficacy,655384538; 655384537; 655384536,AA:Patients with the AA genotype and breast cancer who are treated with cyclophosphamide may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.; AG:Patients with the AG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype or may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.; GG:Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.,699642290,Allele G is associated with decreased survival when treated with cyclophosphamide in people with Breast Neoplasms as compared to allele A.,19509150,1,cyclophosphamide,Breast Neoplasms,
981201535,rs2297595,DPYD (PA145),2A,Toxicity/ADR,981201536; 981201537; 981201538,CC:Patients with the CC genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.; CT:Patients with the CT genotype may have increased risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.; TT:Patients with the TT genotype may have decreased but not absent risk of severe toxicity when treated with fluoropyrimidines as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patients chance of adverse events.,769169640; 827810914; 827892931,"Allele C is associated with increased risk of toxicity of fluoropyrimidine-based chemotherapy when treated with capecitabine and fluorouracil in people with Breast Neoplasms as compared to allele T.; Genotypes CC + CT are associated with increased severity of Drug Toxicity when treated with bevacizumab, capecitabine, cetuximab and oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT.; Genotype CT is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype TT.",19104657; 21498394; 14635116,3,capecitabine;fluorouracil,Breast Neoplasms;Colorectal Neoplasms;Drug Toxicity;Neoplasms;Pancreatic Neoplasms,White
655387004,rs9561778,ABCC4 (PA397),3,Toxicity/ADR,655387005; 655387006; 655387007,"GG:Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.; GT:Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.; TT:Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.",655387574; 655387577; 655387580,"Allele T is associated with increased risk of gastrointestinal toxicity when treated with cyclophosphamide in people with Breast Neoplasms as compared to allele G.; Allele T is associated with increased severity of Neutropenia when treated with cyclophosphamide in people with Breast Neoplasms as compared to allele G.; Allele T is associated with increased risk of ADR when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to allele G.",19696793; 19696793; 19696793,3,cyclophosphamide,Breast Neoplasms;Drug Toxicity,Asian
655385033,rs1136201,ERBB2 (PA27844),3,Toxicity/ADR,655385036; 655385035; 655385034,AA:Patients with the AA genotype may have decreased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.; AG:Patients with the AG genotype may have increased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.; GG:Cardiotox was not not found in GG group in this small study. The GG genotype (Val form) is more sensitive to trastuzamab in vitro. There was no link between tumor response or survival and HER2 genotype in clinical study.,613977311,Allele G is associated with response to trastuzumab.,17693647,1,trastuzumab,Breast Neoplasms;Drug Toxicity,White
655385860,rs2032582,ABCB1 (PA267),3,Efficacy,655385861; 655385862; 655385863,"AA:Patients with the AA genotype and cancer who are treated with anthracyclines: 1) may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype 2) may have increased overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines.; AC:Patients with the CA genotype and cancer who are treated with anthracyclines: 1) may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype 2) may have increased overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines.; CC:Patients with the CC, CT or TT genotype and cancer who are treated with anthracyclines 1) may have an increased risk of resistance as compared to patients with the AC and AA genotype 2) may have decreased overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines.",769152976; 769250973; 769169476; 655388061; 655388064; 699638627; 769152967; 827811288,"Genotype AA is associated with increased sensitivity in vitro when treated with mitoxantrone as compared to genotypes CC + AC.; Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype CC.; Genotypes AA + AC are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma.; CC:Genotype CC is associated with increased likelihood of complete remission in people with Leukemia, Myeloid, Acute.; Genotype CC is associated with increased likelihood of 3 year event free survival in people with Leukemia, Myeloid, Acute.; Genotype CC is associated with increased risk of resistance when treated with anthracyclines and related substances in people with Breast Neoplasms as compared to genotype AC.; Genotype CC is associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AC.; Genotypes CT + TT are associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes AC + CC.",20938465; 18377430; 18408561; 16331627; 16331627; 18836089; 20938465; 20179710,8,anthracyclines and related substances,"Breast Neoplasms;Leukemia, Myeloid, Acute;Multiple Myeloma",
655386075,rs1045642,ABCB1 (PA267),3,Efficacy,655386076; 655386077; 655386078,"AA:Patients with the AA genotype may have 1) increased exposure to doxorubicin metabolites and 2) increased response to anthracycline regimens as compared to patients with the GG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.; AG:Patients with the AG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory and analysis of the heterozygote is limited. Other genetic and clinical factors may also influence response to anthracycline regimens.; GG:Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.",655386281; 769250961; 655385849; 769152970; 769169480; 827817217,"Genotype AA is associated with increased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to genotypes GG + AG.; Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype GG.; Genotype GG is associated with increased time to progression when treated with anthracyclines and related substances, doxorubicin and epirubicin in people with Breast Neoplasms as compared to genotypes AA + AG.; Genotype GG is not associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype AA.; Genotype GG is associated with decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype AA.; Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.",12684679; 18377430; 19752884; 20938465; 18408561; 22026922,6,anthracyclines and related substances;cytarabine;doxorubicin;epirubicin;idarubicin,"Breast Neoplasms;Leukemia, Myeloid, Acute;Multiple Myeloma",
827848548,rs9561778,ABCC4 (PA397),3,Toxicity/ADR,827848549; 827848550; 827848551,"GG:Patients with the GG genotype may have a decreased but not absent risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for ADRs.; GT:Patients with the GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for ADRs.; TT:Patients with the TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for ADRs.",655387580,"Allele T is associated with increased risk of ADR when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to allele G.",19696793,1,cyclophosphamide;doxorubicin;fluorouracil,Breast Neoplasms;Neoplasms,Asian
655386635,rs1042522,TP53 (PA36679),2B,Efficacy;Toxicity/ADR,981478468; 981478469; 981478470,CC:Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.; CG:Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.; GG:Patients with the GG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.,827810841; 827810856; 827828096; 827828127; 769245653; 637879888; 655386329,Genotypes CG + GG are associated with decreased response to cisplatin and paclitaxel in people with Stomach Neoplasms as compared to genotype CC.; Genotypes CG + GG are associated with decreased one year progression free survival when treated with cisplatin and paclitaxel in people with Stomach Neoplasms as compared to genotype GG.; Genotype GG is not associated with increased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotypes CC + CG.; Genotypes CG + GG are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.; Allele G is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele C.; Genotype GG is associated with decreased survival time when treated with fluorouracil in people with Stomach Neoplasms as compared to genotypes CC + GC.; Genotype GG is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes CC + CG.,19052714; 19052714; 22188361; 22188361; 20638924; 18357466; 19786980,7,antineoplastic agents;cisplatin;cyclophosphamide;fluorouracil;paclitaxel,Breast Neoplasms;Neoplasms;Neutropenia;Ovarian Neoplasms;Stomach Neoplasms,
655387972,rs2032582,ABCB1 (PA267),3,Efficacy,655387973; 655387975; 655387974,"AC:Patients with the AC genotype may have decreased, but not absent, risk for resistance to taxanes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to taxanes.; CC:Patients with the CC genotype may have 1) increased risk for resistance 2) decreased response to taxanes as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence a patient's response to taxanes.; CT:Patients with the CT genotype may have decreased, but not absent, risk for resistance to taxanes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to taxanes.",655387959; 699638624,Genotype AA is associated with increased chance of positive response to paclitaxel when treated with paclitaxel in people with Ovarian Neoplasms as compared to genotype CC.; Genotype CC is associated with increased risk of resistance when treated with paclitaxel in people with Breast Neoplasms as compared to genotype AC.,16467099; 18836089,2,paclitaxel;taxanes,Breast Neoplasms;Neoplasms;Ovarian Neoplasms,
652882846,rs8133052,CBR3 (PA26122),3,Efficacy;Toxicity/ADR,652882847; 652882848; 652882849,"AA:Patients with the AA genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.; AG:Patients with the AG genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype, or 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.; GG:Patients with the GG genotype and breast cancer who are treated with doxorubicin: 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.",699642239; 699639388; 699642230; 699642233,Allele A is associated with decreased expression of CBR3 in breast tissue.; Allele G is associated with increased doxorubicinol AUC when treated with doxorubicin in people with Breast Neoplasms as compared to allele A.; Allele G is associated with decreased severity of Neutropenia when treated with doxorubicin in people with Breast Neoplasms as compared to allele A.; Allele G is associated with decreased tumor response when treated with doxorubicin in people with Breast Neoplasms as compared to genotype AA.,18551042; 18551042; 18551042; 18551042,4,doxorubicin,Breast Neoplasms;Neutropenia,Asian
655384573,rs1056836,"CYP1B1 (PA27094),FAM82A1 (PA162387925)",3,Efficacy,655384575; 655384576; 655384577,CC:Patients with the CC genotype who are treated with taxanes may have shorter disease-free progression as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.; CG:Patients with the CG genotype who are treated with taxanes may have shorter disease-free progression as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.; GG:Patients with the GG genotype who are treated with taxanes may have longer disease-free progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.,655387529; 655387526; 827817238; 827922834,"Allele G is associated with decreased progression free survival when treated with paclitaxel in people with Breast Neoplasms as compared to allele C.; Genotype GG is associated with decreased survival when treated with docetaxel in people with Prostatic Neoplasms as compared to genotypes CC + CG.; Genotypes CG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.; Genotypes CC + CG are not associated with increased response to paclitaxel in women with Breast Neoplasms as compared to genotype GG.",17224914; 18187806; 22026922; 22527101,4,docetaxel;paclitaxel;taxanes,Breast Neoplasms;Prostatic Neoplasms,
827847744,rs9679162,GALNT14 (PA134920089),3,Efficacy,827847745; 827847746; 827847747,"GG:Patients with the GG genotype may have decreased response, including decreased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.; GT:Patients with the GT genotype may have decreased response, including decreased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.; TT:Patients with the TT genotype may have increased response, including increased survival, when treated with cisplatin, fluorouracil and mitoxantrone as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence a patient's response to treatment.",827812110; 827812125; 827812137,"Genotype TT is associated with increased response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to genotypes GG + GT.; Genotype TT is associated with increased likelihood of progression-free survival when treated with cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to genotypes GG + GT.; Genotype TT is associated with increased overall survival when treated with cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to genotypes GG + GT.",21635146; 21635146; 21635146,3,cisplatin;fluorouracil;mitoxantrone,"Carcinoma, Hepatocellular;Neoplasms",
827831417,rs3212986,"CD3EAP (PA142672156),ERCC1 (PA155),PPP1R13L (PA34195)",3,Efficacy,827831418; 827831419; 827831420,AA:Patients with the AA genotype may have better overall survival rate when treated with platinum in people with Non-Small-Cell Lung Carcinoma as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to Platinum compounds.; AC:Patients with the AC genotype may have better overall survival rate when treated with platinum in people with Non-Small-Cell Lung Carcinoma as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to Platinum compounds.; CC:Patients with the CC genotype may have worse overall survival rate when treated with platinum in people with Non-Small-Cell Lung Carcinoma as compared to patients with AA and AC genotypes. Other genetic and clinical factors may also influence a patient's response to Platinum compounds.,769172559,"Genotypes AA + AC are associated with better overall survival rate when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.",19362955,1,Platinum compounds,"Carcinoma, Non-Small-Cell Lung",
827847768,rs9597,"BAIAP3 (PA25252),RPS20P2 (PA34809),UBE2I (PA37134)",3,Efficacy,827847769; 827847770; 827847771,"CC:Patients with the CC genotype may have a decreased response to cisplatin and irinotecan as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.; CG:Patients with the CG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.; GG:Patients with the GG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype, although the GG genotype was not observed in the supporting study. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.",769164968,"Genotype CG is associated with increased response to cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.",19859084,1,cisplatin;irinotecan,"Carcinoma, Non-Small-Cell Lung",Asian
655386310,rs870995,PIK3CA (PA33308),4,Dosage,655386311; 655386312; 655386313,AA:Patients with the AA genotype may have decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.; AC:Patients with the CA genotype may have increased clearance of docetaxel compared to patients with the AA genotype or decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.; CC:Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.,699638956,"Allele C is associated with increased clearance of docetaxel in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.",20157331,1,docetaxel,"Carcinoma, Non-Small-Cell Lung",White
655386315,rs518329,PRDX4 (PA33725),4,Dosage,655386316; 655386317; 655386318,CC:Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.; CT:Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.; TT:Patients with the TT genotype may have decreased clearance of docetaxel compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.,699638960,"Genotype TT is associated with decreased clearance of docetaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.",20157331,1,docetaxel,"Carcinoma, Non-Small-Cell Lung",White
655386320,rs2234922,EPHX1 (PA27829),4,Dosage,655386321; 655386322; 655386323,AA:Patients with the AA genotype may have increased clearance of docetaxel compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence docetaxel clearance.; AG:Patients with the AG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.; GG:Patients with the GG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.,655388313,"Genotype AA is associated with increased clearance of docetaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GG + AG.",20157331,1,docetaxel,"Carcinoma, Non-Small-Cell Lung",White
655386324,rs1382368,XRCC4 (PA37423),4,Dosage,655386325; 655386326; 655386327,"CC:Patients with the CC genotype may have decreased clearance of docetaxel compared to patients with TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.; CT:Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the CC genotype, or decreased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.; TT:Patients with the TT genotype may have increased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.",655388312,"Allele T is associated with increased clearance of docetaxel in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.",20157331,1,docetaxel,"Carcinoma, Non-Small-Cell Lung",White
981475838,rs121434568,EGFR (PA7360),1B,Efficacy;Toxicity/ADR,981476128; 981476129; 981476130,"GG:GG is associated with increased response rate (RR), increased progression-free survival (PFS), increased overall survival (OS) time and decreased serious adverse events when treated with erlotinib in advanced non-small-cell lung cancer patients as compared to TT. The association of increased RR and PFS time with GG genotype well replicated. The results of manuscripts were presented according to EGFR mutation status. In this annotation, the rs121434568 (L858R), exon 19 deletion, and other activating somatic mutations were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having somatic mutation.; GT:GT is associated with increased response rate (RR), increased progression-free survival (PFS), increased overall survival (OS) time and decreased serious adverse events when treated with erlotinib in advanced non-small-cell lung cancer patients as compared to TT. The association of increased RR and PFS time with GT genotype well replicated. The results of manuscripts were presented according to EGFR mutation status. In this annotation, the rs121434568 (L858R), exon 19 deletion, and other activating somatic mutations were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having somatic mutation.; TT:TT is associated with decreased response rate (RR), decreased progression-free survival (PFS), decreased overall survival (OS) time and increased serious adverse events when treated with erlotinib in advanced non-small-cell lung cancer patients as compared to GT or GG. The association of decreased RR and PFS time with TT vs. GT or GG genotype well replicated. The results of manuscripts were presented according to EGFR mutation status. In this annotation, the rs121434568 (L858R), exon 19 deletion, and other activating somatic mutations were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having somatic mutation.",981417597; 981417607; 981417616; 981417625; 981419202; 981419226; 981419236; 981419373; 981419400; 981419498; 981419523; 981419813; 981475368; 827921493,"Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib in people with non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased Overall survival (OS) time when treated with erlotinib in people with non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased response rate when treated with erlotinib in people with lung adenocarcinoma as compared to allele T.; Allele G is associated with increased response rate when treated with erlotinib in people with lung adenocarcinoma as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when exposed to erlotinib in people with advanced non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in EGFR mutation positive non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased overall survival (OS) time when treated with erlotinib or gefitinib in EGFR mutation positive non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with carboplatin, erlotinib and paclitaxel in people with non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased overall survival time when treated with carboplatin, erlotinib and paclitaxel in people with non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased response rate when treated with erlotinib in bronchioloalveolar carcinoma and adenocarcinoma patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib in bronchioloalveolar carcinoma and adenocarcinoma patients as compared to allele T.; Allele G is associated with increased response rate when treated with erlotinib or gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.; Genotypes GT + TT are associated with decreased response to erlotinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.",22982650; 22982650; 22740981; 22740981; 21969500; 22760226; 22760226; 16043828; 16043828; 18349398; 18349398; 17285735; 22215752; 19692684,14,erlotinib,"Carcinoma, Non-Small-Cell Lung",
981420042,rs121434568,EGFR (PA7360),1B,Efficacy,981477428; 981477429; 981477430,"GG:GG is associated with increased response rate (RR), increased progression-free survival (PFS) and increased overall survival (OS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to TT. The association of increased RR and PFS time with GG genotype well replicated. The results of manuscripts were presented according to EGFR mutation status. In this annotation, the rs121434568 (L858R), exon 19 deletion, and other activating somatic mutations were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having somatic mutation.; GT:GT is associated with increased response rate (RR), increased progression-free survival (PFS) and increased overall survival (OS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to TT. The association of increased RR and PFS time with GT genotype well replicated. The results of manuscripts were presented according to EGFR mutation status. In this annotation, the rs121434568 (L858R), exon 19 deletion, and other activating somatic mutations were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having somatic mutation.; TT:TT is associated with decreased response rate (RR), decreased progression-free survival (PFS) and decreased overall survival (OS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to GT or GG. The association of decreased RR and PFS time with GT or GG genotype well replicated. The results of manuscripts were presented according to EGFR mutation status. In this annotation, the rs121434568 (L858R), exon 19 deletion, and other activating somatic mutations were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having somatic mutation.",981419226; 981419236; 981419322; 981419331; 981419441; 981419460; 981419469; 981419477; 981419589; 981419598; 981419607; 981419616; 981419624; 981419634; 981419643; 981419653; 981419668; 981419710; 981419719; 981419727; 981419736; 981419746; 981419755; 981419803; 981419813; 981475192; 981475201; 981475368; 981477340; 981477349; 981477357; 827926134,"Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in EGFR mutation positive non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased overall survival (OS) time when treated with erlotinib or gefitinib in EGFR mutation positive non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rates when treated with gefitinib in people with non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased median survial time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in people with non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with non-small-cell lung cancer as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased median survival time (MST) when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with gefitinib in chemorefractory advanced non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate when treated with erlotinib or gefitinib in non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased overall survival (OS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.; Allele G is associated with increased response rate (RR) when treated with gefitinib in lung adenocarcinoma patients as compared to allele T.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in lung adenocarcinoma patients as compared to allele T.; Allele G is not associated with Overall survival (OS) time when treated with gefitinib in lung adenocarcinoma patients as compared to allele T.; Genotype GT is associated with increased response to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.",22760226; 22760226; 20038723; 20038723; 16204011; 17047654; 17047654; 17473659; 17106442; 17106442; 16956694; 16956694; 16956694; 15897572; 15897572; 16203769; 17317677; 17387341; 17387341; 17192902; 17192902; 16865253; 16865253; 16115929; 17285735; 17429313; 17429313; 22215752; 22370314; 22370314; 22370314; 15118073,32,gefitinib,"Carcinoma, Non-Small-Cell Lung",
981475871,rs121434568,EGFR (PA7360),2A,Efficacy,981477437; 981477438; 981477439,"GG:Patients with GG genotype included in this annotation and effects of gefitinib vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients. Patients with GG genotype had increased response rate (RR) and increased progression-free survival time when treated with gefitinib vs paclitaxel plus carboplatin. There is no genotype comparison in this annotation.The somatic EGFR mutations [rs121434568 (L858R), exon 19 deletion, and other activating mutations] were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity (GT) or homozygocity (GG), it is worded as having somatic mutation.; GT:Patients with GT genotype included in this annotation and effects of gefitinib vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients. Patients with GT genotype had increased response rate (RR) and increased progression-free survival time when treated with gefitinib vs paclitaxel plus carboplatin. There is no genotype comparison in this annotation. The somatic EGFR mutations [rs121434568 (L858R), exon 19 deletion, and other activating mutations] were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity (GT) or homozygocity (GG), it is worded as having somatic mutation.; TT:Patients with TT genotype were NOT included in these studies where this annotation is derived from. in this annotation and effects of gefitinib vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients who have somatic mutation. There is no genotype comparison in this annotation.",981417228; 981417247; 981417256; 981417279; 981417296; 981417305; 981419215; 981477324; 981477332; 981477365; 981477373; 981477381,Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.; Allele G is associated with increased longer median progression-free survival time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.; Allele G is associated with increased response rate when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.; Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.; Allele T is associated with decreased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation negative non-small-cell lung cancer.; Allele G is associated with increased physical and life well-being quality of life (QoL) scales when treated with gefitinib in people with EGFR mutation positive advanced non-small-cell lung cancer.; Allele G is not associated with overall survival (OS) time when treated with gefitinib in people with EGFR mutation negative non-small-cell lung cancer.; Allele T is not associated with overall survival (OS) time when treated with gefitinib in people with EGFR mutation negative non-small-cell lung cancer.; Allele G is associated with increased response rate (RR) when treated with gefitinib in lung adenocarcinoma patients as compared to allele T.; Allele G is not associated with progression-free survival (PFS) time when treated with gefitinib in lung adenocarcinoma patients as compared to allele T.; Allele G is not associated with overall survival (OS) time when treated with gefitinib in lung adenocarcinoma patients as compared to allele T.,20573926; 20573926; 20573926; 21900837; 19692680; 19692680; 22581822; 19692680; 19692680; 22370314; 22370314; 22370314,12,carboplatin;gefitinib;paclitaxel,"Carcinoma, Non-Small-Cell Lung",
981475880,rs121434568,EGFR (PA7360),2A,Efficacy;Toxicity/ADR,981476112; 981476113; 981476114,"GG:Patients with GG genotype included in this annotation and effects of gefitinib vs standard chemotherapy [i) paclitaxel plus carboplatin, ii) cisplatin plus gemcitabine or docetaxel] were compared in non-small-cell lung cancer patients. Patients with GG genotype had increased progression-free survival (PFS) time, decreased toxic effects and decreased serious adverse events when treated with gefitinib vs standard chemotherapy. There is no genotype comparison in this annotation. The somatic EGFR mutations [rs121434568 (L858R), exon 19 deletion, and other activating mutations] were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity (GT) or homozygocity (GG), it is worded as having somatic mutation.; GT:Patients with GT genotype included in this annotation and effects of gefitinib vs standard chemotherapy [i) paclitaxel plus carboplatin, ii) cisplatin plus gemcitabine or docetaxel] were compared in non-small-cell lung cancer patients. Patients with GT genotype had increased progression-free survival (PFS) time, decreased toxic effects and decreased serious adverse events when treated with gefitinib vs standard chemotherapy. There is no genotype comparison in this annotation. The somatic EGFR mutations [rs121434568 (L858R), exon 19 deletion, and other activating mutations] were included in mutation positive group and all mutations are grouped under rs121434568. Very few of the patients have more than one somatic mutation. None of the studies mentioned status for heterozygosity (GT) or homozygocity (GG), it is worded as having somatic mutation.; TT:Patients with TT genotype were NOT included in these studies where this annotation is derived from. In this annotation and effects of gefitinib vs paclitaxel plus carboplatin were compared in non-small-cell lung cancer patients who have somatic mutation. There is no genotype comparison in this annotation.",981417078; 981417107; 981417122; 981417145,Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib in people with EGFR mutation positive non-small-cell lung cancer.; Allele G is associated with decreased grade 3 or 4 toxic effects when treated with erlotinib in people with EGFR mutation positive non-small-cell lung cancer.; Allele G is associated with decreased serious adverse events when treated with erlotinib in people with EGFR mutation positive non-small-cell lung cancer.; Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib in people with EGFR mutation positive non-small-cell lung cancer.,21783417; 21783417; 21783417; 22285168,4,carboplatin;docetaxel;erlotinib;gemcitabine;paclitaxel,"Carcinoma, Non-Small-Cell Lung",
981475450,rs121434569,EGFR (PA7360),2A,Efficacy,981477548; 981477549; 981477550,"CC:CC is associated with decreased acquired resistance and increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to CT or TT. In these studies, patients who have EGFR activating mutations [e.g. rs121434568 (L858R) or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having T790M mutation.; CT:CT is associated with increased acquired resistance and decreased progression-free survival (PFS) time when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to CC. In these studies, patients who have EGFR activating mutations [e.g. rs121434568 (L858R) or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having T790M mutation. ; TT:TT is associated with increased acquired resistance and decreased progression-free survival (PFS) time when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to CC. In these studies, patients who have EGFR activating mutations [e.g. rs121434568 (L858R) or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity, it is worded as having T790M mutation. ",981417754; 981417766; 981475217; 981475231; 981475241; 981475253; 981475265; 981475276; 981475286; 981475298; 981475309; 981475337; 981475352; 981475378; 981475801; 981477537,Allele T is associated with decreased progression-free survival (PFS) time when exposed to erlotinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele C.; Allele T is associated with decreased progression-free survival (PFS) time when treated with erlotinib or gefitinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele C.; Genotype CT is associated with increased resistance when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype CC.; Allele T is associated with decreased response rate (RR) when treated with gefitinib in non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with gefitinib in non-small cell lung cancer as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with decreased progression free survival (PFS) time when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients.; Allele T is associated with increased acquired resistance when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.; Allele T is associated with increased acquired resistance when treated with erlotinib or gefitinib in lung adenocarcinoma patients as compared to allele C.; Allele T is associated with increased acquired resistance to EGFR inhibitor when treated with gefitinib in non-small cell lung cancer patients as compared to allele C.,21233402; 18596266; 18992959; 16912157; 18093943; 17085664; 17020982; 18981003; 20129249; 19381876; 19589612; 21430269; 22215752; 21248300; 21921847; 16258541,16,erlotinib;gefitinib,"Carcinoma, Non-Small-Cell Lung",
981220481,rs1801133,"CLCN6 (PA26551),MTHFR (PA245)",2A,Efficacy,981220482; 981220483; 981220484,AA:Patients with AA genotype may have 1) increased likelihood of response 2) increased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patient's response to carboplatin.; AG:Patients with AG genotype may have 1) decreased likelihood of response 2) decreased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to carboplatin.; GG:Patients with GG genotype may have 1) decreased likelihood of response 2) decreased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to carboplatin.,827807290; 769166424,"Genotype AA is associated with increased likelihood of response to chemotherapy when treated with carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel and vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.; Genotype AA is associated with increased progression free survival when treated with carboplatin and pemetrexed in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GG + AG.",21605004; 19307503,2,carboplatin,"Carcinoma, Non-Small-Cell Lung",Asian
655386639,rs11615,ERCC1 (PA155),2B,Efficacy;Toxicity/ADR,655386640; 655386641; 655386642,AA:Patients with the AA genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.; AG:Patients with the AG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.; GG:Patients with the GG genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.,637880127; 655386332; 769172563; 827699103; 827784148; 827784157; 827816143; 827816972; 827817004; 827817015; 827826160; 827826170; 827832057; 827922697; 827922717; 827922728,"Genotype AA is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.; Genotype AG is associated with increased risk of nephrotoxicity when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotype GG.; Genotypes GG + AG are associated with increased likelihood of response to platinum-based chemotherapy treatment in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.; Allele A is not associated with response to carboplatin and pemetrexed in people with Mesothelioma as compared to allele G.; Genotype GG is associated with increased overall survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.; Genotype GG is associated with increased progression-free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.; Genotype GG is associated with decreased likelihood of nephrotoxicity when treated with cisplatin in people with Neoplasms as compared to genotypes AA + AG.; Genotypes AG + GG are associated with decreased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.; Genotypes AG + GG are not associated with decreased progression-free survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.; Genotypes AG + GG are not associated with increased likelihood of toxicity when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.; Genotypes AG + GG are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype AA.; Genotypes AG + GG are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype AA.; Allele G is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele A.; Genotype AA is associated with decreased response to Platinum compounds in women with Ovarian Neoplasms as compared to genotype GG.; Genotype AA is associated with increased risk of recurrence of disease when treated with Platinum compounds in women Ovarian Neoplasms as compared to genotype GG.; Genotype AA is associated with increased risk of death when treated with Platinum compounds in women Ovarian Neoplasms as compared to genotype GG.",15213713; 19786980; 19362955; 21262916; 21057378; 21057378; 21902499; 22026922; 22026922; 22026922; 22188361; 22188361; 19620936; 22329723; 22329723; 22329723,16,carboplatin;cisplatin;oxaliplatin;platinum;Platinum compounds,"Carcinoma, Non-Small-Cell Lung;Colorectal Neoplasms;Esophageal Neoplasms;Mesothelioma;Neoplasms;Ovarian Neoplasms;Pancreatic Neoplasms",
637880217,rs1695,GSTP1 (PA29028),3,Toxicity/ADR,637880218; 637880219; 637880220,"AA:Patients with the AA genotype and cancer who are treated with oxaliplatin or platinum compounds may have an increased risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AG or GG genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AA might have a decreased, but not absent, risk. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.; AG:Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.; GG:Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.",613979636; 637880188; 637880206; 637880210; 637880145; 637880175,"Genotype AA is associated with increased risk of hematological toxicity when treated with Platinum compounds and taxanes in people with Ovarian Neoplasms as compared to genotypes GG + AG.; Genotype AA is associated with increased severity of Peripheral Nervous System Diseases when treated with oxaliplatin in people with Gastrointestinal Neoplasms as compared to genotypes GG + AG.; Genotype AA is associated with increased severity of Neurotoxicity Syndromes when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GG + AG.; Genotype AA is associated with increased likelihood of discontinuation of oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GG + AG.; Allele G is associated with decreased risk of Neutropenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.; Genotype GG is associated with increased severity of Neurotoxicity Syndromes when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.",19203783; 16707601; 20530282; 20530282; 17409936; 17401013,6,oxaliplatin;Platinum compounds,"Carcinoma, Non-Small-Cell Lung;Colorectal Neoplasms;Gastrointestinal Neoplasms;Ovarian Neoplasms",
655386657,rs25487,XRCC1 (PA369),2B,Efficacy;Toxicity/ADR,655386658; 655386659; 655386660,CC:Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.; CT:Patients with the CT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.; TT:Patients with the TT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with platinum-based regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based regimens.,655386624; 769172568; 827641636; 827784173; 827784178; 827817158; 827817180; 827828058; 827828072; 827828226,"Genotype CC is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes TT + CT.; Genotype TT is associated with worse overall survival outcome when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.; Allele T is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele C.; Genotype CC is associated with increased overall survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CT + TT.; Genotype CC is associated with increased progression-free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CT + TT.; Genotypes CT + TT are associated with decreased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.; Genotypes CT + TT are not associated with decreased toxicity when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.; Genotypes CC + CT are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.; Genotypes CT + TT are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.; Genotypes CT + TT are associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.",19786980; 19362955; 16875718; 21057378; 21057378; 22026922; 22026922; 22188361; 22188361; 22188361,10,carboplatin;cisplatin;oxaliplatin;platinum;Platinum compounds,"Carcinoma, Non-Small-Cell Lung;Colorectal Neoplasms;Neoplasms;Ovarian Neoplasms;Pancreatic Neoplasms;Uterine Cervical Neoplasms",
981201333,rs2227983,EGFR (PA7360),3,Toxicity/ADR,981201336; 981201335; 981201334,"AA:Patients with the AA genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.; AG:Patients with the AG genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GG:Patients with the GG genotype may have an increased risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.",637880031; 769170841; 827812838,Allele A is not associated with response to cetuximab in people with Colorectal Neoplasms as compared to allele G.; Allele A is associated with cytotoxicity of egfr inhibitors.; Genotype GG is associated with increased likelihood of Exanthema when treated with egfr inhibitors in people with Neoplasms as compared to genotypes AA + AG.,16788380; 18006781; 22158333,3,cetuximab;egfr inhibitors;erlotinib,"Carcinoma, Non-Small-Cell Lung;Colorectal Neoplasms;Neoplasms;Pancreatic Neoplasms",
655384592,rs12721627,"CYP3A (PA27114),CYP3A4 (PA130)",3,Dosage,655384594; 655384595; 655384596,CC:Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.; CG:Patients with the CG genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.; GG:Patients with the GG genotype may have increased metabolism of paclitaxel as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence paclitaxel metabolism.,655387863,"Allele C is associated with decreased metabolism of paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.",16890579,1,paclitaxel,"Carcinoma, Non-Small-Cell Lung;Neoplasms",Asian
827847725,rs9981861,DSCAM (PA27491),3,Efficacy,827847726; 827847727; 827847728,CC:Patients with the CC genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.; CT:Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.; TT:Patients with the TT genotype may have decreased survival when treated with carboplatin and paclitaxel as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence survival.,827827855,"Genotype TT is associated with decreased survival when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.",21079520,1,carboplatin;paclitaxel,"Carcinoma, Non-Small-Cell Lung;Neoplasms",Asian
981204090,rs9024,CBR1 (PA26121),3,Toxicity/ADR,981204091; 981204092; 981204093,"AA:Patients with the AA genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.; AG:Patients with the AG genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.; GG:Patients with the GG genotype and Cancer who are treated with anthracyclines and related substances may have an increased risk of developing Cardiomyopathies as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.",827807610; 827808476,Genotypes AA + AG are not associated with increased risk of Cardiomyopathies when treated with anthracyclines and related substances in people with Neoplasms.; Genotype GG is associated with increased risk of Cardiomyopathies when treated with anthracyclines and related substances in people with Neoplasms as compared to genotypes AA + AG.,22124095; 22124095,2,anthracyclines and related substances,Cardiomyopathies;Neoplasms,
981201972,rs1801159,DPYD (PA145),3,,981201973; 981201974; 981201975,CC:CC genotype is not associated with response to fluorouracil in white colon cancer patients as compared to TT genotype. Other genetic and clinical factors may influence a patient's response to fluorouracil.; CT:CT genotype is not associated with response to fluorouracil in white colon cancer patients as compared to TT genotype. Other genetic and clinical factors may influence a patient's response to fluorouracil.; TT:TT genotype is not associated with response to fluorouracil in white colon cancer patients as compared to CC genotype. Other genetic and clinical factors may influence a patient's response to fluorouracil.,827813451,Allele C is not associated with response to fluorouracil in people with Colonic Neoplasms as compared to allele T.,20665215,1,fluorouracil,Colonic Neoplasms,White
981237959,rs13181,ERCC2 (PA27848),3,Efficacy;Toxicity/ADR,981237960; 981237961; 981237962,"GG:Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity 2) an increased risk of early relapse and 3) decreased progression free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin.; GT:Patients with the GT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity as compared to patients with the TT genotype 2) an increased risk of early relapse as compared to patients with the TT genotype. However, a trend of an association is found for the GT genotype with increased progression free survival compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin.; TT:Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) a decreased, but not absent, risk of Drug Toxicity 2) a decreased, but not absent, risk of early relapse and 3) increased progression free survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin.",769261451; 655388448; 769166392,"Allele G is associated with increased risk of Drug Toxicity when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT.; Genotypes GG + GT are associated with increased risk of early relapse when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype TT.; Genotypes TT + GT are associated with increased progression free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.",20385995; 18267032; 20078613,3,fluorouracil;leucovorin;oxaliplatin,Colorectal Neoplasms,
655384485,rs9344,CCND1 (PA75),3,Efficacy,655384489; 655384488; 655384487,"AA:Patients with the AA genotype may have increased survival when treated with cetuximab as compared to patients with the AG or GG genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.; AG:Patients with the AG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.; GG:Patients with the GG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.",827843529; 827843536; 827843546,Allele A is not associated with response to cetuximab in people with Colorectal Neoplasms as compared to allele G.; Genotype AA is associated with decreased survival when treated with cetuximab in people with Colorectal Neoplasms.; Allele G is associated with decreased overall survival and progression-free survival when treated with cetuximab in people with Colorectal Neoplasms as compared to allele A.,18349392; 16788380; 22117530,3,cetuximab,Colorectal Neoplasms,
981204414,rs1045642,ABCB1 (PA267),3,Toxicity/ADR,981204417; 981204416; 981204415,AA:Patients with AA genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.; AG:Patients with AG genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.; GG:Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.,769245657; 769262752,Allele G is not associated with likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele A.; Genotype GG is associated with decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.,20638924; 21142915,2,fluorouracil,Colorectal Neoplasms,
981204965,rs1801133,MTHFR (PA245),3,Toxicity/ADR,981204966; 981204967; 981204968,"AA:Patients with the AA genotype may have increased risk of Drug Toxicity in cancer patients treated with leucovorin, oxaliplatin as compared to patients with the GG genotype. However, conflicting finding of no-association for this genotype has also been reported. Other genetic and clinical factors may also influence a patient's risk of toxicity to leucovorin.; AG:Patients with the AG genotype may have increased risk of Drug Toxicity in cancer patients treated with leucovorin, oxaliplatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to leucovorin.; GG:Patients with the GG genotype may have decreased risk of Drug Toxicity in cancer patients treated with leucovorin, oxaliplatin as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to leucovorin.",827811335; 769176384; 769176385,"Genotype GG is associated with decreased severity of Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotypes AA + AG.; Genotype AA is not associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.; Genotype AG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.",19384296; 20819423; 20819423,3,leucovorin;oxaliplatin,Colorectal Neoplasms,White
827847788,rs1695,GSTP1 (PA29028),2A,Efficacy,827847789; 827847790; 827847791,"AA:Patients with the AA genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have poorer treatment outcome (reduced responsiveness, lower overall survival time, increased risk of death) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil and oxaliplatin treatment.; AG:Patients with the AG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have better treatment outcome as compared to patients with the AA genotype, or may have poorer treatment outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil and oxaliplatin treatment.; GG:Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil and oxaliplatin treatment.",637880107; 637880121; 769166391; 827793307; 827793320,"Genotype AA is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.; Genotype AA is associated with increased risk of disease progression when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.; Genotype GG is associated with increased progression free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.; Genotypes AG + GG are associated with increased response to fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.; Genotypes AG + GG are associated with increased overall survival when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.",15213713; 15213713; 20078613; 21449681; 21449681,5,fluorouracil;oxaliplatin,Colorectal Neoplasms,
981204560,rs1801131,MTHFR (PA245),2A,Efficacy;Toxicity/ADR,981204561; 981204562; 981204563,"GG:Patients with the GG genotype may have 1) increased response, 2) increased risk of Drug Toxicity in people with Colorectal Neoplasms treated with oxaliplatin, capecitabine, fluorouracil, leucovorin as compared to patients with TT genotype. Other genetic and clinical factors may influence a patient's response to these drugs.; GT:Patients with the GT genotype may have 1) increased response, 2) increased risk of Drug Toxicity in people with Colorectal Neoplasms treated with oxaliplatin, capecitabine, fluorouracil, leucovorin as compared to patients with TT genotype. Other genetic and clinical factors may influence a patient's response to these drugs.; TT:Patients with the TT genotype may have 1) decreased response, 2) decreased risk of Drug Toxicity in people with Colorectal Neoplasms treated with oxaliplatin, capecitabine, fluorouracil, leucovorin as compared to patients with GG or GT genotype. Other genetic and clinical factors may influence a patient's response to these drugs.",769166385; 769176381; 769261454,"Allele G is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele T.; Genotype GG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.; Genotypes GG + GT are associated with increased response to oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT.",20078613; 20819423; 20385995,3,capecitabine;fluorouracil;leucovorin;oxaliplatin,Colorectal Neoplasms,White
981204864,rs1801131,MTHFR (PA245),2A,Toxicity/ADR,981204865; 981204866; 981204867,GG:Patients with the GG genotype may have increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to capecitabine.; GT:Patients with the GT genotype may have increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to capecitabine.; TT:Patients with the TT genotype may have decreased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence a patient's risk of toxicity to capecitabine.,769176381; 827811371,"Genotype GG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.; Genotype TT is associated with decreased Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotypes GG + GT.",20819423; 18245544,2,capecitabine,Colorectal Neoplasms,
981202440,rs396991,FCGR3A (PA28065),2B,Efficacy,981202441; 981202442; 981202443,AA:Patients with the AA genotype with Colorectal Cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to therapy.; AC:Patients with the AC genotype with Colorectal Cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype or may have poorer response and treatment outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to therapy.; CC:Patients with the CC genotype with Colorectal Cancer who are treated with cetuximab may have poorer response and treatment outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to therapy.,769171568; 827843556,Allele A is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to allele C.; Allele A is associated with increased overall survival and progression-free survival when treated with cetuximab in people with Colorectal Neoplasms as compared to allele C.,17704420; 22117530,2,cetuximab,Colorectal Neoplasms,
655386616,rs13181,"ERCC2 (PA27848),KLC3 (PA142671588)",3,Efficacy,655386617; 655386618; 655386619,GG:Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.; GT:Patients with the GT genotype may have increased survival when treated with platinum compounds as compared to patients with the GG genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.; TT:Patients with the TT genotype may have increased survival when treated with platinum compounds as compared to patients with the GG genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.,827813109; 827816865; 827816886; 655386609; 637880131; 769166392; 827704200; 827793330; 827827967,"Allele G is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele T.; Genotype GG is associated with decreased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.; Genotype GG is associated with decreased progression-free survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.; Allele G is associated with decreased event free survival when treated with cisplatin in people with Osteosarcoma as compared to genotype TT.; Genotype GG is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype TT.; Genotypes TT + GT are associated with increased progression free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.; Genotype GG is associated with increased event free survival when treated with cisplatin, doxorubicin, ifosfamide and methotrexate in people with Osteosarcoma as compared to genotype TT.; Genotype GT is associated with increased progression-free survival when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GG + TT.; Genotypes GG + GT are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.",19620936; 22026922; 22026922; 19434073; 15213713; 20078613; 21826087; 21449681; 22188361,9,cisplatin;oxaliplatin;platinum;Platinum compounds,Colorectal Neoplasms;Esophageal Neoplasms;Osteosarcoma;Ovarian Neoplasms;Pancreatic Neoplasms,
981201981,rs1801265,DPYD (PA145),3,Toxicity/ADR,981201982; 981201983; 981201984,AA:Genotypes AA is not associated with Drug Toxicity in white cancer patients treated with fluorouracil as compared to genotypes AG and GG. Other genetic and clinical factors may influence a patient's risk of fluorouracil-related toxicity.; AG:Genotypes AG is not associated with Drug Toxicity in white cancer patients treated with fluorouracil as compared to genotype AA. Other genetic and clinical factors may influence a patient's risk of fluorouracil-related toxicity.; GG:Genotypes GG is not associated with Drug Toxicity in white cancer patients treated with fluorouracil as compared to genotype AA. Other genetic and clinical factors may influence a patient's risk of fluorouracil-related toxicity.,827892677; 827892687; 827892796; 827892947,Genotypes AG + GG are not associated with Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype AA.; Genotypes AG + GG are not associated with clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.; Genotypes AG + GG are not associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype AA.; Genotype AG is not associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype AA.,17064846; 17064846; 17121937; 14635116,4,fluorouracil,Colorectal Neoplasms;Neoplasms,White
981203618,rs67376798,DPYD (PA145),2A,Toxicity/ADR,981203619; 981203620; 981203621,"AA:Patients with the AA genotype were not reported, however, patients with the AT genotype and Cancer who are treated with fluorouracil-containing regimens 1) may have decreased clearance of the drug 2) may have an increased risk and severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for fluorouracil-induced toxicity.; AT:Patients with the AT genotype and Cancer who are treated with fluorouracil-containing regimens 1) may have decreased clearance of the drug 2) may have an increased risk and severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for fluorouracil-induced toxicity.; TT:Patients with the TT genotype and Cancer who are treated with fluorouracil-containing regimens 1) may have increased clearance of the drug 2) may have a decreased risk and reduced severity of drug toxicity as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's risk for fluorouracil-induced toxicity.",827823460; 827824687; 827892661; 827892669; 827892780,Allele A is not associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to allele T.; Genotype AT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.; Genotype AT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.; Genotype AT is associated with increased severity of Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype TT.; Genotype AT is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype TT.,19530960; 17700593; 17064846; 17064846; 17121937,5,fluorouracil,Colorectal Neoplasms;Neoplasms,White
981345277,rs25487,XRCC1 (PA369),3,Efficacy,981345278; 981345279; 981345280,"CC:Patients with the CC genotype may have increased response to fluorouracil-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.; CT:Patients with the CT genotype may have decreased response to fluorouracil-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.; TT:Patients with the TT genotype may have decreased response to fluorouracil-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.",769165182; 827641636; 827784173; 827784178,"Genotype CC is associated with increased response to fluorouracil in people with Rectal Neoplasms as compared to genotype CT.; Allele T is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele C.; Genotype CC is associated with increased overall survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CT + TT.; Genotype CC is associated with increased progression-free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CT + TT.",21167658; 16875718; 21057378; 21057378,4,fluorouracil,Colorectal Neoplasms;Neoplasms;Rectal Neoplasms;Uterine Cervical Neoplasms,Asian
981203627,rs67376798,DPYD (PA145),3,Toxicity/ADR,981203628; 981203629; 981203630,"AA:Patients with the AA genotype were not reported, however patients with the AT genotype and Cancer who are treated with regimens containing leucovorin may have increased severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; AT:Patients with the AT genotype and Cancer who are treated with regimens containing leucovorin may have increased severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; TT:Patients with the TT genotype and Cancer who are treated with regimens containing leucovorin may have decreased severity of drug toxicity as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.",827810959; 827892669,Genotype AT is associated with increased severity of Diarrhea when treated with leucovorin and tegafur in people with Rectal Neoplasms as compared to genotype TT.; Genotype AT is associated with increased severity of Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype TT.,21410976; 17064846,2,leucovorin,Colorectal Neoplasms;Rectal Neoplasms,
981202598,rs4444903,EGF (PA27664),2B,Efficacy,981202599; 981202600; 981202601,AA:Patients with the AA genotype who are treated with cetuximab may have a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.; AG:Patients with the AG genotype who are treated with cetuximab may have a poorer response as compared to patients with the GG genotype or may have a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.; GG:Patients with the GG genotype who are treated with cetuximab may have a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.,637880035; 637880058; 827697915,Genotype AA is associated with increased survival when treated with cetuximab in people with Colorectal Neoplasms as compared to genotypes GG + AG.; Genotype AA is associated with decreased overall survival when treated with cetuximab in people with colorectal neoplasms as compared to genotype GG.; Genotype GG is associated with increased likelihood of complete pathologic response when treated with cetuximab in people with Rectal Neoplasms as compared to genotype AA.,16788380; 18349392; 21673069,3,cetuximab,Colorectal Neoplasms;Rectal Neoplasms,White
981201881,rs3093726,"LST1 (PA37856),LTB (PA30475),TNF (PA435)",4,Toxicity/ADR,981201882; 981201883; 981201884,"CC:Patients with the CC genotype may have decreased but not absent risk of hypersensitivity when treated with abacavir as compared to patients with the CT or TT genotypes. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events.; CT:Patients with the CT genotype may have increased risk of hypersensitivity when treated with abacavir as compared to patients with the CC genotype. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events.; TT:Patients with the TT genotype may have increased risk of hypersensitivity when treated with abacavir as compared to patients with the CC genotype. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events.",769179106,Allele T is associated with increased risk of hypersensitivity when treated with abacavir.,11888582,1,abacavir,Drug Hypersensitivity,
827849095,rs9274407,HLA-DQB1 (PA35068),3,Toxicity/ADR,827849096; 827849097; 827849098,AA:Patients with the AA genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.; AT:Patients with the AT genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.; TT:Patients with the TT genotype may have decreased but not absent risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk for drug induced liver injury.,827826967,Allele A is associated with increased likelihood of drug induced liver injury when treated with amoxicillin and clavulanate in people with Drug Toxicity as compared to allele T.,21570397,1,amoxicillin;clavulanate,Drug Toxicity,White
655384558,rs10932125,NRP2 (PA31784),4,Other,655384560; 655384561; 655384562,CC:Patients with the CC genotype may have reduced response to daunorubicin compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment.; CG:Patients with the CG genotype may have reduced response to daunorubicin compared to patients with the GG genotype or may have increased response to daunorubicin compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment.; GG:Patients with the GG genotype may have increased response to daunorubicin compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment.,655387597; 655387598,Allele C is associated with increased expression of CYP1B1 in CEU and YRI cell lines.; Allele C is associated with increased IC50 of daunorubicin as compared to allele G.,18451141; 18451141,2,daunorubicin,Drug Toxicity,
827831021,rs532545,CDA (PA98),4,Toxicity/ADR,827831022; 827831023; 827831024,CC:Patients with the CC genotype who are treated with cytarabine may have an decreased risk of toxicity compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence cytarabine toxicity.; CT:Patients with the CT genotype who are treated with cytarabine may have an increased risk of toxicity compared to patients with the CC genotype. Other genetic and clinical factors may also influence cytarabine toxicity.; TT:Patients with the TT genotype who are treated with cytarabine may have an increased risk of toxicity compared to patients with the CC genotype. Other genetic and clinical factors may also influence cytarabine toxicity.,827803655; 827829873,"Genotypes CT + TT are associated with increased toxicity when exposed to cytarabine in healthy individuals as compared to genotype CC.; Genotype TT is associated with increased cytotoxicity when exposed to cytarabine in people with Leukemia, Myeloid as compared to genotype CC.",21521023; 22304580,2,cytarabine,Drug Toxicity,White
981204941,rs1801019,UMPS (PA363),2B,Toxicity/ADR,981204942; 981204943; 981204944,"CC:Patients with CC genotype and cancer may have an increased risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and leucovorin as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to leucovorin, tegafur and fluorouracil.; CG:Patients with CG genotype and cancer may have a decreased, but not absent, risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and leucovorin as compared to patients with the CC genotype. However, contradictory findings have been reported that show the CG genotype may be associated with increased risk for grade 3 to 4 diarrhea when treated with fluorouracil and leucovorin compared to the GG genotype.Other genetic and clinical factors may also influence response to leucovorin, tegafur and fluorouracil.; GG:Patients with GG genotype and cancer may have a decreased, but not absent, risk for toxicity (Diarrhea, any grade 3 adverse event) when treated with leucovorin and tegafur or fluorouracil and leucovorin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to leucovorin, tegafur and fluorouracil.",769169649; 769245624; 769245627; 769169655,Genotype CC is associated with increased likelihood of experiencing severe toxicity when treated with fluorouracil and leucovorin in people with Adenocarcinoma as compared to genotypes GG + CG.; Genotype CC is associated with increased severity of Diarrhea when treated with leucovorin and tegafur in people with Colorectal Neoplasms as compared to genotypes GG + CG.; Genotype CC is associated with increased likelihood of any grade 3 adverse event when treated with leucovorin and tegafur in people with Colorectal Neoplasms as compared to genotypes GG + CG.; Genotypes CC + CG are associated with grade 3 to 4 diarrhea when treated with fluorouracil and leucovorin in people with Adenocarcinoma as compared to genotype GG.,16818689; 20647221; 20647221; 16818689,4,fluorouracil;leucovorin;tegafur,Drug Toxicity,Asian
655385315,rs1801133,MTHFR (PA245),1B,Toxicity/ADR,655385316; 655385317; 655385318,"AA:Patients with the AA genotype with Leukemia or Lymphoma who are treated with methotrexate regimens may have an increased risk and increased severity of mucositis, as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's risk of oral mucositis.; AG:Patients with the AG genotype with Leukemia or Lymphoma who are treated with methotrexate regimens may have a decreased risk and decreased severity of mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of oral mucositis.; GG:Patients with the GG genotype with Leukemia or Lymphoma who are treated with methotrexate regimens may have a decreased risk and decreased severity of mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of oral mucositis.",637879722; 637879773; 769146371; 769146398,"Genotype AA is associated with increased risk of severe mucositis when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes GG + GA.; Genotype AA is associated with increased risk of oral mucositis when treated with methotrexate in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes GG + GA.; Genotype AA is associated with increased severity of oral mucositis when treated with methotrexate in people with hematopoietic-cell-transplantation as compared to genotype GG.; Genotype AA is associated with increased risk of oral mucositis when treated with busulfan, cyclophosphamide and methotrexate in people with hematopoietic cell transplants for chronic myelogenous leukemia as compared to genotype GG.",17488658; 11418485; 16501586; 15051775,4,methotrexate,"Drug Toxicity;Leukemia;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Transplantation",
655385311,rs1801133,MTHFR (PA245),3,Toxicity/ADR,655385312; 655385313; 655385314,"AA:Patients with the AA genotype and non-Hodgkin lymphoma who are treated with methotrexate may have an increased risk of mucositis, thrombocytopenia and hepatic toxicity as compared to patients with the GG genotype. This association was not found in pediatric patients with non-Hodgkin lymphoma who were treated with methotrexate. Other genetic and clinical factors may also influence a patient's risk for methotrexate-induced toxicity.; AG:Patients with the AG genotype and non-Hodgkin lymphoma who are treated with methotrexate may have a decreased, but not absent, risk of mucositis, thrombocytopenia and hepatic toxicity as compared to patients with the AA genotype. This association was not found in pediatric patients with non-Hodgkin lymphoma who were treated with methotrexate. Other genetic and clinical factors may also influence a patient's risk for methotrexate-induced toxicity.; GG:Patients with the GG genotype and non-Hodgkin lymphoma who are treated with methotrexate may have a decreased, but not absent, risk of mucositis, thrombocytopenia and hepatic toxicity as compared to patients with the AA genotype. This association was not found in pediatric patients with non-Hodgkin lymphoma who were treated with methotrexate. Other genetic and clinical factors may also influence a patient's risk for methotrexate-induced toxicity.",827829042; 827829138; 769170766; 637879722; 637879736; 637879739,"Genotype AA is associated with increased risk of overall toxicity (measured as more than two adverse effects) when treated with as compared to genotype GG.; Genotype AA is associated with increased risk of hepatotoxicity and hematological toxicity when treated with methotrexate as compared to genotype GG.; Allele A is not associated with response to methotrexate in people with Lymphoma, Non-Hodgkin as compared to allele G.; Genotype AA is associated with increased risk of severe mucositis when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes GG + GA.; Genotype AA is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes GG + GA.; Genotype AA is associated with increased risk of Thrombocytopenia when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes GG + GA.",22143415; 22143415; 16463153; 17488658; 17488658; 17488658,6,methotrexate,"Drug Toxicity;Lymphoma, Non-Hodgkin;Thrombocytopenia;Toxic liver disease",White
827849079,rs9282861,"SULT1A1 (PA343),SULT1A2 (PA341)",3,Toxicity/ADR,827849080; 827849081; 827849082,CC:Patients with the CC genotype may have a decreased but not absent risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.; CT:Patients with the CT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.; TT:Patients with the TT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.,827639365,Genotypes TT + CT are associated with increased likelihood of Endometrial Neoplasms when treated with conjugated estrogens as compared to genotype CC.,16985250,1,conjugated estrogens,Endometrial Neoplasms,
978608464,rs1801133,MTHFR (PA245),3,Efficacy,978608465; 978608466; 978608467,AA:Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment.; AG:Patients with the AG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment.; GG:Patients with the GG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have an increased risk of Graft vs Host disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment.,699642245; 769146358,"Allele A is associated with graft vs host disease in people with recipients of HLA-identical hematopoietic stem cell transplantation.; Genotype AA is associated with decreased risk of Graft vs Host Disease when treated with methotrexate in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.",19005482; 16920564,2,methotrexate,"Graft vs Host Disease;Leukemia;Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
652779372,rs1056892,CBR3 (PA26122),2B,Toxicity/ADR,652779373; 652779374; 652779375,AA:Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; AG:Patients with the AG genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; GG:Patients with the GG genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.,655387546; 827807593; 827807601,Allele G is associated with increased risk of Heart Failure when treated with anthracyclines and related substances as compared to allele A.; Genotype GG is associated with increased risk of Cardiomyopathies when treated with anthracyclines and related substances in people with Neoplasms as compared to genotypes AA + AG.; Genotypes AA + AG are not associated with increased risk of Cardiomyopathies when treated with anthracyclines and related substances in people with Neoplasms.,18457324; 22124095; 22124095,3,anthracyclines and related substances,Heart Failure;Neoplasms,
655385818,rs1800629,"LST1 (PA37856),LTA (PA30474),TNF (PA435)",3,Toxicity/ADR,655385819; 655385820; 655385821,AA:Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.; AG:There were too few patients with the AG genotype in this one small study for a conclusion to be drawn.; GG:Patients with the GG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.,655388335,Allele A is associated with increased likelihood of serious hypersensitivity when treated with carbamazepine as compared to allele G.,11294926,1,carbamazepine,Hypersensitivity,White
655387023,rs2072671,CDA (PA98),3,Toxicity/ADR,655387024; 655387025; 655387026,"AA:Patients with the AA genotype who are treated with cytarabine may have a decreased, but not absent, risk of toxicity as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; AC:Patients with the AC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; CC:Patients with the CC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.",699639373; 827803684; 827829894; 827922313,"Genotype AA is associated with decreased risk of grade III/IV liver toxicity when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes CC + AC.; Genotypes AC + CC are associated with increased toxicity when treated with cytarabine as compared to genotype AA.; Genotype CC is associated with increased cytotoxicity when exposed to cytarabine in people with Leukemia, Myeloid as compared to genotype AA.; Genotype CC is associated with increased risk of Drug Toxicity when treated with cytarabine in children with Lymphoma, T-Cell.",19458626; 21521023; 22304580; 22379997,4,cytarabine,"Leukemia, Myeloid, Acute",White
655387027,rs532545,CDA (PA98),3,Efficacy,655387028; 655387029; 655387030,"CC:Patients with the genotype CC and Myeloid Leukemia who are treated with cytarabine 1) may have an increased survival time 2) may have a decreased risk for death, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.; CT:Patients with the genotype CT and Myeloid Leukemia who are treated with cytarabine may have a decreased survival time and an increased risk for death as compared to patients with the CC genotype, or may have an increased survival time and a decreased risk for death as compared to patients with the TT genotype, though this may not be statistically significant. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.; TT:Patients with the genotype TT and Myeloid Leukemia who are treated with cytarabine 1) may have a decreased survival time 2) may have an increased risk for death, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.",699639367; 699639370,"Genotype TT is associated with decreased 5 year survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype CC.; Genotype TT is associated with increased risk of Death when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype CC.",19458626; 19458626,2,cytarabine,"Leukemia, Myeloid, Acute",White
827848365,rs1801133,MTHFR (PA245),3,Dosage;Efficacy;Toxicity/ADR,827848366; 827848367; 827848368,AA:Patients with the AA genotype and Leukemia who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate as compared to patients with the GG genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patient's risk for toxicity and response with methotrexate treatment.; AG:Patients with the AG genotype and Leukemia who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate as compared to patients with the GG genotype or may be at decreased risk of toxicity as compared to patients with the AA genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patient's risk for toxicity and response with methotrexate treatment.; GG:Patients with the GG genotype and Leukemia who are treated with methotrexate: 1) may have better response to treatment 2) may be at decreased risk of toxicity 3) may require a higher dose of methotrexate as compared to patients with the AA genotype. This association has been contradicted or not found in several studies. Other genetic and clinical factors may also influence a patient's risk for toxicity and response with methotrexate treatment.,827829042; 827829138; 608431574; 608431599; 751696635; 769170744; 769170968; 769171000; 769173703; 769174309; 637879745; 637879749; 637879769; 655387891; 769171101; 769170671; 769171025; 827698212; 827698220,"Genotype AA is associated with increased risk of overall toxicity (measured as more than two adverse effects) when treated with as compared to genotype GG.; Genotype AA is associated with increased risk of hepatotoxicity and hematological toxicity when treated with methotrexate as compared to genotype GG.; Allele A is associated with decreased likelihood of event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; Allele A is associated with increased risk of relapse when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; Allele A is not associated with risk of MTX-induced toxicity (seizures or thrombosis) when treated with methotrexate in people with Leukemia.; Allele A is not associated with response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; Allele A is not associated with increased risk of Neoplasms, Second Primary when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; Allele A is not associated with Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Allele A is not associated with decreased IQ when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Allele A is not associated with catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.; Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + GA.; Genotype AA is associated with decreased mortality when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Leukemia as compared to genotype GA.; Genotype AA is associated with increased risk of hepatotoxicity, leukopenia and gastrointestinal toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; Genotype AA is associated with increased plasma drug concentrations when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + AG.; Genotypes AA + AG are associated with increased likelihood of treatment interruptions when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; Genotypes AA + AG are associated with decreased severity of Leukopenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; Genotype GG is associated with increased dose of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.; Genotype GG is associated with increased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.",22143415; 22143415; 14647408; 15781665; 12915598; 16462575; 16019535; 17323057; 16013960; 15797993; 17512587; 17512587; 12453860; 19648163; 17180579; 18458567; 16870553; 21747412; 21747412,19,methotrexate,Leukemia;Precursor Cell Lymphoblastic Leukemia-Lymphoma,
655384674,rs396991,FCGR3A (PA28065),2B,Efficacy,655384678; 655384677; 655384676,AA:Lymphoma patients with the AA genotype who are treated with rituximab may be less likely to have tumor shrinkage as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.; AC:Lymphoma patients with the AC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.; CC:Lymphoma patients with the CC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.,769143864; 769143868; 769143871,"Genotype AA is associated with decreased levels of IgG when treated with rituximab in people with non-Hodgkin's lymphoma and stem cell transplantation as compared to genotypes CC + AC.; Allele C is associated with increased complete response rate when treated with rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to allele A.; Genotype CC is associated with response rate when treated with rituximab in people with Lymphoma, Non-Hodgkin as compared to genotypes AA + AC.",19018870; 16609067; 12975461,3,rituximab,"Lymphoma, B-Cell;Lymphoma, Follicular;Lymphoma, Large-Cell, Diffuse;Lymphoma, Non-Hodgkin",
655386079,rs8187710,ABCC2 (PA116),3,Toxicity/ADR,655386080; 655386081; 655386082,"AA:Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.; AG:Patients with the AG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.; GG:Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.",655385943,"Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.",16330681,1,doxorubicin,"Lymphoma, Non-Hodgkin",White
699639332,rs1801131,MTHFR (PA245),3,Toxicity/ADR,699639333; 699639334; 699639335,"GG:Patients with the GG genotype and non-Hodgkin lymphoma who are treated with methotrexate may have an increased risk of mucositis as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for mucositis when treated with methotrexate.; GT:Patients with the GT genotype and non-Hodgkin lymphoma who are treated with methotrexate may have a decreased, but not absent, risk of mucositis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for mucositis when treated with methotrexate.; TT:Patients with the TT genotype and non-Hodgkin lymphoma who are treated with methotrexate may have a decreased, but not absent, risk of mucositis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for mucositis when treated with methotrexate.",637879731,"Genotype GG is associated with increased risk of mucositis when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes TT + TG.",17488658,1,methotrexate,"Lymphoma, Non-Hodgkin",White
827848325,rs1801133,MTHFR (PA245),3,Efficacy,827848326; 827848327; 827848328,AA:Patients with the AA genotype with non-hodgkin lymphoma who are treated with methotrexate may be less likely to have event free survival at 5 years as compared to patients with the GG genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.; AG:Patients with the AG genotype with non-hodgkin lymphoma who are treated with methotrexate may be less likely to have event free survival at 5 years as compared to patients with the GG genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.; GG:Patients with the GG genotype with non-hodgkin lymphoma who are treated with methotrexate may be more likely to have event free survival at 5 years as compared to patients with the AA genotype. This genotype was not associated with treatment outcome in pediatric patients with non-hodgkin lymphoma as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.,637879719; 769170766,"Allele A is associated with decreased likelihood of event free survival when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotype GG.; Allele A is not associated with response to methotrexate in people with Lymphoma, Non-Hodgkin as compared to allele G.",17488658; 16463153,2,methotrexate,"Lymphoma, Non-Hodgkin",White
981201684,rs4124874,"UGT1A1 (PA420),UGT1A10 (PA37174),UGT1A3 (PA37178),UGT1A4 (PA37179),UGT1A5 (PA37180),UGT1A6 (PA37181),UGT1A7 (PA37182),UGT1A8 (PA37183),UGT1A9 (PA419)",3,Toxicity/ADR,981201685; 981201686; 981201687,"GG:Patients with the GG genotype and Cancer who are treated with irinotecan may have an increased risk of Neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; GT:Patients with the GT genotype and Cancer who are treated with irinotecan may have an increased risk of Neutropenia as compared to patients with the TT genotype, or may have a decreased risk of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; TT:Patients with the TT genotype and Cancer who are treated with irinotecan may have a decreased risk of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.",827552123,Allele G is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to allele T.,15007088,1,irinotecan,Lymphoma;Neoplasms,
981188379,rs2072671,CDA (PA98),3,Toxicity/ADR,981188380; 981188381; 981188382,AA:Patients with the AA genotype who are treated with gemcitabine may have an increased risk of hematological toxicity and decreased risk of gastrointestinal toxicity as compared to patients with the the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; AC:Patients with the AC genotype who are treated with gemcitabine may have an increased risk of hematological toxicity as compared to patients with the the CC genotype and an increased risk of gastrointestinal toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.; CC:Patients with the CC genotype who are treated with gemcitabine may have an increased risk of gastrointestinal toxicity and decreased risk of hematological toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.,655386820; 769245523; 827641523; 827803765; 827815544; 827817256,"Allele C is not associated with decreased metabolism of gemcitabine in people with Neoplasms as compared to allele A.; Allele C is not associated with expression of CDA in CEPH cell lines.; Genotypes AA + AC are associated with increased severity of Drug Toxicity when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.; Genotype CC is associated with increased expression of CDA in PBMCs.; Allele C is associated with increased frequency of nausea/vomiting grade>=2 events when treated with gemcitabine and Platinum compounds in people with Mesothelioma as compared to allele A.; Genotypes AC + CC are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.",17194903; 21325291; 21625252; 21521023; 22134350; 22026922,6,gemcitabine,Mesothelioma;Pancreatic Neoplasms,
981204433,rs1045642,ABCB1 (PA267),3,Efficacy,981204436; 981204435; 981204434,"AA:Patients with the AA genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.; AG:Patients with the AG genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.; GG:Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.",769169480,"Genotype GG is associated with decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype AA.",18408561,1,dexamethasone;doxorubicin;vincristine,Multiple Myeloma,
981238041,rs2032582,ABCB1 (PA267),3,Efficacy,981238042; 981238043; 981238044,"AA:Patients with the AA genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.; AC:Patients with the AC genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.; CC:Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.",769169476,"Genotypes AA + AC are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma.",18408561,1,dexamethasone;doxorubicin;vincristine,Multiple Myeloma,
655384597,rs1934951,CYP2C8 (PA125),3,Toxicity/ADR,655384601; 655384600; 655384599,CC:Patients with the CC genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.; CT:Patients with the CT genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.; TT:Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.,699638940; 827863672,Genotype TT is associated with increased risk of Osteonecrosis of the jaw when treated with Bisphosphonates in people with Multiple Myeloma as compared to genotypes CC + CT.; Genotypes CT + TT are not associated with increased likelihood of Osteonecrosis when treated with Bisphosphonates in men with Prostatic Neoplasms as compared to genotype CC.,18594024; 21151627,2,Bisphosphonates;pamidronate;zoledronate,Multiple Myeloma;Osteonecrosis,White
655385328,rs9345389,,3,Toxicity/ADR,655385332; 655385331; 655385330,"AA:Patients with the AA genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have a decreased, but not absent, risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of end-of-induction minimal residual disease (MRD).; AG:Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.; GG:Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.",751755636,Allele G is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance. as compared to allele A.,19176441,1,methotrexate,"Neoplasm, Residual;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
655385333,rs4888024,,3,Toxicity/ADR,655385337; 655385336; 655385335,"AA:Patients with the AA genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have a decreased, but not absent, risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for MRD.; AG:Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.; GG:Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.",751776639,Allele G is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance..,19176441,1,methotrexate,"Neoplasm, Residual;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
981237871,rs11045585,SLCO1B3 (PA35844),3,Toxicity/ADR,981237872; 981237873; 981237874,"AA:Patients with the AA genotype and Neoplasms who are treated with docetaxel may have 1) a decreased, but not absent, risk of leukopenia, 2) an increased clearance of docetaxel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.; AG:Patients with the AG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.; GG:Patients with the GG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.",769180246; 827784589; 827784616,Allele G is associated with increased risk of leukopenia when treated with docetaxel as compared to allele A.; Allele G is associated with increased AUC of docetaxel in people with Nasopharyngeal Neoplasms.; Allele G is associated with decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms.,18294295; 21995462; 21995462,3,docetaxel,Neoplasms,Asian
655386585,rs1142345,TPMT (PA356),3,Toxicity/ADR,981478429; 981478430; 981478431,"CC:Patients with the CC genotype who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.; CT:Patients with the TC genotype who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.; TT:Patients with the TT genotype who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to patients with the TC or CC genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.",655386562,Allele C is associated with increased risk of Deafness when treated with cisplatin in people with Neoplasms as compared to allele T.,19898482,1,cisplatin,Neoplasms,
655386593,rs12201199,TPMT (PA356),3,Toxicity/ADR,655386594; 655386595; 655386596,AA:Patients with the AA genotype may have decreased risk for hearing loss with cisplatin treatment compared to patients with the TT or AT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; AT:Patients with the AT genotype may have increased risk for hearing loss with cisplatin treatment compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; TT:Patients with the TT genotype may have increased risk for hearing loss with cisplatin treatment compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,655386554,Allele T is associated with increased risk of Deafness when treated with in people with Neoplasms as compared to allele A.,19898482,1,cisplatin,Neoplasms,
655386597,rs1800460,TPMT (PA356),3,Toxicity/ADR,981478420; 981478421; 981478422,"CC:Patients with the CC genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to patients with the TC or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.; CT:Patients with the TC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.; TT:Patients with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.",655386568,Allele T is associated with increased risk of Deafness when treated with cisplatin in people with Neoplasms as compared to allele C.,19898482,1,cisplatin,Neoplasms,
637880078,rs2075252,LRP2 (PA30452),3,Toxicity/ADR,637880079; 637880080; 637880081,CC:Patients with the CC genotype treated with cisplatin may have a reduced but not non-existent risk for hearing loss as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's chance of adverse events.; CT:Patients with the CT genotype treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of adverse events.; TT:Patients with the TT genotype treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of adverse events.,637880063,Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in people with Neoplasms as compared to allele C.,17457342,1,cisplatin,Neoplasms,
637880087,rs316019,SLC22A2 (PA331),3,Toxicity/ADR,637880088; 637880089; 637880090,AA:Patients with the AA genotype may have reduced but not non-existent risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; AC:Patients with the AC genotype may have reduced but not non-existent risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; CC:Patients with the CC genotype may have increased risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,637880083; 827816530,Genotype CA is associated with decreased risk of nephrotoxicity when treated with cisplatin in people with neoplasms as compared to genotype CC.; Genotype CC is not associated with increased likelihood of nephrotoxicity when treated with cisplatin in people with Neoplasms as compared to genotypes AA + AC.,19625999; 21902499,2,cisplatin,Neoplasms,White
637880226,rs1695,GSTP1 (PA29028),3,Efficacy,637880227; 637880228; 637880229,AA:Patients with the AA genotype may have increased risk for progression and decreased survival with platinum-based treatments with colorectal cancer but studies of ovarian cancer found increased survival and studies of non-small cell lung cancer found no association with survival. Other genetic and clinical factors may also influence a patient's response.; AG:Patients with the AG genotype may have average risk for progression and survival with platinum-based treatments. Other genetic and clinical factors may also influence a patient's response.; GG:Patients with the AA genotype may have average risk for progression and survival with platinum-based treatments. Other genetic and clinical factors may also influence a patient's response.,637880107; 637880121; 655386344; 637880148,"Genotype AA is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.; Genotype AA is associated with increased risk of disease progression when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.; Genotype AA is associated with increased progression free survival when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes GG + AG.; Allele G is not associated with survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.",15213713; 15213713; 19786980; 17409936,4,Platinum compounds,Neoplasms,
637880267,rs712829,EGFR (PA7360),3,Efficacy,637880268; 637880269; 637880270,GG:Patients with the GG genotype who are treated with gefitinib may be less likely to respond compared to a patient with one or more T alleles. Other genetic and clinical factors may also influence a patient's response.; GT:Patients with the GT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the TT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.,655386406,Genotypes GT + TT are associated with increased progression-free survival (PFS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype GG.,17375033,1,gefitinib,Neoplasms,
655384578,rs2740574,"CYP3A (PA27114),CYP3A4 (PA130)",3,Dosage,655384579; 655384580; 655384581,CC:Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of docetaxel.; CT:Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the TT genotype or decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of docetaxel.; TT:Patients with the TT genotype may have decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of docetaxel.,699642219; 699642223,Allele C is associated with increased clearance of docetaxel in people with Neoplasms as compared to allele T.; Allele C is associated with expression of CYP3A5.,18509327; 18509327,2,docetaxel,Neoplasms,White
655385164,rs1138272,GSTP1 (PA29028),3,,655385167; 655385166; 655385165,CC:Patients with the CC genotype may have decreased clearance of thiotepa as compared to patients with the TT genotype.; CT:Patients with the CT genotype may have decreased clearance of thiotepa as compared to patients with the TT genotype.; TT:Patients with the TT genotype may have increased clearance of thiotepa as compared to patients with the CT or TT genotype.,699642171,"Allele T is associated with increased non-inducible thiotepa clearance by 52% [95% confidence interval (CI) 41, 64, P < 0.001] and decreased tepa clearance by 32% (95% CI 29, 35, P < 0.001).",19076156,1,thiotepa,Neoplasms,White
827831123,rs712829,EGFR (PA7360),3,Toxicity/ADR,827831124; 827831125; 827831126,GG:Patients with the GG genotype and cancer who are treated with erlotinib may have increased severity of Diarrhea compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.; GT:Patients with the GT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.; TT:Patients with the TT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.,827807448,Genotype GG is associated with increased severity of Diarrhea when treated with erlotinib in people with Neoplasms as compared to genotypes GT + TT.,18309947,1,erlotinib,Neoplasms,
827848555,rs9514091,SLC10A2 (PA318),3,Toxicity/ADR,827848556; 827848557; 827848558,AA:Patients with the AA genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for cardiotoxicity.; AG:Patients with the AG genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for cardiotoxicity.; GG:Patients with the GG genotype may have an increased risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk for cardiotoxicity.,827805749,Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.,21900104,1,anthracyclines and related substances,Neoplasms,
981201946,rs1801158,DPYD (PA145),3,Toxicity/ADR,981201947; 981201948; 981201949,CC:Patients with the CC genotype may have decreased risk of fluorouracil-related toxicity in cancer patients as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of fluorouracil-related toxicity.; CT:Patients with the CT genotype may have an increased risk of fluorouracil-related toxicity in cancer patients as compared to patients with the CC genotype. Genotype CT is also associated with decreased DPYD activity. Other genetic and clinical factors may also influence a patient's risk of fluorouracil-related toxicity.; TT:Patients with the TT genotype may have an increased risk of fluorouracil-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of fluorouracil-related toxicity.,827825116; 827892811; 827892923,Genotype CT is associated with severity of Drug Toxicity when treated with fluorouracil and leucovorin.; Genotype CT is associated with decreased DPYD activity in people with Neoplasms as compared to genotype CC.; Genotype CT is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.,15591715; 10803677; 14635116,3,fluorouracil,Neoplasms,
981201994,rs1801265,DPYD (PA145),3,Toxicity/ADR,981201995; 981201996; 981201997,AA:Patients with the AA genotype may have decreased likelihood of middle-severe nausea and vomiting in Asian cancer patients treated with fluorouracil as as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patient's risk for fluorouracil-related toxicity.; AG:Patients with the AG genotype may have increased likelihood of middle-severe nausea and vomiting in Asian cancer patients treated with fluorouracil as as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk for fluorouracil-related toxicity.; GG:Patients with the GG genotype may have increased likelihood of middle-severe nausea and vomiting in Asian cancer patients treated with fluorouracil as as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk for fluorouracil-related toxicity.,769169883; 827824640,Genotype AG is associated with increased likelihood of middle-severe nausea and vomiting when treated with fluorouracil in people with Neoplasms as compared to genotype AA.; Allele G is not associated with decreased catalytic activity of DPYD in peripheral blood.,17848752; 18452418,2,fluorouracil,Neoplasms,Asian
981201962,rs1801159,DPYD (PA145),3,Toxicity/ADR,981201963; 981201964; 981201965,"CC:Patients with the CC genotype may have increased likelihood of middle-severe nausea, vomiting and white blood cell decreases in cancer patients treated with fluorouracil as compared to patients with the TT genotype. Genotype CC is also associated with decreased clearance of fluorouracil. Other genetic and clinical factors may also influence a patient's risk of fluorouracil related adverse events.; CT:Patients with the CT genotype may have increased likelihood of middle-severe nausea, vomiting and white blood cell decreases in cancer patients treated with fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of fluorouracil related adverse events.; TT:Patients with the TT genotype may have decreased likelihood of middle-severe nausea, vomiting and white blood cell decreases in cancer patients treated with fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of fluorouracil related adverse events.",769169847; 769169854; 769169871; 827824648; 827892939,Genotype CC is associated with increased likelihood of middle-severe nausea and vomiting when treated with fluorouracil in people with Neoplasms as compared to genotype TT.; Genotype CC is associated with increased incidence of middle-severe white blood cell decreases when treated with fluorouracil in people with Neoplasms as compared to genotype TT.; Genotype CC is associated with decreased clearance of fluorouracil.; Allele C is not associated with decreased catalytic activity of DPYD in peripheral blood.; Genotype CT is not associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype TT.,17848752; 17848752; 17848752; 18452418; 14635116,5,fluorouracil,Neoplasms,Asian
981201713,rs4148323,"UGT1A1 (PA420),UGT1A10 (PA37174),UGT1A3 (PA37178),UGT1A4 (PA37179),UGT1A5 (PA37180),UGT1A6 (PA37181),UGT1A7 (PA37182),UGT1A8 (PA37183),UGT1A9 (PA419)",3,Other,981201714; 981201715; 981201716,"AA:Patients with the AA genotype and Cancer may have decreased inactivation of irinotecan metabolite SN38, as compared to patients with the GG genotype. This variant is not associated with risk of severe toxicities. Other genetic and clinical factors may also influence metabolism of irinotecan.; AG:Patients with the AG genotype and Cancer may have decreased inactivation of irinotecan metabolite SN38 as compared to patients with the GG genotype, or may have increased inactivation of irinotecan metabolite SN38 as compared to patients with the AA genotype. This variant is not associated with risk of severe toxicities. Other genetic and clinical factors may also influence metabolism of irinotecan.; GG:Patients with the GG genotype and Cancer may have increased inactivation of irinotecan metabolite SN38 as compared to patients with the AA genotype. This variant is not associated with risk of severe toxicities. Other genetic and clinical factors may also influence metabolism of irinotecan.",827552273; 827639062; 827675836,Allele A is associated with decreased metabolism of irinotecan in people with Neoplasms as compared to allele G.; Allele A is not associated with increased likelihood of severe toxicities when treated with irinotecan in people with Neoplasms as compared to allele G.; Allele A is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.,15179405; 11156391; 12181437,3,irinotecan,Neoplasms,Asian
981204466,rs1045642,ABCB1 (PA267),3,Toxicity/ADR,981204469; 981204468; 981204467,"AA:Patients with AA genotype may have decreased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype GG. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.; AG:Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.; GG:Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.",769262755; 827817217,"Genotype GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.; Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.",21142915; 22026922,2,capecitabine,Neoplasms,White
981204525,rs1801131,MTHFR (PA245),3,Efficacy,981204526; 981204527; 981204528,"GG:Genotype GG may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.; GT:Genotype GT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.; TT:Genotype TT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype GG and GT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.",769166427; 769258433; 827825848,"Genotype GG is associated with decreased progression free survival when treated with carboplatin and pemetrexed in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes TT + GT.; Genotypes GG + GT are associated with decreased overall survival when treated with cisplatin and pemetrexed in people with Stomach Neoplasms as compared to genotype TT.; Genotypes GG + GT are associated with increased overall survival when treated with bevacizumab, cyanocobalamin, folic acid and pemetrexed in people with Head and Neck Neoplasms as compared to genotype TT.",19307503; 20634689; 21343546,3,bevacizumab;carboplatin;cisplatin;cyanocobalamin;folic acid;pemetrexed,Neoplasms,
637880243,rs712829,EGFR (PA7360),4,Efficacy,637880244; 637880245; 637880246,GG:Patients with the GG genotype may be less sensitive to treatment with erlotinib compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence drug sensitivity.; GT:Patients with the GT genotype may be more sensitive to treatment with erlotinib compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.; TT:Patients with the TT genotype may be more sensitive to treatment with erlotinib compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.,655386396,Genotypes TT + GT are associated with increased sensitivity when exposed to erlotinib as compared to genotype GG.,18652519,1,erlotinib,Neoplasms,
637880250,rs712829,EGFR (PA7360),4,Efficacy,637880251; 637880252; 637880253,GG:Cancer patients with genotype GG may be more likely to respond to topoisomerase I inhibitors compared to patients with genotypes GT or TT (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.; GT:Cancer patients with genotype GT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.; TT:Cancer patients with genotype TT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.,655386400,Genotypes TT + GT are associated with decreased sensitivity when treated with topoisomerase I inhibitors as compared to genotype GG.,18652519,1,topoisomerase I inhibitors,Neoplasms,
637880258,rs712829,EGFR (PA7360),4,Efficacy,637880259; 637880260; 637880261,GG:Patients with the genotype GG who are treated with geldanamycin may be more likely to respond as compared to patients with genotype GT or TT (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.; GT:Patients with the genotype GT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the genotype TT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.,655386399,Genotypes TT + GT are associated with decreased sensitivity when exposed to geldanamycin as compared to genotype GG.,18652519,1,geldanamycin,Neoplasms,
637880263,rs712829,EGFR (PA7360),4,Efficacy,637880264; 637880265; 637880266,GG:Cancer cells with the GG genotype may be more sensitive to Alkylating agents than are cells with genotype GT or TT. Other genetic and clinical factors may also influence tumor response to Alkylating agents.; GT:Cancer cells with the GT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.; TT:Cancer cells with the TT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.,655386403,Genotypes TT + GT are associated with decreased sensitivity when exposed to Alkylating Agents as compared to genotype GG.,18652519,1,Alkylating Agents,Neoplasms,
655386589,rs4646316,COMT (PA117),1B,Toxicity/ADR,655386590; 655386591; 655386592,"CC:Patients with the CC genotype and cancer who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.; CT:Patients with the CT genotype and cancer who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.; TT:Patients with the TT genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk of hearing loss as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.",655386573,Allele C is associated with increased risk of Deafness when treated with cisplatin in people with Neoplasms as compared to allele T.,19898482,1,cisplatin,Neoplasms,
655386601,rs9332377,COMT (PA117),1B,Toxicity/ADR,981478457; 981478458; 981478459,"CC:Patients with the CC genotype who are treated with cisplatin may have a decreased, but not absent, risk of hearing loss as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.; CT:Patients with the CT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.; TT:Patients with the TT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.",655386579,Allele T is associated with increased risk of Deafness when treated with cisplatin in people with Neoplasms as compared to allele C.,19898482,1,cisplatin,Neoplasms,
637880221,rs1695,GSTP1 (PA29028),2A,Toxicity/ADR,637880222; 637880223; 637880224,"AA:Patients with the AA genotype and cancer who are treated with platinum-based drugs may have the highest risk of toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; AG:Patients with the AG genotype and cancer who are treated with platinum-based drugs may have an increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GG:Patients with the GG genotype and cancer who are treated with platinum-based drugs may have a decreased, but not absent, risk of toxicity as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.",613979636; 637880107; 637880121; 637880210; 637880145,"Genotype AA is associated with increased risk of hematological toxicity when treated with Platinum compounds and taxanes in people with Ovarian Neoplasms as compared to genotypes GG + AG.; Genotype AA is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.; Genotype AA is associated with increased risk of disease progression when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.; Genotype AA is associated with increased likelihood of discontinuation of oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GG + AG.; Allele G is associated with decreased risk of Neutropenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.",19203783; 15213713; 15213713; 20530282; 17409936,5,Platinum compounds,Neoplasms,
981204912,rs1801133,MTHFR (PA245),2A,Toxicity/ADR,981204913; 981204914; 981204915,"AA:Patients with the AA genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. However, conflicting finding of no-association for this genotype has also been reported. Other genetic and clinical factors may also influence a patient's risk of toxicity to fluorouracil.; AG:Patients with the AG genotype may have increased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to fluorouracil.; GG:Patients with the GG genotype may have decreased risk of Drug Toxicity in cancer patients treated with fluorouracil-based therapy as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to fluorouracil.",827811335; 769245648; 769176384; 769176385,"Genotype GG is associated with decreased severity of Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotypes AA + AG.; Allele A is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele G.; Genotype AA is not associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.; Genotype AG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.",19384296; 20638924; 20819423; 20819423,4,fluorouracil,Neoplasms,
981204258,rs1045642,ABCB1 (PA267),3,Toxicity/ADR,981204259; 981204260; 981204261,AA:Patients with the AA genotype may have increased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype GG. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.; AG:Patients with the AG genotype may have increased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype GG. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.; GG:Patients with the GG genotype may have decreased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.,769169025; 769169021,Genotype AA is associated with increased risk of Neutropenia when treated with paclitaxel in people with Neoplasms as compared to genotype GG.; Genotype GG is associated with decreased risk of Neurotoxicity Syndromes when treated with paclitaxel in people with Neoplasms as compared to allele A.,16950614; 16950614,2,paclitaxel,Neoplasms;Neurotoxicity Syndromes;Neutropenia,
655386830,rs60369023,CDA (PA98),3,Toxicity/ADR,655386831; 655386832; 655386833,"AA:Patients with the AA genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.; AG:Patients with the AG genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity Neutropenia as compared to patients with the GG genotype, or 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.; GG:Patients with the GG genotype and cancer who are treated with gemcitabine 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.",655386824; 655386827; 655386814,Allele A is associated with decreased metabolism of gemcitabine in people with Neoplasms as compared to allele G.; Allele A is associated with increased severity of Neutropenia when treated with gemcitabine in people with Neoplasms as compared to allele G.; Genotype AA is associated with increased severity of Drug Toxicity when treated with cisplatin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype GG.,17194903; 17194903; 15814642,3,gemcitabine,Neoplasms;Neutropenia,Asian
655386612,rs2228001,XPC (PA37413),1B,Toxicity/ADR,981478446; 981478447; 981478448,"GG:Patients with the GG genotype may have an increased risk for toxicity with cisplatin treatment, including hearing loss and neutropenia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GT:Patients with the GT genotype may have an increased risk for toxicity with cisplatin treatment, including hearing loss and neutropenia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; TT:Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.",655386605; 769165283; 827695853; 827695864; 827695873,Allele G is associated with increased risk of Ototoxicity when treated with cisplatin in people with Osteosarcoma as compared to allele T.; Genotypes GG + GT are associated with increased risk of Neutropenia when treated with cisplatin in people with Urinary Bladder Neoplasms as compared to genotype TT.; Genotype GG is associated with increased risk of Neutropenia when treated with cisplatin in people with Urinary Bladder Neoplasms as compared to genotype TT.; Genotypes GG + GT are associated with increased risk of Drug Toxicity when treated with cisplatin in people with Urinary Bladder Neoplasms as compared to genotype TT.; Genotype GG is associated with increased risk of Drug Toxicity when treated with cisplatin in people with Urinary Bladder Neoplasms as compared to genotype TT.,19434073; 21047201; 21047201; 21047201; 21047201,5,cisplatin,Neoplasms;Osteosarcoma;Urinary Bladder Neoplasms,
981345285,rs25487,XRCC1 (PA369),3,Efficacy;Toxicity/ADR,981345286; 981345287; 981345288,"CC:Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.; CT:Patients with the CT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.; TT:Patients with the TT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.",655386624; 827828058; 827828072; 827828226,Genotype CC is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes TT + CT.; Genotypes CC + CT are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.; Genotypes CT + TT are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.; Genotypes CT + TT are associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.,19786980; 22188361; 22188361; 22188361,4,cyclophosphamide,Neoplasms;Ovarian Neoplasms,White
655386661,rs3212986,ERCC1 (PA155),2B,Toxicity/ADR,655386662; 655386663; 655386664,AA:Patients with the AA genotype may have decreased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.; AC:Patients with the AC genotype may have increased risk for nephrotoxicity with platinum-based regimens as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.; CC:Patients with the CC genotype may have increased risk for nephrotoxicity with platinum-based regimens as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.,827816070; 827826211; 655386628,Genotype AA is associated with decreased likelihood of nephrotoxicity when treated with cisplatin in people with Neoplasms as compared to genotypes AC + CC.; Genotypes AA + AC are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.; Genotype AC is associated with increased risk of nephrotoxicity when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms.,21902499; 22188361; 19786980,3,cisplatin;platinum;Platinum compounds,Neoplasms;Ovarian Neoplasms,White
981204995,rs1799793,ERCC2 (PA27848),3,Efficacy;Toxicity/ADR,981204996; 981204997; 981204998,CC:Patients with the CC genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of overall survival as compared to patients with the CT genotype. This has been contradicted in another studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide.; CT:Patients with the CT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of overall survival as compared to patients with the CC genotype. Genotype CT is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide. Both findings have been contradicted in another studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide.; TT:Genotype TT is not associated with increased risk of Drug Toxicity or decreased progression-free or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.,655386620; 827827919; 827827949; 827828246,Genotype CT is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms.; Genotypes CT + TT are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.; Genotypes CT + TT are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.; Genotype CT is associated with increased likelihood of overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.,19786980; 22188361; 22188361; 22188361,4,cisplatin;cyclophosphamide,Ovarian Neoplasms,
981238332,rs1695,GSTP1 (PA29028),3,Efficacy,981238333; 981238334; 981238335,AA:Patients with the AA genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased progression free survival as compared to patients with the AG and GG genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide.; AG:Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide.; GG:Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide.,655386344; 827824994,Genotype AA is associated with increased progression free survival when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes GG + AG.; Genotype AA is not associated with increased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotypes AG + GG.,19786980; 22188361,2,cisplatin;cyclophosphamide,Ovarian Neoplasms,
981237930,rs11615,ERCC1 (PA155),3,Toxicity/ADR,981237931; 981237932; 981237933,"AA:Genotype AA is not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide as compared to genotypes AG and GG. Please note, patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.No result; AG:Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.; GG:Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the AG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.",655386332; 827826160,Genotype AG is associated with increased risk of nephrotoxicity when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotype GG.; Genotypes AG + GG are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype AA.,19786980; 22188361,2,cisplatin;cyclophosphamide,Ovarian Neoplasms,
655386665,rs3212986,"CD3EAP (PA142672156),ERCC1 (PA155),PPP1R13L (PA34195)",3,Efficacy,655386666; 655386667; 655386668,AA:Patients with the AA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.; AC:Patients with the CA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.; CC:Patients with the CC genotype and ovarian cancer who are treated with platinum compounds may have increased survival as compared to patients with the CA or AA genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.,613979640,Genotype CC is associated with increased survival when treated with Platinum compounds in people with Ovarian Neoplasms as compared to genotypes AA + CA.,19203783,1,Platinum compounds,Ovarian Neoplasms,Asian
637880014,rs2032582,ABCB1 (PA267),3,Toxicity/ADR,637880016; 637880015; 637880017,"AC:Patients with the AC genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.; CC:Patients with the CC genotype may have decreased but not non-existent risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CA, CT, AA or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.; CT:Patients with the CT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.",613979632,Genotype CC is associated with decreased risk of grade 3 or 4 gastrointestinal toxicity when treated with platinum and taxanes in people with Ovarian Neoplasms.,19203783,1,Platinum compounds;taxanes,Ovarian Neoplasms,Asian
655384474,rs2032582,ABCB1 (PA267),3,Toxicity/ADR,655384478; 655384480; 655384476,"AA:Patients with the AA genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.; AT:Patients with the AT genotype and cancer who are treated with taxanes and platinum therapy may have a decreased, but not absent, risk for gastrointestinal toxicity as compared to patients with the CA and AA genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxanes and platinum therapy.; TT:Patients with the TT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.",613979632,Genotype CC is associated with decreased risk of grade 3 or 4 gastrointestinal toxicity when treated with platinum and taxanes in people with Ovarian Neoplasms.,19203783,1,Platinum compounds;taxanes,Ovarian Neoplasms,Asian
981237950,rs1695,GSTP1 (PA29028),3,Efficacy,981237951; 981237952; 981237953,"AA:Patients with the AA genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression free survival as compared to patients with the AG and GG genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.; AG:Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.; GG:Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.",655386344; 827824994,Genotype AA is associated with increased progression free survival when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes GG + AG.; Genotype AA is not associated with increased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotypes AG + GG.,19786980; 22188361,2,cisplatin;cyclophosphamide,Ovarian Neoplasms,
981238562,rs1051266,SLC19A1 (PA327),3,Efficacy;Toxicity/ADR,981238563; 981238564; 981238565,"CC:Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) increased likelihood of Toxic liver disease 2) decreased, but not absent, risk of Drug Toxicity 3) decreased likelihood of treatment interruptions as compared to patients with the CT and TT genotype. Further, patients with the CC genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patient's response to leucovorin, mercaptopurine and methotrexate.; CT:Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) decreased, but not absent, risk of Toxic liver disease 2) increased risk of Drug Toxicity 3) increased likelihood of treatment interruptions as compared to patients with the CC genotype. Further, patients with the CT genotype may have 4) decreased likelihood of Myelosuppression and 5) decreased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the TT genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patient's response to leucovorin, mercaptopurine and methotrexate.; TT:Patients with the TT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with mercaptopurine and methotrexate or leucovorin, mercaptopurine and methotrexate may have 1) decreased, but not absent, risk of Toxic liver disease 2) increased risk of Drug Toxicity 3) increased likelihood of treatment interruptions as compared to patients with the CC genotype. Further, patients with the TT genotype may have 4) increased likelihood of Myelosuppression and 5) increased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate as compared to patients with the CT and CC genotype. However, contradictory findings (association with drug toxicity) have been reported. Other genetic and clinical factors may influence a patient's response to leucovorin, mercaptopurine and methotrexate.",769171135; 769171002; 769171125; 769171132; 769170677; 769171074; 978639812,"Genotype CC is associated with increased likelihood of Toxic liver disease when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes TT + CT.; Allele T is not associated with Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotype TT is associated with increased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.; Genotype TT is associated with increased likelihood of Myelosuppression when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.; Genotypes TT + CT are associated with increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.; Genotypes TT + CT are associated with increased likelihood of Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.; Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.",20335220; 17323057; 20335220; 20335220; 18458567; 17264302; 22838948,7,leucovorin;mercaptopurine;methotrexate,Precursor Cell Lymphoblastic Leukemia-Lymphoma,
655385466,rs7992226,NALCN (PA162396840),3,Other,655385467; 655385468; 655385469,AA:Patients with the AA genotype and childhood acute lymphoblastic leukemia (ALL) may have reduced exposure to methotrexate and higher likelihood of minimal residual disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate.; AG:Patients with the AG genotype and childhood acute lymphoblastic leukemia (ALL) may have increased exposure to methotrexate and lower likelihood of minimal residual disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.; GG:Patients with the GG genotype and childhood acute lymphoblastic leukemia (ALL) may have increased exposure to methotrexate and lower likelihood of minimal residual disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.,622888380,Allele A is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.,19176441,1,methotrexate,Precursor Cell Lymphoblastic Leukemia-Lymphoma,
655385471,rs10821936,ARID5B (PA134943193),3,Other,655385472; 655385473; 655385474,CC:Pediatric patients with the CC genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.; CT:Pediatric patients with the CT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.; TT:Pediatric patients with the TT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have lower methotrexate polyglutamate accumulation as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.,637879601,Allele C is associated with greater methotrexate polyglutamate accumulation in people with B-hyperdiploid subtype of Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.,19684603,1,methotrexate,Precursor Cell Lymphoblastic Leukemia-Lymphoma,White
655387938,rs4149081,SLCO1B1 (PA134865839),3,Toxicity/ADR,655387939; 655387940; 655387941,"AA:Patients with the AA genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the AG or GG genotype 2) may have a decreased, but not absent, risk of GI toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.; AG:Patients with the AG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the AA genotype 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.; GG:Patients with the GG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the AA genotype 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.",655387918; 655387922; 655387925,Allele G is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Allele G is associated with increased risk of GI toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.; Allele G is associated with clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.,19901119; 19901119; 19901119,3,methotrexate,Precursor Cell Lymphoblastic Leukemia-Lymphoma,
655387942,rs11045879,SLCO1B1 (PA134865839),3,Toxicity/ADR,655387943; 655387944; 655387945,"CC:Patients with the CC genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the CT or TT genotype 2) may have a decreased, but not absent, risk for GI toxicity (mucositis) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity when treated with methotrexate.; CT:Patients with the CT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the CC genotype 2) may have an increased risk for GI toxicity (mucositis) when treated with methotrexate as compared to patients with the CC genotype.; TT:Patients with the TT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the CC genotype 2) may have an increased risk for GI toxicity (mucositis) when treated with methotrexate as compared to patients with the CC genotype.",655387928; 655387932; 655387935,Allele T is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.; Allele T is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.; Allele T is associated with increased risk of gastrointestinal toxicity (mucositis) when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.,19901119; 19901119; 19901119,3,methotrexate,Precursor Cell Lymphoblastic Leukemia-Lymphoma,
655387949,rs4149056,SLCO1B1 (PA134865839),3,Other,655387950; 655387951; 655387952,CC:Patients with the CC genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the TT genotype 2) may not require additional monitoring as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; CT:Patients with the CT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the TT genotype 2) may not require additional monitoring as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; TT:Patients with the TT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the CT or CC genotype 2) may require additional monitoring as compared to patients with the CT or CC genotype.,655387946,Allele C is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.,19901119,1,methotrexate,Precursor Cell Lymphoblastic Leukemia-Lymphoma,
637879869,rs11545078,GGH (PA432),3,Toxicity/ADR,637879870; 637879871; 637879872,AA:Patients with the AA genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.; AG:Patients with the AG genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.; GG:Patients with the GG genotype who are treated with methotrexate: 1) may have reduced accumulation of active methotrexate metabolites 2) may have a decreased risk for thrombocytopenia as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.,637879857; 769173745,Allele A is associated with decreased clearance of methotrexate.; Allele A is associated with increased likelihood of Thrombocytopenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.,15284538; 16999998,2,methotrexate,Precursor Cell Lymphoblastic Leukemia-Lymphoma,
652595205,rs10836235,CAT (PA26099),3,Toxicity/ADR,652595206; 652595207; 652595209,CC:Patients with the CC genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; CT:Patients with the CT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the CT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; TT:Patients with the TT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the TT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.,655387557,Genotype CC is associated with increased risk of cardiac damage when treated with anthracyclines and related substances in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes TT + CT.,19863340,1,anthracyclines and related substances,Precursor Cell Lymphoblastic Leukemia-Lymphoma,White
827848732,rs9344,CCND1 (PA75),3,Efficacy;Toxicity/ADR,827848733; 827848734; 827848735,"AA:Patients with the AA genotype may have 1) decreased but not absent risk for drug toxicity 2) decreased event free survival when treated with methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to methotrexate, particularly rs34743033.; AG:Patients with the AG genotype may have 1) increased risk for drug toxicity 2) increased event free survival when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate, particularly rs34743033.; GG:Patients with the GG genotype may have 1) increased risk for drug toxicity 2) increased event free survival when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate, particularly rs34743033.",769171028; 769171268,Genotype AA is associated with decreased severity of Drug Toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + AG.; Genotype AA is associated with decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + AG.,16870553; 12972956,2,methotrexate,Precursor Cell Lymphoblastic Leukemia-Lymphoma,White
827847738,rs9895420,ABCC3 (PA376),3,Efficacy;Toxicity/ADR,827847739; 827847740; 827847741,"AA:Patients with the AA genotype may have 1) decreased event free survival 2) increased risk of central nervous system relapse 3) decreased risk of thrombocytopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; AT:Patients with the AT genotype may have 1) decreased event free survival 2) increased risk of central nervous system relapse 3) decreased risk of thrombocytopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.; TT:Patients with the TT genotype may have 1) increased event free survival 2) decreased, but not non-existent, risk of central nervous system relapse 3) increased risk of thrombocytopenia when treated with methotrexate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence a patient's response to methotrexate.",827573981; 827573986; 827573991; 827573996,Genotypes AA + AT are associated with decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.; Genotypes AA + AT are associated with increased plasma levels of in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.; Genotypes AA + AT are associated with increased risk of relapse in the central nervous system when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.; Genotypes AA + AT are associated with decreased likelihood of Thrombocytopenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.,21606946; 21606946; 21606946; 21606946,4,methotrexate,Precursor Cell Lymphoblastic Leukemia-Lymphoma,White
981201387,rs2236225,MTHFD1 (PA31236),3,Efficacy,981201388; 981201389; 981201390,AA:Patients with the AA genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for response to therapy.; AG:Patients with the AG genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for response to therapy.; GG:Patients with the GG genotype may have increased event free survival when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for response to therapy.,608431578; 769174305,Allele A is associated with decreased likelihood of event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; Allele A is not associated with catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.,14647408; 15797993,2,methotrexate,Precursor Cell Lymphoblastic Leukemia-Lymphoma,White
981238370,rs1979277,SHMT1 (PA35753),3,Toxicity/ADR,981481601; 981481602; 981481603,"AA:Pediatric patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased catalytic activity of TYMS as compared to pediatric patients with the AG and GG genotype. Patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.; AG:Pediatric patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Toxic liver disease as compared to patients with the AA and GG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.; GG:Pediatric patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.",769174314; 769170716; 978639846,Genotype AA is associated with increased catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.; Genotype AG is associated with decreased likelihood of Toxic liver disease when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + GG.; Allele A is not associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.,15797993; 18368069; 22838948,3,methotrexate,Precursor Cell Lymphoblastic Leukemia-Lymphoma,
981204975,rs1801133,MTHFR (PA245),3,Toxicity/ADR,981204976; 981204977; 981204978,"AA:Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.; AG:Patients with the AG genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.; GG:Patients with the GG genotype may have decreased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype AA or AG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.",978639856; 769171000; 769170674,Allele A is not associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; Allele A is not associated with Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotypes AA + AG are associated with increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.,22838948; 17323057; 18458567,3,mercaptopurine,Precursor Cell Lymphoblastic Leukemia-Lymphoma,
981238397,rs1695,GSTP1 (PA29028),3,Toxicity/ADR,981238398; 981238399; 981238400,AA:Patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Drug Toxicity as compared to patients with the GG genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.; AG:Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Drug Toxicity as compared to patients with the GG genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.; GG:Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased likelihood of Drug Toxicity as compared to patients with the AG and AA genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.,769171104; 769171080,Allele G is not associated with toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotype GG is associated with increased likelihood of Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.,17180579; 17264302,2,methotrexate,Precursor Cell Lymphoblastic Leukemia-Lymphoma,
981202393,rs1801394,MTRR (PA31277),2B,Toxicity/ADR,981478307; 981478308; 981478309,"AA:Pediatric ALL patients with AA genotypes may have decreased likelihood of methotrexate induced toxicity (oral mucositis) and decreased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the GG and AG genotype. Other genetic and clinical factors may also influence response to methotrexate.; AG:Pediatric ALL patients with AG genotypes may have increased likelihood of methotrexate induced toxicity (oral mucositis), increased speed of platelet recovery and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate.; GG:Pediatric ALL patients with GG genotypes may have increased likelihood of methotrexate induced toxicity (oral mucositis) and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate.",981202405; 769170712; 769173709; 769174311,Genotypes AG + GG are associated with increased likelihood of MTX induced toxicity (oral mucositis) when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotype AG is associated with increased speed of platelet recovery when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + GG.; Allele G is not associated with decreased IQ when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotypes GG + AG are associated with increased catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.,18368069; 18368069; 16013960; 15797993,4,methotrexate,Precursor Cell Lymphoblastic Leukemia-Lymphoma,
655386093,rs7769719,PPARD (PA33557),3,Efficacy,655386094; 655386095; 655386096,AA:Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.,655388209,Allele G is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
655386099,rs730720,CHST3 (PA26503),3,Efficacy,655386100; 655386101; 655386102,CC:Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.,699638963,Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
655386104,rs6922548,PPARD (PA33557),3,Efficacy,655386105; 655386106; 655386107,AA:Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.,655388206,Allele G is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
655386109,rs4646487,CYP4B1 (PA27119),3,Toxicity/ADR,655386110; 655386111; 655386112,CC:Patients with the CC genotype may have a decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.,655388200,Allele T is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
655386114,rs4148950,CHST3 (PA26503),3,Efficacy;Toxicity/ADR,655386115; 655386116; 655386117,AA:Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.,699638968; 699638971,Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.; Allele A is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.,20038957; 20038957,2,docetaxel;thalidomide,Prostatic Neoplasms,
655386120,rs4148947,CHST3 (PA26503),3,Efficacy,655386121; 655386122; 655386123,CC:Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.,699638975,Allele T is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
655386126,rs4148945,CHST3 (PA26503),3,Efficacy;Toxicity/ADR,655386127; 655386128; 655386129,CC:Patients with the CC genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.,655388257; 655388260,Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.; Allele C is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.,20038957; 20038957,2,docetaxel;thalidomide,Prostatic Neoplasms,
655386131,rs4148943,CHST3 (PA26503),3,Efficacy,655386132; 655386133; 655386134,CC:Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.,655388254,Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
655386136,rs3734254,PPARD (PA33557),3,Efficacy,655386137; 655386138; 655386139,CC:Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.,655388251,Allele T is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
655386141,rs2301159,SLC10A2 (PA318),3,Toxicity/ADR,655386142; 655386143; 655386144,AA:Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.,655388248,Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
655386146,rs2292954,SPG7 (PA36067),3,Toxicity/ADR,655386147; 655386148; 655386149,AA:Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.,655388245,Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
655386151,rs2238472,ABCC6 (PA58),3,Toxicity/ADR,655386152; 655386153; 655386154,CC:Patients with the CC genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.,655388242,Allele C is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
655386156,rs2227291,ATP7A (PA72),3,Toxicity/ADR,655386157; 655386158; 655386159,CC:Patients with the CC genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.; CG:Patients with the CG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.,655388239,Allele G is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
655386161,rs2016520,PPARD (PA33557),3,Efficacy,655386162; 655386163; 655386164,CC:Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.,655388236,Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
655386166,rs1883322,PPARD (PA33557),3,Efficacy,655386167; 655386168; 655386169,CC:Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; CT:Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.; TT:Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.,655388213,Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
655386171,rs1871450,CHST3 (PA26503),3,Efficacy;Toxicity/ADR,655386172; 655386173; 655386174,AA:Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.,655388228; 655388232,Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.; Allele A is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.,20038957; 20038957,2,docetaxel;thalidomide,Prostatic Neoplasms,
655386176,rs1799931,NAT2 (PA18),3,Toxicity/ADR,655386177; 655386178; 655386179,AA:Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.,655388223,Allele G is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
655386181,rs1402467,SULT1C4 (PA162405070),3,Efficacy,655386182; 655386183; 655386184,CC:Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.; CG:Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.,655388203,Allele G is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
655386186,rs12960,"RPL13 (PA34670),SNORD68 (PA145007789),SPG7 (PA36067)",3,Toxicity/ADR,655386187; 655386188; 655386189,AA:Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.,655388219,Allele G is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
655386191,rs12418,CHST3 (PA26503),3,Efficacy,655386192; 655386193; 655386194,AA:Patients with the AA genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; AG:Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.; GG:Patients with the GG genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.,655388216,Allele A is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.,20038957,1,docetaxel;thalidomide,Prostatic Neoplasms,
769171387,rs1695,GSTP1 (PA29028),3,Toxicity/ADR,769171388; 769171389; 769171390,"AA:Patients with the AA genotype and cancer who are treated with fluorouracil may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.; AG:Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.; GG:Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to flourouracil.",769171384,Genotype GG is associated with decreased risk of haematological toxicity when exposed to fluorouracil in people with Rectal Neoplasms as compared to genotype AA.,18540691,1,fluorouracil,Rectal Neoplasms,White
981204746,rs1801131,MTHFR (PA245),3,Toxicity/ADR,981204747; 981204748; 981204749,GG:Patients with the GG genotype may have decreased risk of Drug Toxicity when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.; GT:Patients with the GT genotype may have decreased risk of Drug Toxicity when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.; TT:Patients with the TT genotype may have increased risk of Drug Toxicity when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence a patients risk of toxicity to fluorouracil.,827783261,Genotype TT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Rectal Neoplasms as compared to genotypes GG + GT.,22045187,1,fluorouracil,Rectal Neoplasms,
981238570,rs1050828,G6PD (PA28469),3,Toxicity/ADR,981238571; 981238572; 981238573,"CC:Pediatric patients with the CC genotype may have decreased, but not absent, risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.; CT:Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.; TT:Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.",827793071; 827793083,"Genotype TT is associated with increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine in children as compared to genotype CC.; Genotype CT is associated with increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine in children as compared to genotype CC.",20194698; 20194698,2,artesunate;primaquine;pyrimethamine;sulfadoxine,,Black or African American
655387745,rs11188072,CYP2C19 (PA124),3,Dosage,655387746; 655387747; 655387748,"CC:Patients with the CC genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.; CT:Patients with the CT genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.; TT:Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.",655387714,Genotype TT is associated with increased metabolism of mephenytoin in people with no disease as compared to genotype CC.,16413245,1,mephenytoin,,Black or African American
655385579,rs2070744,NOS3 (PA254),3,Efficacy,655385580; 655385581; 655385582,"CC:Patients with the CC genotype who are treated with antihypertensive drugs may have an increased risk for resistance as compared to patients with the CT or TT genotype.; CT:Patients with the CT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistance.; TT:Patients with the TT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistance.",769164961; 699638662,Allele C is associated with increased likelihood of response when treated with Antihypertensives in people with Pre-Eclampsia as compared to allele T.; Genotype CC is associated with increased risk of resistant hypertension when treated with Antihypertensives and diuretics in people with Hypertension as compared to genotypes TT + CT.,19704415; 19650939,2,Antihypertensives And Diuretics In Combination,,White
655385604,rs762551,CYP1A2 (PA27093),3,Efficacy,655385605; 655385606; 655385607,AA:Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have decreased response to olanzapine based on decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.; AC:Patients with the AC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.; CC:Patients with the CC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.,655385601,Genotype AA is associated with decreased mean dose-/body weight-normalized serum concentrations when treated with olanzapine in people with psychiatric disorders as compared to allele C.,19636338,1,olanzapine,,White
655385613,rs7997012,HTR2A (PA193),3,Toxicity/ADR,655385614; 655385615; 655385616,"AA:Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have an increased risk for more side effects as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.; AG:Patients with the AG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.; GG:Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.",655385610,Genotype AA is associated with increased risk of side effects when treated with olanzapine in people with psychiatric disorders as compared to allele G.,19636338,1,olanzapine,,White
655386028,rs1045642,ABCB1 (PA267),3,Dosage,655386029; 655386030; 655386031,AA:Healthy individuals with the AA genotype who are treated with fexofenadine may have lower plasma drug levels as compared to healthy individuals with the AG or GG genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.; AG:Healthy individuals with the AG genotype who are treated with fexofenadine may have higher plasma drug levels as compared to healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.; GG:Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.,655386010; 655386021,Genotype AA is not associated with plasma concentration of fexofenadine in people with no disease (healthy volunteers) as compared to genotype GG.; Genotype AA is associated with decreased plasma concentration of fexofenadine in people with no disease (healthy volunteers) as compared to genotypes GG + AG.,11994059; 11503014,2,fexofenadine,,White
655387257,rs7799039,LEP (PA228),3,Toxicity/ADR,655387258; 655387259; 655387260,AA:Patients with the AA genotype may have excessive risperidone-associated weight gain in youths as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; AG:Patients with the AG genotype may have excessive risperidone-associated weight gain in youths as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GG:Patients with the GG genotype may less likely to be overweight/obese in risperidone treated youth as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,655387253,Allele A is associated with increased likelihood of wight gain when treated with risperidone as compared to genotype GG.,19873684,1,risperidone,,
655387672,rs1799978,DRD2 (PA27478),3,Toxicity/ADR,655387673; 655387674; 655387675,"CC:Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; CT:Patients with the CT genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; TT:Patients with the TT genotype may have decreased but not absent, risk of Hyperprolactinemia when treated with risperidone as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.",655387669,Allele C is associated with increased risk of Hyperprolactinemia when treated with risperidone as compared to allele T.,19339912,1,risperidone,,White
655387767,rs12248560,CYP2C19 (PA124),3,Dosage,655387768; 655387769; 655387770,"CC:Patients with the CC genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.; CT:Patients with the CT genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.; TT:Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.",655387719,Genotype TT is associated with increased metabolism of mephenytoin in people with no disease as compared to genotype CC.,16413245,1,mephenytoin,,Black or African American
655387835,rs1801133,MTHFR (PA245),3,Toxicity/ADR,655387836; 655387837; 655387838,AA:Patients with the AA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.; AG:Patients with the GA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.; GG:Patients with the GG genotype who undergo elective surgery with nitrous oxide anesthesia may have lower plasma total homocysteine concentrations as compared to patients with the GA of AA genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.,655387832,Genotype AA is associated with higher plasma total homocysteine concentrations after nitrous oxide anesthesia when exposed to nitrous oxide in people with surgery as compared to genotype GG.,18580170,1,nitrous oxide,,
655387839,rs1801131,MTHFR (PA245),3,Toxicity/ADR,655387840; 655387841; 655387842,GG:Patients with the GG genotype may have higher homocysteine levels after nitrous oxide anesthesia as compared to patients with the TG and TT genotype.Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.; GT:Patients with the TG genotype may have lower homocysteine levels after nitrous oxide anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.; TT:Patients with the TT genotype may have lower homocysteine levels after nitrous oxide anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.,655387829,Genotype GG is associated with higher plasma total homocysteine concentrations after nitrous oxide anesthesia when exposed to nitrous oxide in people with surgery as compared to genotype TT.,18580170,1,nitrous oxide,,
699639249,rs776746,"CYP3A (PA27114),CYP3A5 (PA131)",3,Toxicity/ADR,699639250; 699639251; 699639252,CC:Patients with the CC genotype may have decreased but not absent risk of neurotoxicity when treated with paclitaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.; CT:Patients with the CT genotype may have decreased but not absent risk of neurotoxicity when treated with paclitaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.; TT:Patients with the TT genotype may have an increased risk of neurotoxicity when treated with paclitaxel as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.,655387903,Allele C is associated with decreased risk of neurotoxicity when treated with paclitaxel in people with Neoplasms as compared to allele T.,20212519,1,paclitaxel,,
699639328,rs1113129,CYP2C8 (PA125),3,Toxicity/ADR,699639329; 699639330; 699639331,CC:Patients with the CC genotype may have increased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; CG:Patients with the CG genotype may have decreased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GG:Patients with the GG genotype may have decreased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,655388360,Allele G is associated with decreased risk of neurotoxicity when treated with paclitaxel in people with Neoplasms as compared to allele C.,20212519,1,paclitaxel,,
769143802,rs4343,ACE (PA139),3,Efficacy,769143803; 769143804; 769143805,"AA:Patients with the AA genotype is associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.; AG:Patients with the AG genotype is associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.; GG:Patients with the GG genotype may have less improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response.",699638681,"Genotypes AA + AG are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume when treated with spironolactone in people with chronic heart failure as compared to genotype GG.",15121491,1,spironolactone,,
613976848,rs750332,"BAT2 (PA25263),BAT3 (PA25264)",3,Toxicity/ADR,613976849; 613976850; 613976851,"CC:Patients with the CC genotype who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.; CT:Patients with the CT genotype who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.; TT:Patients with the TT genotype who are treated with carbamazepine may have a decreased, but not absent, risk of Stevens-Johnson syndrome as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.",613976809,Allele C is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine as compared to allele T.,16538176,1,carbamazepine,,Asian
637879785,rs2292566,EPHX1 (PA27829),3,Dosage,637879786; 637879787; 637879788,AA:Patients with the AA genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.; AG:Patients with the AG genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.; GG:Patients with the GG genotype may require a higher dose of warfarin than patients with the AA or AG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.,608431768; 827690618,Allele A is associated with decreased dose of warfarin.; Allele A is not associated with dose of warfarin.,19794411; 21593757,2,warfarin,,White
655384616,rs17238540,HMGCR (PA189),3,Efficacy,655384620; 655384619; 655384618,GG:Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.; GT:Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.; TT:Patients with the TT genotype who are treated with statins may be more likely to reach target LDL levels as compared to patients with the GT and GG genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.,699639067; 769152897; 699638678; 699638985; 699639070; 699638688; 827925965,"Allele G is not associated with response to pravastatin as compared to genotype TT.; Allele G is not associated with response to pravastatin in people with Vascular Diseases as compared to allele T.; Genotype GT is associated with decreased reduction in LDL when exposed to pravastatin as compared to genotype TT.; Genotype GT is associated with decreased likelihood of reaching target cholesterol levels when treated with atorvastatin, cerivastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin in people with Diabetes Mellitus as compared to genotype TT.; Allele T is not associated with response to fluvastatin in people with renal tranplantation as compared to allele G.; Genotype TT is associated with increased reduction of LDL cholesterol when treated with simvastatin as compared to genotypes GG + GT.; Genotype GT is associated with decreased reduction in total cholesterol when treated with pravastatin as compared to genotype TT.",16103896; 18261733; 15199031; 18815589; 17563401; 18332269; 15199031,7,atorvastatin;fluvastatin;hmg coa reductase inhibitors;lovastatin;pravastatin;simvastatin,,
655384645,rs4149056,SLCO1B1 (PA134865839),3,Efficacy,655384646; 655384647; 655384648,CC:Patients with the CC genotype may have increased mean plasma AUC of repaglinide and greater blood glucose-lowering effect in response to repaglinide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.; CT:Patients with the CT genotype may have decreased mean plasma AUC of repaglinide and lower blood glucose-lowering effect in response to repaglinide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.; TT:Patients with the TT genotype may have decreased mean plasma AUC of repaglinide and lower blood glucose-lowering effect in response to repaglinide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.,747790540,Genotype CC is associated with increased mean plasma AUC of repaglinide as compared to genotypes CT + TT.,18187595,1,repaglinide,,White
655384653,rs10509681,CYP2C8 (PA125),3,Dosage,655384654; 655384655; 655384656,"CC:Patients with the CC genotype (CYP2C8*3/*3) may have increased metabolism of rosiglitazone compared to patients with the TT genotype (CYP2C8*1/*1), but this is not associated with differences in blood glucose lowering efficacy compared to patients with the TT genotype. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of rosiglitazone and blood glucose levels.; CT:Patients with the CT (CYP2C8*3/*1) genotype may have increased metabolism of rosiglitazone compared to patients with the TT genotype (CYP2C8*1/*1), or may have decreased metabolism of rosiglitazone compared to patients with the CC genotype (CYP2C8*3/*3). This is not associated with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of rosiglitazone and blood glucose levels.; TT:Patients with the TT (CYP2C8*1/*1) genotype may have decreased metabolism of rosiglitazone compared to patients with the CC genotype (CYP2C8*3/*3), but this is not associated with differences in blood glucose lowering efficacy compared to patients with the CC genotype. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of rosiglitazone and blood glucose levels.",655387147; 655387153,Allele C is associated with increased metabolism of rosiglitazone in people with no disease as compared to allele T.; Allele C is not associated with glucose lowering when treated with rosiglitazone in people with no disease as compared to allele T.,17178266; 17178266,2,rosiglitazone,,White
655384679,rs20417,PTGS2 (PA293),3,Efficacy,655384681; 655384682; 655384683,CC:Patients with the CC genotype may have better pain relief response to rofecoxib as compared to patients with GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.; CG:Patients with the CG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.; GG:Patients with the GG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.,699638652,Genotype CC is associated with increased pain relief when treated with rofecoxib as compared to genotypes GG + CG.,16678543,1,rofecoxib,,White
655384724,rs4086116,CYP2C9 (PA126),3,Dosage,655384728; 655384727; 655384726,CC:Patients with the CC genotype may require an increased dose of acenocoumarol as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence acenocoumarol dose.; CT:Patients with the CT genotype may require a lower dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.; TT:Patients with the TT genotype may require the lowest dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.,769146304,Allele T is associated with decreased dose of acenocoumarol as compared to allele C.,19578179,1,acenocoumarol,,White
655384738,rs17708472,VKORC1 (PA133787052),3,Dosage,655384740; 655384741; 655384742,AA:Patients with the AA genotype: 1) may require a higher dose of warfarin as compared to patients with the GG genotype 2) may have an increased risk of warfarin resistance as compared to patients with the GG genotype.; AG:Patients with the AG genotype: 1) may require a higher dose of warfarin as compared to patients with the GG genotype 2) may have an increased risk of warfarin resistance as compared to patients with the GG genotype.; GG:Patients with the GG genotype: 1) may require a lower dose of warfarin as compared to patients with the AG and AA genotype 2) may have a decreased risk of warfarin resistance as compared to patients with the AA genotype. Patients with the GG genotype may still be at risk for warfarin resistance based on their genotype. Other genetic and clinical factors may also influence a patient's response to warfarin.,769146206,Genotype AA is associated with increased dose of warfarin.,18781852,1,warfarin,,
655384821,rs2306283,SLCO1B1 (PA134865839),3,Other,655384824; 655384823; 655384822,"AA:Patients with the AA genotype may have higher plasma concentrations of repaglinide in people with no health problems compared to GG genotype. Other genetic and clinical factors may also influence a patient's response.; AG:While the GG genotype is associated with reduced plasma concentrations of repaglinide, no results are shown for the GA genotype.; GG:Patients with the GG genotype may have reduced plasma concentrations of repaglinide and higher blood glucose concentrations after repaglinide intake in people with no health problems compared to AA genotype. Other genetic and clinical factors may also influence a patient's response.",827831546,Genotype GG is associated with decreased repaglinide plasma concentration (AUC) and Cmax when exposed to repaglinide in healthy individuals as compared to genotype AA.,18854776,1,repaglinide,,White
655384914,rs3775291,TLR3 (PA36551),3,Efficacy,655384915; 655384916; 655384917,CC:Children with the CC genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.; CT:Children with the CT genotype may have a decreased response to measles vaccination as compared to patients with the CC and TT genotype. Other genetic and clinical factors may also influence response to measles vaccination.; TT:Children with the TT genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.,608431157,Genotype TC is associated with decreased response to Measles vaccines as compared to genotype CC.,18325643,1,Measles vaccines,,White
655385016,rs10871454,STX4 (PA36236),3,Dosage,655385019; 655385018; 655385017,CC:Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CT or TT genotype.; CT:Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype.; TT:Patients with the TT genotype who are treated with warfarin may require the lowest dose as compared to patients with the CT or CC genotype.,608431827,Allele T is associated with decreased dose of warfarin.,18535201,1,warfarin,,White
655385024,rs2359612,"PRSS53 (PA165450635),VKORC1 (PA133787052)",3,Dosage,655385025; 655385026; 655385027,AA:Patients with the AA genotype who are treated with warfarin may require the lowest dose as compared to patients with the AG or GG genotype.; AG:Patients with the AG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype.; GG:Patients with the GG genotype who are treated with warfarin may require a higher dose as compared to patients with the AG or AA genotype.,613977249,Allele A is associated with decreased dose of warfarin.,16270629,1,warfarin,,
655385028,rs8050894,"PRSS53 (PA165450635),VKORC1 (PA133787052)",3,Dosage,655385032; 655385031; 655385030,CC:Patients with the CC genotype who are treated with warfarin may require a higher dose as compared to patients with the CG or GG genotype.; CG:Patients with the CG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype.; GG:Patients with the GG genotype who are treated with warfarin may require the lowest dose as compared to patients with the CG or CC genotype.,769160740,Allele G is associated with decreased dose of warfarin.,16270629,1,warfarin,,
655385041,rs2306283,SLCO1B1 (PA134865839),3,Efficacy,655385044; 655385043; 655385042,AA:Patients with the AA genotype may have increased plasma AUC of pravastatin as compared to patients with the AG or GG genotype.; AG:Patients with the AG genotype may have decreased plasma AUC of pravastatin as compared to patients with the AA genotype.; GG:Patients with the GG genotype may have decreased plasma AUC of pravastatin as compared to patients with the AA genotype.,613977375,Allele G is associated with decreased plasma AUC of pravastatin.,15116054,1,pravastatin,,White
655385144,rs2273697,ABCC2 (PA116),3,,655385146; 655385147; 655385148,AA:People with the AA genotype may have increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol as compared to people with GG genotype. Other genetic and clinical factors may also influence the clearance of talinolol.; AG:People with the AG genotype may have increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol as compared to people with the GG genotype. Other genetic and clinical factors may also influence the clearance of talinolol.; GG:People with the GG genotype may have higher bioavailablilty of orally administered talinolol as compared to people with the AA or AG genotype. Other genetic and clinical factors may also influence the clearance of talinolol.,699639419,Allele A is associated with increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol as compared to allele G.,18334920,1,talinolol,,White
655385149,rs4986938,ESR2 (PA27886),3,Toxicity/ADR,655385151; 655385152; 655385153,CC:Patients with the CC genotype may have higher tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the TT or CT genotype. Other genetic and clinical factors may influence the response to tamoxifen.; CT:Patients with the CT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.; TT:Patients with the TT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.,699639424,Genotype CC is associated with tamoxifen-induced increase in triglycerides in postmenopausal woman..,17713466,1,tamoxifen,,
655385154,rs9340799,ESR1 (PA156),3,Toxicity/ADR,655385158; 655385157; 655385156,AA:The AA genotype carriers had smaller tamoxifen-induced decrease in total cholesterol in postmenopausal woman and tamoxifen-induced decrease in triglycerides and increase in high density lipoprotein in premenopausal women compared to GG genotype carriers; AG:The AG genotype carriers had smaller tamoxifen-induced decrease in total cholesterol in postmenopausal woman and intermediate tamoxifen-induced increase in triglycerides and decrease in high density lipoprotein in premenopausal women compared to GG genotype carriers.; GG:The GG genotype carriers had larger tamoxifen-induced decrease in total cholesterol in postmenopausal woman compared to GA/AA genotypes (P=0.03; GG vs GA/AA) and tamoxifen-induced increase in triglycerides (P=0.002; gene-dose effect) and decrease in high density lipoprotein (P=0.004; gene-dose effect) in premenopausal women.,699639427,Genotype GG is associated with tamoxifen-induced decrease in total cholesterol in postmenopausal woman (P=0.03; GG vs GA/AA) and tamoxifen-induced increase in triglycerides (P=0.002; gene-dose effect) and decrease in high density lipoprotein (P=0.004; gene-dose effect) in premenopausal women..,17713466,1,tamoxifen,,
655385223,rs2278293,IMPDH1 (PA29862),3,Toxicity/ADR,655385227; 655385226; 655385225,"CC:Patients with the CC genotype may have an increased risk for acute rejection after kidney transplantation as compared to patients with the CT or TT genotypes but the CC genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.; CT:Patients with the CT genotype may have a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the CC genotype but the CT genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.; TT:Patients with the TT genotype may have a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the CC genotype but the TT genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.",769262708; 731672567,Allele T is not associated with increased risk of adverse drug reactions and risk of biopsy-proven acute rejection when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.; Genotypes TT + CT are associated with decreased risk of biopsy-proven acute rejection when treated with mycophenolate mofetil in people with Transplantation as compared to genotype CC.,21142914; 17851563,2,mycophenolate mofetil,,
655385352,rs3892097,CYP2D6 (PA128),3,Efficacy,655385355; 655385354; 655385353,"CC:Patients with CC genotype may have lower plasma concentrations of metoprolol and have smaller reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.; CT:Patients with CT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.; TT:Patients with TT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.",769181593,"Allele T is associated with increased higher plasma concentrations of metoprolol and greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure in PMs than in non-PMs. of metoprolol as compared to allele C.",19037197,1,metoprolol,,White
981238459,rs1057910,CYP2C9 (PA126),3,Efficacy,981238460; 981238461; 981238462,AA:Subjects with the AA genotype who are treated with losartan may have increased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.; AC:Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.; CC:Subjects with the CC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.,769169612; 769169634,Allele C is associated with decreased clearance of losartan.; Allele C is associated with decreased metabolism of losartan in people with no disease as compared to allele A.,11408373; 11823761,2,losartan,,White
981237922,rs1128503,ABCB1 (PA267),3,Other,981237923; 981237924; 981237925,AA:Patients with the AA genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.; AG:Patients with the AG genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.; GG:Patients with the GG genotype who receive phenytoin may have decreased plasma drug levels of phenytoin as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.,769250001,Allele A is associated with increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG.,16220110,1,phenytoin,,Black or African American
655387749,rs11188072,CYP2C19 (PA124),3,Dosage,655387750; 655387751; 655387752,"CC:Patients with the CC genotype who are treated with pantoprazole may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration; CT:Patients with the CT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.; TT:Patients with the TT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.",604828714; 655387709,Allele T is associated with increased metabolism of pantoprazole.; Allele T is associated with CYP2C19*17.,20223877; 16413245,2,pantoprazole,,
827831435,rs2032582,ABCB1 (PA267),3,Dosage,827831436; 827831437; 827831438,"AA:Patients with the AA genotype may have higher blood trough concentrations of cyclosporine compared to patients with the CC genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.; AC:Patients with the AC genotype may have higher blood trough concentrations of cyclosporine compared to patients with the CC genotype, or may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.; CC:Patients with the CC genotype may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.",655388177; 827814005,Genotype AA is associated with increased trough blood concentration of cyclosporine in people with Myasthenia Gravis as compared to genotype CC.; Genotype AT is not associated with dose of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele C.,18717915; 21806386,2,cyclosporine,,Asian
827832280,rs1801253,ADRB1 (PA38),3,Efficacy,827832281; 827832282; 827832283,"CC:Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to Beta Blocking Agents.; CG:Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Beta Blocking Agents.; GG:Patients with the GG genotype may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Beta Blocking Agents.",613979015; 748396572; 827567343; 827567370; 827603889; 827782095; 827808186; 827816261; 827863984; 827863996; 827864008; 827864029,"Allele C is not associated with response to Beta Blocking Agents in people with Heart Failure as compared to allele G.; Allele C is associated with increased response to metoprolol in people with Hypertension as compared to allele G.; Genotype CC is associated with increased response to metoprolol in healthy individuals as compared to genotype GG.; Allele C is not associated with increased response to metoprolol in people with Heart Failure as compared to allele G.; Genotypes GG + CG are associated with increased likelihood of requiring more heart failure medication when treated with metoprolol in people with Heart Failure as compared to genotype CC.; Genotype CC is associated with increased reduction in blood pressure when treated with atenolol in healthy individuals as compared to genotype GG.; Allele G is not associated with the reduction in systolic blood pressure, diastolic blood pressure, pulse pressure, mean arterial pressure, or heart rate, or treatment differences between losartan and atenolol on these endpoints or risk of the primary composite endpoint or its components stroke, myocardial infarction, and cardiovascular death, or treatment differences between losartan and atenolol on these endpoints when treated with atenolol or losartan as compared to allele C.; Genotypes CG + GG are associated with increased response to atenolol, carvedilol, diltiazem, metoprolol or verapamil in people with Atrial Fibrillation as compared to genotype CC.; Genotype CC is associated with increased response when treated with bucindolol in people with Heart Failure.; Genotype CC is associated with greater increase in LVEF (left ventricular ejection fraction), and a larger improvement in left ventricular(LV) remodeling when treated with Beta Blocking Agents and metoprolol in people with Heart Failure as compared to genotypes CG + GG.; Genotype CC is associated with significantly greater improvement in left ventricular ejection fraction (LVEF) when treated with Beta Blocking Agents and carvedilol in people with Heart Failure as compared to genotypes CG + GG.; Genotype CC is associated with greater improvement in left ventricular function (LVEF) when treated with carvedilol in people with Heart Failure as compared to genotype GG.",15861037; 12844134; 14534524; 12921807; 15735607; 12709726; 20065889; 22192668; 16844790; 15864115; 18075464; 14502278,12,atenolol;Beta Blocking Agents;bucindolol;carvedilol;metoprolol,,
827836551,rs20417,PTGS2 (PA293),3,Efficacy,827836552; 827836553; 827836554,CC:Patients with the CC genotype may have decreased pain relief to ibuprofen as compared to patients with GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.; CG:Patients with the CG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.; GG:Patients with the GG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.,699638654,Genotypes GG + CG are associated with increased pain relief when treated with ibuprofen as compared to genotype CC.,16678543,1,ibuprofen,,
827848751,rs9340799,ESR1 (PA156),3,Efficacy,827848752; 827848753; 827848754,"AA:Patients with the AA genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density.; AG:Patients with the AG genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density.; GG:Patients with the GG genotype may experience 1) greater increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) smaller decreases in spine bone mineral density when untreated, as compared to patient with the AA genotype. Other genetic and clinical factors may also influence spine bone mineral density.",769164633,Genotype GG is associated with increased spine Bone Mineral Density when treated with conjugated estrogens and medroxyprogesterone as compared to genotype AA.,9860300,1,conjugated estrogens;medroxyprogesterone,,White
827848725,rs9349256,ABCC10 (PA24392),3,Toxicity/ADR,827848726; 827848727; 827848728,AA:Patients with the AA genotype may have decreased but not absent risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse events.; AG:Patients with the AG genotype may have increased risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; GG:Patients with the GG genotype may have increased risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.,827815689,Allele G is associated with increased kidney tubular dysfunction when exposed to tenofovir as compared to allele A.,21628669,1,tenofovir,,
827849109,rs9272105,HLA-DQA1 (PA35066),3,Efficacy,827849110; 827849111; 827849112,AA:Patients with the AA genotype may have decreased but not absent risk for developing neutralizing anti-IFN-beta antibodies (i.e. decreased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to interferon-beta therapy.; AG:Patients with the AG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.; GG:Patients with the GG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.,769258178,Allele G is associated with increased anti-IFN-beta antibodies when treated with interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.,21502966,1,interferon beta-1a;interferon beta-1b,,White
981201937,rs12714145,GGCX (PA28660),3,Dosage,981201938; 981201939; 981201940,"CC:Genotype CC may be associated with decreased dose of warfarin as compared to genotype TT. However, contradictory findings (no association) have been reported. Other genetic and clinical factors may influence a patient's dose of warfain.; CT:Genotype CT may be associated with decreased dose of warfarin as compared to genotype TT. However, contradictory findings (no association) have been reported. Other genetic and clinical factors may influence a patient's dose of warfain.; TT:Genotype TT may be associated with increased dose of warfarin as compared to genotype GG. However, contradictory findings (no association) have been reported. Other genetic and clinical factors may influence a patient's dose of warfain.",608431741; 769168963; 827567352,Allele T is not associated with dose of warfarin.; Allele T is not associated with dose of warfarin.; Allele C is associated with decreased dose of warfarin as compared to allele T.,19794411; 20694283; 15883587,3,warfarin,,
978639596,rs10509681,CYP2C8 (PA125),3,Other,978639597; 978639598; 978639599,"CC:Individuals with the CC genotype were not studied, however individuals with the CT (CYP2C8*3/*1) genotype may have increased metabolism of repaglinide compared to patients with the TT genotype (CYP2C8*1/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide and blood glucose levels.; CT:Individuals with the CT (CYP2C8*3/*1) genotype may have increased metabolism of repaglinide compared to patients with the TT genotype (CYP2C8*1/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide.; TT:Individuals with the TT (CYP2C8*1/*1) genotype may have decreased metabolism of repaglinide compared to patients with the CT genotype (CYP2C8*3/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide.",655387159,Allele C is associated with increased metabolism of repaglinide in people with no disease as compared to allele T.,14534525,1,repaglinide,,White
981204044,rs9923231,VKORC1 (PA133787052),3,Dosage,981204047; 981204046; 981204045,CC:Patients with the CC genotype who are treated with acenocoumarol may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's acenocoumarol dose requirement.; CT:Patients with the CT genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the CC genotype or may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's acenocoumarol dose requirement.; TT:Patients with the TT genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's acenocoumarol dose requirement.,827814729,Allele T is associated with decreased dose of acenocoumarol as compared to allele C.,21148049,1,acenocoumarol,,Asian
981204055,rs9923231,"PRSS53 (PA165450635),VKORC1 (PA133787052)",3,Dosage,981204056; 981204057; 981204058,"CC:Children with the CC genotype who are treated with vitamin K antagonists may require a higher dose as compared to children with the TT genotype. Other genetic and clinical factors may also influence warfarin and phenprocoumon dose requirement in children.; CT:This genotype was not reported, however children with the CT genotype who are treated with vitamin K antagonists may require a higher dose as compared to children with the TT genotype or may require a lower dose as compared to children with the CC genotype. Other genetic and clinical factors may also influence warfarin and phenprocoumon dose requirement in children.; TT:Children with the TT genotype who are treated with vitamin K antagonists may require a lower dose as compared to children with the CC genotype. Other genetic and clinical factors may also influence warfarin and phenprocoumon dose requirement in children.",827864542,Genotype TT is associated with decreased dose of phenprocoumon and warfarin as compared to genotype CC.,20833980,1,phenprocoumon;warfarin,,White
981237713,rs1805087,MTR (PA31272),3,Toxicity/ADR,981237714; 981237715; 981237716,AA:Patients with the AA genotype may have decreased likelihood of Drug Toxicity when treated with cisplatin in people with Osteosarcoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk for toxicity to cisplatin.; AG:Patients with the AG genotype may have decreased likelihood of Drug Toxicity when treated with cisplatin in people with Osteosarcoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk for toxicity to cisplatin.; GG:Patients with the GG genotype may have increased likelihood of Drug Toxicity when treated with cisplatin in people with Osteosarcoma as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence a patient's risk for toxicity to cisplatin.,769174400; 827807299,"Genotype GG is associated with increased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to genotypes AA + AG.; Genotype AA is not associated with increased likelihood of response to chemotherapy when treated with carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel and vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.",19159907; 21605004,2,cisplatin,,
981204317,rs1045642,ABCB1 (PA267),3,Dosage,981204318; 981204319; 981204320,"AA:Patients with genotype AA may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.; AG:Patients with genotype AG may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.; GG:Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.",613978575; 769250004,Allele A is not associated with increased dose of phenytoin in people with Epilepsy as compared to allele G.; Allele A is associated with increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG.,15805193; 16220110,2,phenytoin,,
981203518,rs5751876,ADORA2A (PA24584),3,Dosage;Toxicity/ADR,981203519; 981203520; 981203521,CC:Individuals with the CC genotype 1) may be less sensitive to caffeine and less likely to experience anxiety 2) may consume more caffeine as compared to individuals with the TT genotype. Please note contradictory results have been reported. Other genetic and clinical factors may also influence an individual's response to caffeine.; CT:Individuals with the CT genotype 1) may be less sensitive to caffeine and less likely to experience anxiety 2) may consume more caffeine as compared to individuals with the TT genotype. Please note contradictory results have been reported. Other genetic and clinical factors may also influence an individual's response to caffeine.; TT:Individuals with the TT genotype 1) may be more sensitive to caffeine and more likely to experience anxiety 2) may consume less caffeine as compared to individuals with the CC genotype. Please note contradictory results have been reported. Other genetic and clinical factors may also influence an individual's response to caffeine.,769278094; 769278098; 769278090; 769278113; 769278124; 827783588; 827783690,Genotype CC is associated with increased likelihood of being sensitive to caffeine when exposed to caffeine as compared to genotype TT.; Genotype CC is associated with increased likelihood of insomnia when exposed to caffeine as compared to genotype TT.; Genotype TT is associated with increased anxiety when exposed to caffeine.; Genotype TT is associated with decreased habitual consumption of caffeine as compared to genotypes CC + CT.; Genotype TT is associated with increased anxiety when exposed to caffeine in people with no disease as compared to genotype CC.; Genotype TT is associated with increased anxiety when exposed to caffeine in healthy individuals as compared to genotypes CC + CT.; Genotype TT is not associated with anxiety when exposed to caffeine in healthy individuals as compared to genotypes CC + CT.,17329997; 17329997; 20520601; 17616786; 18305461; 12825092; 22012471,7,caffeine,,
981203970,rs7439366,UGT2B7 (PA361),3,Efficacy,981203971; 981203972; 981203973,CC:Healthy individuals with the CC genotype who are treated with valproic acid and lorazepam may have poorer responses in psychocognitive function tests as compared to those with the TT genotype. Other genetic and clinical factors may also influence an individual's response to valproic acid and lorazepam treatment.; CT:Healthy individuals with the CT genotype who are treated with valproic acid and lorazepam may have poorer responses in psychocognitive function tests as compared to those with the TT genotype or may have better responses in psychocognitive function tests as compared to patients with the CC genotype. Other genetic and clinical factors may also influence an individual's response to valproic acid and lorazepam treatment.; TT:Healthy individuals with the TT genotype who are treated with valproic acid and lorazepam may have better responses in psychocognitive function tests as compared to those with the CC genotype. Other genetic and clinical factors may also influence an individual's response to valproic acid and lorazepam treatment.,769164776,Allele T is associated with increased response to lorazepam and valproic acid in people with no disease as compared to allele C.,17687269,1,lorazepam;valproic acid,,Asian
981204455,rs1045642,ABCB1 (PA267),3,Other,981204458; 981204457; 981204456,"AA:Genotype AA may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.; AG:Genotype AG may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.; GG:Genotype GG may be associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.",655385617; 827923082,Allele A is not associated with pharmacokinetics of dicloxacillin.; Genotype GG is associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG.,15778422; 18576903,2,dicloxacillin,,
981204985,rs1801133,MTHFR (PA245),3,Efficacy;Toxicity/ADR,981204986; 981204987; 981204988,"AA:Patients with the AA genotype may have: 1) increased likelihood of response to chemotherapy, 2) increased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotypes AG or GG. Other genetic and clinical factors may also influence a patient's response to cisplatin.; AG:Patients with the AG genotype may have: 1) decreased likelihood of response to chemotherapy, 2) decreased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to cisplatin.; GG:Patients with the GG genotype may have: 1) decreased likelihood of response to chemotherapy, 2) decreased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to cisplatin.",827807290; 769174403,"Genotype AA is associated with increased likelihood of response to chemotherapy when treated with carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel and vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.; Genotype AA is associated with increased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to genotypes GG + AG.",21605004; 19159907,2,cisplatin,,Asian
981237704,rs1805087,MTR (PA31272),3,Efficacy;Toxicity/ADR,981237705; 981237706; 981237707,"AA:Patients with the AA genotype may have: 1) decreased likelihood of Drug Toxicity, 2) increased response when treated with methotrexate as compared to patients with genotypes GG. However, contradictory findings have also been reported. Other genetic and clinical factors may also influence a patient's response to methotrexate.; AG:Patients with the AG genotype may have: 1) decreased likelihood of Drug Toxicity, 2) increased response when treated with methotrexate as compared to patients with genotypes GG. However, contradictory findings have also been reported. Other genetic and clinical factors may also influence a patient's response to methotrexate.; GG:Patients with the GG genotype may have: 1) increased likelihood of Drug Toxicity, 2) decreased response when treated with methotrexate as compared to patients with genotypes AA or AG. However, contradictory findings have also been reported. Other genetic and clinical factors may also influence a patient's response to methotrexate.",769171236; 769173710; 769174400; 769174419; 769174421; 978639863,"Allele A is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele G.; Allele G is not associated with decreased IQ when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Genotype GG is associated with increased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to genotypes AA + AG.; Genotype GG is associated with increased risk of Brain Diseases when treated with methotrexate.; Genotype GG is associated with increased likelihood of methotrexate-induced nodulosis when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.; Allele G is not associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.",18322994; 16013960; 19159907; 17855192; 17611986; 22838948,6,methotrexate,,
981345311,rs4149056,SLCO1B1 (PA134865839),3,Other,981345312; 981345313; 981345314,"CC:Patients with the CC genotype may have increased plasma concentrations of atorvastatin as compared to patients with the TT genotype. Patients with the CC genotype may have smaller increases in plasma atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.; CT:Patients with the CT genotype may have increased plasma concentrations of atorvastatin as compared to patients with the TT genotype. Patients with the CT genotype may have smaller increases in plasma atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.; TT:Patients with the TT genotype may have decreased plasma concentrations of atorvastatin as compared to patients with the CC or CT genotype. However, patients with the TT genotype may have greater increases in plasma atorvastatin when treated concomitantly with rifampin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.",827827481; 769164520; 769169405; 769171454; 827810986,"Genotype CC is associated with increased AUC when exposed to atorvastatin in healthy individuals as compared to genotype TT.; Allele C is not associated with risk of Muscular Diseases when treated with atorvastatin in people with Hyperlipidemias as compared to allele T.; Allele C is associated with increased risk of composite adverse events when treated with atorvastatin, hmg coa reductase inhibitors and simvastatin in people with Hypercholesterolemia as compared to allele T.; Genotype TT is associated with a nearly tripled increased percentage of atorvastatin AUC(0 - 48) values after a single oral dose of rifampicin when exposed to atorvastatin and rifampin in people with no disease as compared to genotype CC.; Genotypes CC + CT are not associated with increased risk of myalgia or abnormal CK values when treated with atorvastatin in people with Hyperlipoproteinemia Type II as compared to genotype TT.",17473846; 21243006; 19833260; 19374892; 21928084,5,atorvastatin;rifampin,,
981238108,rs2032582,ABCB1 (PA267),3,Other,981238111; 981238110; 981238109,AA:Patients with genotype AA may have decreased metabolism of digoxin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of digoxin.; AC:Patients with genotype AC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.; CC:Patients with genotype CC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.,827807741; 827925294,Allele A is associated with increased serum concentrations digoxin as compared to allele C.; Genotype CC is associated with increased metabolism of digoxin as compared to genotype AA.,18334914; 12189368,2,digoxin,,
981345350,rs4149056,SLCO1B1 (PA134865839),3,Other,981345351; 981345352; 981345353,CC:Patients with the CC genotype may have increased plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism and response to rosuvastatin.; CT:Patients with the CT genotype may have increased plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism and response to rosuvastatin.; TT:Patients with the TT genotype may have decreased plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism and response to rosuvastatin.,827827497,Genotype CC is associated with increased AUC (p=0.002) and Cmax (p=0.003) when exposed to rosuvastatin in healthy individuals as compared to genotype TT.,17473846,1,rosuvastatin,,
981237683,rs1799853,CYP2C9 (PA126),3,Efficacy,981237684; 981237685; 981237686,CC:Patients with the CC genotype who are treated with celecoxib may have an increased metabolism of celecoxib and as compared to patients with the CT and TT genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to celecoxib.; CT:Patients with the CT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to celecoxib.; TT:Patients with the TT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to celecoxib.,827826389; 827826410; 827826431; 827826458,Allele T is associated with decreased metabolism of celecoxib.; Allele T is not associated with increased AUC of celecoxib when treated with celecoxib.; Allele T is not associated with celecoxib AUC or total clearance when exposed to celecoxib in healthy individuals as compared to allele C.; Genotype CT is associated with higher plasma concentrations of celecoxib when exposed to celecoxib in healthy individuals as compared to genotype CC.,11337938; 11337938; 12893985; 16401468,4,celecoxib,,
981239568,rs104894542,VKORC1 (PA133787052),4,Dosage,981239569; 981239570; 981239571,"AA:Patients with the AA genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence warfarin dose.; AC:Patients with the AC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.; CC:Patients with the CC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.",981239489; 981239497,Allele C is associated with increased dose of warfarin as compared to allele A.; Allele C is associated with increased dose of warfarin as compared to allele A.,14765194; 18234403,2,warfarin,,
981239556,rs104894541,VKORC1 (PA133787052),4,Dosage,981239557; 981239558; 981239559,"CC:Patients with the CC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose.; CT:Patients with the CT genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose.; TT:Patients with the TT genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence warfarin dose.",981239471; 981239505,Allele C is associated with increased dose of warfarin as compared to allele T.; Allele C is associated with increased dose of warfarin as compared to allele T.,14765194; 18234403,2,warfarin,,
981239532,rs104894539,VKORC1 (PA133787052),4,Dosage,981239533; 981239534; 981239535,"AA:Patients with the AA genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dose.; AC:Patients with the AC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dose.; CC:Patients with the CC genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence warfarin dose.",981239462; 981239523,Allele A is associated with increased dose of warfarin as compared to allele C.; Allele A is associated with increased dose of warfarin as compared to allele C.,14765194; 18234403,2,warfarin,,
655385749,rs12721627,"CYP3A (PA27114),CYP3A4 (PA130)",4,Other,655385750; 655385751; 655385752,"CC:The expression of a construct caring the C variant is associated with decreased clearance of midazolam in transfected cells.; CG:While the expression of a construct caring the C variant is associated with decreased clearance of midazolam in transfected cells, it is not clear what the influence of one G allele with the C allele is.; GG:The expression of a construct caring the G variant is not associated with decreased clearance of midazolam in transfected cells.",655385744,Allele C is associated with decreased clearance of midazolam.,19255940,1,midazolam,,
655385997,rs2784917,SLIT1 (PA35938),4,Toxicity/ADR,655385998; 655385999; 655386000,AA:Patients with the AA genotype may have increased risk of toxicity with etoposide compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; AG:Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GG:Patients with the GG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,769143881,Genotype AA is associated with increased gene expression of WNT5 and etoposide toxicity  based upon IC50 values in cell lines from 30 parent-child trios.,17537913,1,etoposide,,Black or African American
655386002,rs6539870,,4,Toxicity/ADR,655386003; 655386004; 655386005,AA:Patients with the AA genotype may have lower risk of toxicity with etoposide compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; AG:Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; GG:Patients with the GG genotype may have increased risk of toxicity with etoposide compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,748448812,Genotype GG is associated with increased gene expression of IL1B and etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios.,17537913,1,etoposide,,White
637879590,rs11572080,CYP2C8 (PA125),4,Toxicity/ADR,637879591; 637879592; 637879593,CC:Patients with the CC genotype may have decreased risk of side effects with amodiaquine as compared to patients with the CT or TT genotype. Patients with the CC genotype may still be at risk for adverse events when taking amodiaquine based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; CT:Patients with the CT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; TT:Patients with the TT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.,655386098,Genotype CC is associated with decreased risk of side effects when treated with amodiaquine as compared to genotypes TT + CT.,18855526,1,amodiaquine,,
637879595,rs10509681,CYP2C8 (PA125),4,Toxicity/ADR,637879596; 637879597; 637879598,CC:Patients with the CC genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.; CT:Patients with the CT genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.; TT:Patients with the TT genotype may have decreased but not non-existent risk of side effects to amodiaquine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.,655386119,Genotype TT is associated with decreased risk of side effects when treated with amodiaquine as compared to genotypes CC + CT.,18855526,1,amodiaquine,,
637880446,rs2229109,ABCB1 (PA267),4,Other,637880447; 637880448; 637880449,CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.,655386731; 655386911,Genotype TT is not associated with decreased clearance of bisantrene.; Genotype TT is not associated with decreased expression of ABCB1.,12065748; 12065748,2,bisantrene,,
637880451,rs2229109,ABCB1 (PA267),4,Other,637880452; 637880453; 637880454,CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.,655386741; 655386911,Genotype TT is not associated with decreased clearance of calcein.; Genotype TT is not associated with decreased expression of ABCB1.,12065748; 12065748,2,calcein,,
637880455,rs2229109,ABCB1 (PA267),4,Other,637880456; 637880457; 637880458,CC:Cells with the C allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.; CT:Cells with this genotype would show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other genotypes (inferred).; TT:Cells with the T allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.,655386742; 655386911,Genotype TT is not associated with decreased clearance of forskolin.; Genotype TT is not associated with decreased expression of ABCB1.,12065748; 12065748,2,forskolin,,
637880459,rs2229109,ABCB1 (PA267),4,Other,637880460; 637880461; 637880462,CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.,655386743; 655386911,Genotype TT is not associated with decreased clearance of prazosin.; Genotype TT is not associated with decreased expression of ABCB1.,12065748; 12065748,2,prazosin,,
637880463,rs2229109,ABCB1 (PA267),4,Other,637880464; 637880465; 637880466,CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.,655386744; 655386911,Genotype TT is not associated with decreased clearance of verapamil.; Genotype TT is not associated with decreased expression of ABCB1.,12065748; 12065748,2,verapamil,,
637880467,rs2229109,ABCB1 (PA267),4,Other,637880468; 637880469; 637880470,CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.,655386745; 655386911,Genotype TT is not associated with decreased clearance of vinblastine.; Genotype TT is not associated with decreased expression of ABCB1.,12065748; 12065748,2,vinblastine,,
637880471,rs2229109,ABCB1 (PA267),4,Other,637880472; 637880473; 637880474,CC:Cells with the CC genotype have normal ability to efflux fluorescently labelled paclitaxel.; CT:Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.; TT:Cells with the TT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.,655386746; 655386747,Genotype CT is associated with decreased clearance of paclitaxel.; Genotype TT is associated with decreased clearance of paclitaxel.,12065748; 12065748,2,paclitaxel,,
637880505,rs9282564,ABCB1 (PA267),4,Other,637880506; 637880507; 637880508,CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.,655386748; 655386912,Genotype CC is not associated with decreased clearance of bisantrene.; Genotype CC is not associated with decreased expression of ABCB1.,12065748; 12065748,2,bisantrene,,
637880510,rs9282564,ABCB1 (PA267),4,Other,637880511; 637880512; 637880513,CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.,655386756; 655386912,Genotype CC is not associated with decreased clearance of calcein.; Genotype CC is not associated with decreased expression of ABCB1.,12065748; 12065748,2,calcein,,
637880518,rs9282564,ABCB1 (PA267),4,Other,637880519; 637880520; 637880521,CC:Cells with the C allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.; CT:Cells with the CT genotype would show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other genotypes(inferred).; TT:Cells with the T allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.,655386764; 655386912,Genotype CC is not associated with decreased clearance of forskolin.; Genotype CC is not associated with decreased expression of ABCB1.,12065748; 12065748,2,forskolin,,
637880522,rs9282564,ABCB1 (PA267),4,Other,637880523; 637880524; 637880525,CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.,655386903; 655386912,Genotype CC is not associated with decreased clearance of prazosin.; Genotype CC is not associated with decreased expression of ABCB1.,12065748; 12065748,2,prazosin,,
637880526,rs9282564,ABCB1 (PA267),4,Other,637880527; 637880528; 637880529,CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.,655386906; 655386912,Genotype CC is not associated with decreased clearance of verapamil.; Genotype CC is not associated with decreased expression of ABCB1.,12065748; 12065748,2,verapamil,,
637880530,rs9282564,ABCB1 (PA267),4,Other,637880531; 637880532; 637880533,CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastinel compared to cells with other genotypes.,655386907; 655386912,Genotype CC is not associated with decreased clearance of vinblastine.; Genotype CC is not associated with decreased expression of ABCB1.,12065748; 12065748,2,vinblastine,,
637880534,rs9282564,ABCB1 (PA267),4,Other,637880535; 637880536; 637880537,CC:Cells with the CC genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype TT.; CT:Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype TT.; TT:Cells with the TT genotype have normal ability to efflux fluorescently labelled paclitaxel.,655386908; 655386909,Genotype CC is associated with decreased clearance of paclitaxel.; Genotype CT is associated with decreased clearance of paclitaxel.,12065748; 12065748,2,paclitaxel,,
637880538,rs72552784,ABCB1 (PA267),4,Other,637880539; 637880540; 637880541,CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport bisantrene compared to cells with other genotypes.,655386917; 655386918,Genotype TT is not associated with decreased expression of ABCB1.; Genotype TT is not associated with decreased clearance of bisantrene.,12065748; 12065748,2,bisantrene,,
637880543,rs72552784,ABCB1 (PA267),4,Other,637880544; 637880545; 637880546,CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport calcein compared to cells with other genotypes.,655386917; 655386919,Genotype TT is not associated with decreased expression of ABCB1.; Genotype TT is not associated with decreased clearance of calcein.,12065748; 12065748,2,calcein,,
637880547,rs72552784,ABCB1 (PA267),4,Other,637880548; 637880549; 637880550,CC:Cells with the C allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.; CT:Cells with this genotype would show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other genotypes.; TT:Cells with the T allele show no difference in P-glycoprotein expression or ability to transport forskolin compared to cells with other alleles.,655386917; 655386920,Genotype TT is not associated with decreased expression of ABCB1.; Genotype TT is not associated with decreased clearance of forskolin.,12065748; 12065748,2,forskolin,,
637880551,rs72552784,ABCB1 (PA267),4,Other,637880552; 637880553; 637880554,CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport prazosin compared to cells with other genotypes.,655386917; 655386921,Genotype TT is not associated with decreased expression of ABCB1.; Genotype TT is not associated with decreased clearance of prazosin.,12065748; 12065748,2,prazosin,,
637880555,rs72552784,ABCB1 (PA267),4,Other,637880556; 637880557; 637880558,CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport verapamil compared to cells with other genotypes.,655386917; 655386922,Genotype TT is not associated with decreased expression of ABCB1.; Genotype TT is not associated with decreased clearance of verapamil.,12065748; 12065748,2,verapamil,,
637880559,rs72552784,ABCB1 (PA267),4,Other,637880560; 637880561; 637880562,CC:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.; CT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.; TT:Cells with this genotype show no difference in P-glycoprotein expression or ability to transport vinblastine compared to cells with other genotypes.,655386917; 655386924,Genotype TT is not associated with decreased expression of ABCB1.; Genotype TT is not associated with decreased clearance of vinblastine.,12065748; 12065748,2,vinblastine,,
637880563,rs72552784,ABCB1 (PA267),4,Other,637880564; 637880565; 637880566,CC:Cells with the CC genotype have normal ability to efflux fluorescently labelled paclitaxel.; CT:Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.; TT:Cells with the TT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.,655386926; 655386925,Genotype CT is associated with decreased clearance of paclitaxel.; Genotype TT is associated with decreased clearance of paclitaxel.,12065748; 12065748,2,paclitaxel,,
655384587,rs11572103,CYP2C8 (PA125),4,Dosage,655384589; 655384590; 655384591,"AA:Patients with the AA genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.; AT:Patients with the AT genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.; TT:Patients with the TT genotype may have increased clearance of paclitaxel as compared to patients with the AA or AT genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.",655387869; 655388183,Allele A is associated with decreased clearance of paclitaxel.; Allele T is not associated with metabolism of paclitaxel in people with Neoplasms as compared to allele A.,11668219; 16299241,2,paclitaxel,,White
655384635,rs58597806,UGT1A9 (PA419),4,Toxicity/ADR,655384637; 655384638; 655384639,AA:Patients with the AA genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.; AG:Patients with the AG genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.; GG:Patients with the GG genotype may have decreased but not non-existent risk of adverse effects when treated with propofol as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to propofol.,748897582,Allele A is associated with lower UGT1A9 activity for propofol as compared to allele G.,18816295,1,propofol,,
655384830,rs4987161,"CYP3A (PA27114),CYP3A4 (PA130)",4,Other,655384831; 655384832; 655384833,"AA:In vitro, the construct expressing the wild type allelic protein has average nifedipine metabolism.; AG:Expression study did not included heterozygous genotype.; GG:In vitro, the recombinant CYP3A4*17 allelic protein exhibits significantly decreased catalytic activity for nifedipine oxidation by 98 to 99% compared to wild-type construct at high concentration of nifedipine.",608431726,Allele G is associated with decreased metabolism of nifedipine as compared to allele A.,15634941,1,nifedipine,,
655384834,rs11572080,CYP2C8 (PA125),4,Other,655384837; 655384836; 655384835,"CC:Patients with the CC genotype may have increased clearance of paclitaxel as compared to patients with the CT or TT genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.; CT:Patients with the CT genotype may have decreased metabolism of paclitaxel as compared to patients with the CC genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.; TT:Patients with the TT genotype may have decreased metabolism of paclitaxel as compared to patients with the CC genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.",608431735; 655388190,Allele T is associated with decreased metabolism of paclitaxel as compared to allele C.; Allele T is not associated with metabolism of paclitaxel in people with Neoplasms as compared to allele C.,11668219; 16299241,2,paclitaxel,,
655384838,rs10509681,CYP2C8 (PA125),4,Other,655384839; 655384840; 655384841,"CC:Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.; CT:Patients with the CT genotype may have decreased metabolism of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.; TT:Patients with the TT genotype may have increased metabolism of paclitaxel as compared to patients with the CT or CC genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.",608431745,Allele C is associated with decreased metabolism of paclitaxel as compared to allele T.,11668219,1,paclitaxel,,
655385004,rs61750900,UGT2B10 (PA37186),4,,655385007; 655385006; 655385005,GG:The GG genotype is not associated with changes in nicotine metabolism/clearance in human liver microsomes from subjects with GG genotype and HEK293 over expressing UGT2B10.; GT:The GT genotype is significantly associated with a decrease in nicotine metabolism/clearance in human liver microsomes from subjects with GT genotype compared to GG genotype.; TT:The TT genotype is significant associated with a decrease in nicotine metabolism/clearance in human liver microsomes from subjects with TT genotype compared to GG genotype and HEK293 over expressing UGT2B10.,608431753; 769169917,Allele T is associated with decreased metabolism of nicotine as compared to allele G.; Allele T is associated with decreased clearance of nicotine.,17909004; 18300939,2,nicotine,,
655385045,rs2472677,NR1I2 (PA378),4,Other,655385049; 655385048; 655385047,"CC:Genotype CC is associated with higher CYP3A4 acitvity induced by rifampin compared to genotype CT or TT in liver samples.; CT:Genotype CT is associated with lower CYP3A4 acitvity induced by rifampin compared with genotype CC, particularly in livers from male subjects.; TT:Genotype TT is associated with lower CYP3A4 acitvity induced by rifampin compared with genotype CC, particularly in livers from male subjects.",699638854,Allele T is associated with decreased CYP3A4 acitvity when exposed to rifampin.,17925385,1,rifampin,,White
655385253,rs4149056,SLCO1B1 (PA134865839),4,,655385254; 655385255; 655385256,CC:This genotype has no significant effect on the PK or PD of nateglinide.; CT:This genotype has no significant effect on the PK or PD of nateglinide.; TT:This genotype has no significant effect on the PK or PD of nateglinide.,747884257,Allele C is not associated with PK of nateglinide as compared to genotype TT.,18187595,1,nateglinide,,White
827848762,rs9332239,CYP2C9 (PA126),4,Other,827848763; 827848764; 827848765,CC:Patients with the CC genotype may have increased metabolism of tolbutamide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence tolbutamide metabolism.; CT:Patients with the CT genotype may have decreased metabolism of tolbutamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolbutamide metabolism.; TT:Patients with the TT genotype may have decreased metabolism of tolbutamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolbutamide metabolism.,827788986,Allele T is associated with decreased catalytic activity of CYP2C9 when assayed with tolbutamide.,15284535,1,tolbutamide,,
981201653,rs35350960,"UGT1A1 (PA420),UGT1A10 (PA37174),UGT1A3 (PA37178),UGT1A4 (PA37179),UGT1A5 (PA37180),UGT1A6 (PA37181),UGT1A7 (PA37182),UGT1A8 (PA37183),UGT1A9 (PA419)",4,Other,981201655; 981201654; 981201656,"AA:Patients with the AA, AC, or AT genotype may have decreased metabolism of SN-38 compared to patients with the CC genotype, as determined by in vitro assays. Other genetic and clinical factors may also influence metabolism of SN-38.; CC:Patients with the CC genotype may have increased metabolism of SN-38 compared to patients with the A or T allele at this position, as determined by in vitro assays. Other genetic and clinical factors may also influence metabolism of SN-38.; TT:Patients with the TT, CT or AT genotype may have decreased metabolism of SN-38 compared to patients with the CC genotype, as determined by in vitro assays. Other genetic and clinical factors may also influence metabolism of SN-38.",827666647; 827677344,Allele A is associated with decreased metabolism of SN-38 as compared to allele C.; Allele A is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.,15572581; 12181437,2,SN-38,,
981201797,rs28399433,CYP2A6 (PA121),4,Other,981201798; 981201799; 981201800,AA:Patients with the AA genotype may have increased metabolism of nicotine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.; AC:Patients with the AC genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.; CC:Patients with the CC genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.,827641958; 827641986; 827698774,Allele C is associated with decreased expression of enzyme contributing to the metabolism of coumarin and nicotine.; Allele C is associated with decreased metabolism of nicotine.; Genotypes AC + CC are associated with decreased expression of CYP2A6 in human liver samples.,11394901; 12844137; 21521021,3,nicotine,,
981201805,rs28399433,CYP2A6 (PA121),4,Other,981201806; 981201807; 981201808,AA:Patients with the AA genotype may have increased metabolism of coumarin as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.; AC:Patients with the AC genotype may have decreased metabolism of coumarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.; CC:Patients with the CC genotype may have decreased metabolism of coumarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.,827641958; 827642007; 827698774,Allele C is associated with decreased expression of enzyme contributing to the metabolism of coumarin and nicotine.; Allele C is associated with decreased metabolism of coumarin.; Genotypes AC + CC are associated with decreased expression of CYP2A6 in human liver samples.,11394901; 16041240; 21521021,3,coumarin,,
981201827,rs28399468,CYP2A6 (PA121),4,Other,981201828; 981201829; 981201830,"AA:Patients with the AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked.; AC:Patients with the AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked.; CC:Patients with the CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked.",769278040; 827551899,Allele A is associated with decreased metabolism of nicotine as compared to allele C.; Allele A is associated with decreased metabolism of nicotine as compared to allele C.,12445030; 11779172,2,nicotine,,
981202046,rs5031016,CYP2A6 (PA121),4,Other,981202047; 981202048; 981202049,"AA:Patients with the AA genotype may have increased metabolism of nicotine as compared to patients with the GG or AG genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. Other genetic and clinical factors may also influence metabolism of nicotine.; AG:Patients with the AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. Other genetic and clinical factors may also influence metabolism of nicotine.; GG:Patients with the GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. Other genetic and clinical factors may also influence metabolism of nicotine.",769278041; 769278059,Allele G is associated with decreased metabolism of nicotine as compared to allele A.; Allele G is associated with decreased metabolism of nicotine as compared to allele A.,12445030; 11779172,2,nicotine,,Asian
981239544,rs104894540,VKORC1 (PA133787052),4,Dosage,981239545; 981239546; 981239547,"AA:Patients with the AA genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence warfarin dose.; AG:Patients with the AG genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.; GG:Patients with the GG genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.",981239480; 981239514,Allele G is associated with increased dose of warfarin as compared to allele A.; Allele G is associated with increased dose of warfarin as compared to allele A.,14765194; 18234403,2,warfarin,,
981204444,rs1045642,ABCB1 (PA267),4,Other,981204447; 981204446; 981204445,"AA:Genotype AA may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported.; AG:Genotype AG may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported.; GG:Genotype GG may be associated with increased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes AA + AG. However, contradictory finding has been reported.",655386370; 655388038,Allele A is not associated with difference in efflux of rhodamine 123 as compared to allele G.; Genotype GG is associated with increased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes AA + AG.,12914549; 11434506,2,rhodamine 123,,White
981203532,rs602950,CDA (PA98),4,Toxicity/ADR,981203533; 981203534; 981203535,AA:Patients with the AA genotype who are treated with cytarabine may have lower levels of toxicity as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.; AG:Patients with the AG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.; GG:Patients with the GG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.,827803666; 827829878,"Genotypes AG + GG are associated with increased toxicity when treated with cytarabine as compared to genotype AA.; Genotype GG is associated with increased cytotoxicity when exposed to cytarabine in people with Leukemia, Myeloid as compared to genotype AA.",21521023; 22304580,2,cytarabine,,
827864179,rs1801272,CYP2A6 (PA121),4,Other,827864180; 827864181; 827864182,AA:Patients with the AA genotype may have increased 7-hydroxylation of coumarin compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of coumarin.; AT:Patients with the AT genotype may have increased 7-hydroxylation of coumarin compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of coumarin.; TT:Patients with the TT genotype may have minimal 7-hydroxylation of coumarin compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of coumarin.,769278048; 769278055,Genotype TT is associated with decreased metabolism of coumarin as compared to genotype AT.; Genotype TT is associated with decreased metabolism of coumarin as compared to genotypes AA + AT.,9409631; 9827545,2,coumarin,,
637879781,rs1799853,CYP2C9 (PA126),1A,Dosage,637879782; 637879783; 637879784,CC:Patients with the CC genotype who are treated with warfarin may require a higher dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.; CT:Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.; TT:Patients with the TT genotype who are treated with warfarin may require a lower dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.,608431758; 655387565; 827864546; 827602050; 827641894; 827657784; 827823816,Allele T is associated with decreased dose of warfarin.; Allele T is associated with decreased dose of warfarin.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Genotype CT is associated with decreased dose of warfarin as compared to genotype CC.; Allele T is associated with decreased dose of warfarin as compared to allele C.,19794411; 19228618; 21228733; 18305455; 19300499; 17111199; 21110192,7,warfarin,,White
637880569,rs1800584,TPMT (PA356),1A,Toxicity/ADR,637880570; 637880571; 637880572,CC:Patients with the CC genotype who are treated with standard doses of mercaptopurine may not be at increased risk for life-threatening myelosuppression. Other genetic and clinical factors may also influence a patient's risk for adverse events.; CT:Patients with the CT genotype who are treated with standard doses of mercaptopurine may be at increased risk for life-threatening myelosuppression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; TT:Patients with the TT genotype who are treated with standard doses of mercaptopurine may be at increased risk for life-threatening myelosuppression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.,655386679,Genotype CC is not associated with increased risk of myelosuppresion when treated with mercaptopurine as compared to genotypes TT + CT.,9486974,1,mercaptopurine,,White
655384022,rs1142345,TPMT (PA356),1A,Toxicity/ADR,655384023; 655384024; 655384025,CC:Patients with the CC genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; CT:Patients with the CT genotype 1) may have decreased inactivation of thiopurines 2) may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; TT:Patients with the TT genotype 1) may have increased inactivation of thiopurines 2) a decreased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CT or CC genotype. Patients with the TT genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based on their genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,827924549; 699638938; 769173727; 655386931; 655387032; 827551852; 827641965; 827641975; 827823905,"Genotypes CC + CT are associated with increased severity of hematopoietic toxicity when treated with azathioprine, mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Allele C is associated with decreased catalytic activity of TPMT in human liver samples.; Allele C is associated with increased risk of toxicity when treated with thiopurines as compared to allele T.; Genotype CT is associated with decreased metabolism of purine analogues as compared to genotype TT.; Genotype CT is associated with decreased metabolism of purine analogues as compared to genotype TT.; Allele C is associated with decreased enzyme activity of TPMT when exposed to mercaptopurine and s-adenosylmethionine.; Allele C is associated with decreased half-life of TPMT.; Allele C is associated with decreased steady-state level of TPMT.; Allele C is not associated with dose of azathioprine as compared to allele T.",8644731; 8561894; 15228163; 9103127; 9246020; 16220112; 10591545; 10591545; 21819368,9,azathioprine;mercaptopurine;purine analogues;thioguanine,,
655384640,rs1800460,TPMT (PA356),1A,Toxicity/ADR,655384644; 655384643; 655384642,"CC:Patients with the CC genotype may have a decreased, but not absent, risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CT or TT genotype. Patients with the CC genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based on their genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; CT:Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.; TT:Patients with the TT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.",699638934; 699638939; 769173741; 827551878; 827924562,"Allele T is associated with increased risk of Drug Toxicity when treated with mercaptopurine and purine analogues as compared to genotype CC.; Allele T is associated with decreased catalytic activity of TPMT in human liver samples.; Allele T is associated with increased risk of toxicity when treated with thiopurines.; Allele T is associated with decreased enzyme activity of TPMT when treated with mercaptopurine and s-adenosylmethionine.; Genotypes CT + TT are associated with increased severity of hematopoietic toxicity when treated with azathioprine, mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.",8561894; 8561894; 15228163; 16220112; 8644731,5,azathioprine;mercaptopurine;purine analogues;thioguanine,,
655384720,rs1057910,CYP2C9 (PA126),1A,Dosage;Toxicity/ADR,655384723; 655384722; 655384721,AA:Patients with the AA genotype: 1) may require an increased dose of warfarin as compared to patients with the AC or CC genotype 2) may have a decreased risk for adverse events as compared to patients with the AC or CC genotype. Patients with the AA genotype may still be at risk for adverse events when taking warfarin based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.; AC:Patients with the AC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.; CC:Patients with the CC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.,608431732; 655387562; 655388494; 655388497; 655388486,Allele C is associated with decreased dose of warfarin.; Allele C is associated with decreased dose of warfarin.; Allele C is associated with decreased dose of warfarin as compared to allele A.; Allele C is associated with increased risk of bleeding when treated with warfarin as compared to allele A.; Genotype CC is associated with increased risk of overanticoagulation when treated with acenocoumarol.,19794411; 19228618; 11127854; 11127854; 11692083,5,warfarin,,
655384776,rs1800462,TPMT (PA356),1A,Toxicity/ADR,981420075; 981420076; 981420077,"CC:Patients with the CC genotype (e.g. TPMT*1/*1): 1) may have increased deactivation of thiopurines 2) may have a decreased, but not absent, risk for toxicity with thiopurine drugs as compared to patients with the GG genotype (TPMT*2/*2). Other genetic and clinical factors may also influence a patient's risk for toxicity.; CG:Patients with the CG genotype (e.g. TPMT*1/*2): may have increased deactivation of thiopurines and a decreased, but not absent, risk for toxicity with thiopurine drugs as compared to patients with the GG genotype (TPMT*2/*2) or may have decreased deactivation of thiopurines and an increased risk for toxicity with thiopurine drugs as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patient's risk for toxicity.; GG:Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patient's risk for toxicity.",769146082; 769146083; 769146102; 769173715; 769146079; 827551865; 827641912; 827641920; 827663302; 827663582,Allele G is associated with decreased catalytic activity of TPMT in yeast.; Allele G is associated with TPMT*2.; Allele G is associated with decreased TPMT activity when treated with purine analogues as compared to allele C.; Allele G is associated with increased risk of hematopoietic toxicity when treated with thiopurines.; Genotype GG is associated with increased severity of Drug Toxicity when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; Allele G is associated with decreased enzyme activity of TPMT when exposed to mercaptopurine and s-adenosylmethionine.; Allele G is associated with decreased steady-state level of TPMT.; Allele G is associated with decreased half-life of TPMT.; Allele G is associated with decreased steady-state level of TPMT.; Allele G is associated with decreased half-life of TPMT.,7862671; 11304783; 9831928; 15228163; 7862671; 16220112; 10591545; 10591545; 9177237; 9177237,10,azathioprine;mercaptopurine;purine analogues;thioguanine,,
655385012,rs9923231,VKORC1 (PA133787052),1A,Dosage,655385015; 655385014; 655385013,CC:Patients with the CC genotype may require an increased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the dose of warfarin.; CT:Patients with the CT genotype may require a lower dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the dose of warfarin.; TT:Patients with the TT genotype may require the lowest dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the dose of warfarin.,608431774; 637879838; 637880237; 637880240; 637880249; 637880256; 827864542; 827864552; 827814719; 827823796; 827826043; 978614455; 827567282; 827567361; 827601694; 827602484; 827603022; 827603306; 827664180; 827783301; 827925119,Allele T is associated with decreased dose of warfarin.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Allele T is associated with decreased dose of warfarin.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Genotype TT is associated with decreased dose of phenprocoumon and warfarin as compared to genotype CC.; Genotypes TT + CT are associated with decreased dose of warfarin as compared to genotype CC.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Genotype CC is associated with increased dose of warfarin as compared to genotypes CT + TT.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Allele T is associated with dose of warfarin.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.; Allele T is associated with decreased dose of warfarin as compared to allele C.; Allele T is associated with decreased transcription of VKORC1.; Allele T is associated with decreased dose of warfarin.; Allele T is associated with decreased expression of VKORC1.; Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.; Genotype TT is associated with decreased dose of warfarin in people with Atrial Fibrillation.; Genotype CT is associated with increased dose of warfarin in people with Thromboembolism as compared to genotype TT.,19794411; 20203262; 19300499; 19300499; 19228618; 18535201; 20833980; 21228733; 21148049; 21110192; 21747589; 22676192; 15883587; 15888487; 18305455; 15888487; 15930419; 15930419; 16580898; 22040439; 22528326,21,warfarin,,
655384733,rs7294,VKORC1 (PA133787052),1B,Dosage,655384737; 655384736; 655384735,CC:Patients with the CC genotype who are treated with warfarin may require a lower dose as compared to patients with the TC or TT genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.; CT:Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.; TT:Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.,769277912; 655388073; 769277903; 827567329; 827649690,Genotype CT is associated with increased dose of warfarin as compared to genotype CC.; Allele T is associated with increased dose of warfarin.; Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.; Allele C is associated with decreased dose of warfarin as compared to allele T.; Allele T is associated with increased dose of warfarin as compared to allele C.,17049586; 16676068; 15358623; 15883587; 16611750,5,warfarin,,
981238437,rs1057910,CYP2C9 (PA126),2A,Toxicity/ADR,981238438; 981238439; 981238440,"AA:Patients with the AA genotype who are treated with non-steroid antiinflammatory agents, celecoxib or diclofenac may have a decreased, but not absent, risk of gastrointestinal bleeding as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.; AC:Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.; CC:Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.",827826832; 827826844,"Allele C is associated with increased risk of acute  gastrointestinal bleeding when treated with Antiinflammatory agents, non-steroids, celecoxib or diclofenac as compared to allele A.; Allele C is associated with increased risk of gastrointestinal bleeding when treated with Antiinflammatory agents, non-steroids, celecoxib, diclofenac, ibuprofen, naproxen or piroxicam as compared to allele A.",14707031; 17681167,2,"Antiinflammatory agents, non-steroids;celecoxib;diclofenac",,
769181841,rs1057910,CYP2C9 (PA126),2A,Dosage;Toxicity/ADR,769181842; 769181843; 769181844,AA:Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.; AC:Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.; CC:Patients with the CC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.,769169804; 655388486; 827814749; 827814788,Genotype AC is associated with response to acenocoumarol in people with no disease as compared to genotype AA.; Genotype CC is associated with increased risk of overanticoagulation when treated with acenocoumarol.; Allele C is associated with decreased dose of acenocoumarol as compared to allele A.; Allele C is not associated with bleeding events when treated with acenocoumarol or warfarin.,15116053; 11692083; 21148049; 21148049,4,acenocoumarol,,
655384611,rs17244841,HMGCR (PA189),2A,Efficacy,655384615; 655384614; 655384613,AA:Patients with the AA genotype who are treated with statins may be more likely to respond as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.; AT:Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.; TT:Patients with the TT genotype are too infrequent to have been assessed for this response.,699638701; 699638684; 699638675; 827925947,Allele A is not associated with response to fluvastatin in people with renal transplantation as compared to allele T.; Genotype AA is associated with increased reduction of LDL cholesterol when treated with simvastatin.; Genotype AT is associated with decreased reduction in LDL when treated with pravastatin as compared to genotype AA.; Genotype AT is associated with decreased reduction in total cholesterol when treated with pravastatin as compared to genotype AA.,17563401; 18332269; 15199031; 15199031,4,fluvastatin;hmg coa reductase inhibitors;pravastatin;simvastatin,,
655384626,rs4149015,SLCO1B1 (PA134865839),2A,Efficacy,655384628; 655384629; 655384630,AA:Patients carrying the AA genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. This variant is part of the SLCO1B1*17 haplotype. Other genetic and clinical factors may also influence a patient's response.; AG:Patients carrying the AG genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. Other genetic and clinical factors may also influence a patient's response.; GG:Patients carrying the GG genotype may have increased chance of response to pravastatin compared to patients carrying the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response.,769146231; 769146445,Genotype AG is associated with decreased response to pravastatin as compared to genotype GG.; Genotype AG is associated with increased AUC0-12 when exposed to pravastatin as compared to genotype GG.,15864131; 15226675,2,pravastatin,,White
655384790,rs12248560,CYP2C19 (PA124),2A,Dosage,655384793; 655384792; 655384791,"CC:Adult patients with the CC genotype who are treated with omeprazole may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration. May not be applicable to pediatric patients.; CT:Patients with this genotype were not studied.; TT:Adult patients with the TT genotype who are treated with omeprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration. May not be applicable to pediatric patients.",655387717; 655387758; 655387718; 655387742,Allele T is associated with CYP2C19*17.; Allele T is not associated with increased metabolism of omeprazole as compared to allele C.; Genotype TT is associated with increased metabolism of omeprazole in people with no disease as compared to genotype CC.; Genotype TT is associated with decreased AUC of omeprazole in people with no disease as compared to genotype CC.,16413245; 20223877; 16413245; 18294333,4,omeprazole,,White
655384786,rs11188072,CYP2C19 (PA124),2A,Dosage,655384789; 655384788; 655384787,"CC:Adult patients, but not pediatric patients, with the CC genotype who are treated with omeprazole may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration. This might not be applicable to pediatric patients.; CT:Patients with this genotype were not studied.; TT:Adult patients, but not pediatric patients, with the TT genotype who are treated with omeprazole may require an increased dose as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration. This might not be applicable to pediatric patients.",605077264; 655387709; 655387711; 655387738,Allele T is not associated with increased metabolism of omeprazole as compared to allele C.; Allele T is associated with CYP2C19*17.; Genotype TT is associated with increased metabolism of omeprazole in people with no disease as compared to genotype CC.; Genotype TT is associated with decreased AUC of omeprazole in people with no disease as compared to genotype CC.,20223877; 16413245; 16413245; 18294333,4,omeprazole,,White
827862258,rs1057910,CYP2C9 (PA126),2A,Dosage,827862261; 827862260; 827862259,AA:Patients with the AA genotype may require higher dose of celecoxib as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.; AC:Patients with the AC genotype may have reduced metabolism of celecoxib and may require dose reduction when starting celecoxib therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.; CC:Patients with the CC genotype may have greatly reduced metabolism of celecoxib and may require dose reduction (50% of standard starting dose) when starting celecoxib therapy or alternative management in juvenile rheumatoid arthritis patients who carry this genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.,827826380; 827826398; 827826422; 827826446,Allele C is associated with decreased metabolism of celecoxib.; Allele C is associated with increased AUC of celecoxib when treated with celecoxib as compared to allele A.; Genotype CC is associated with decreased oral clearance of celecoxib (3-fold) and a 1.5-fold prolonged elimination half-life when exposed to celecoxib in healthy individuals as compared to genotype AA.; Genotype CC is associated with increased AUC of celecoxib (10 fold higher) when treated with celecoxib in children as compared to genotype AA.,11337938; 11337938; 12893985; 16153401,4,celecoxib,,White
981204929,rs1801133,MTHFR (PA245),2A,Toxicity/ADR,981204930; 981204931; 981204932,AA:Patients with the AA genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to cyclophosphamide.; AG:Patients with the AG genotype may have decreased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to cyclophosphamide.; GG:Patients with the GG genotype may have decreased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to cyclophosphamide.,769245648; 769146398; 769174403,"Allele A is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele G.; Genotype AA is associated with increased risk of oral mucositis when treated with busulfan, cyclophosphamide and methotrexate in people with hematopoietic cell transplants for chronic myelogenous leukemia as compared to genotype GG.; Genotype AA is associated with increased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to genotypes GG + AG.",20638924; 15051775; 19159907,3,cyclophosphamide,,
981345293,rs4149056,SLCO1B1 (PA134865839),2A,Other,981345294; 981345295; 981345296,"CC:Patients with the CC genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype, although this does not appear to influence risk for statin-related myopathy. Other genetic and clinical factors may also influence a patient's metabolism and response to pravastatin.; CT:Patients with the CT genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype, although this does not appear to influence risk for statin-related myopathy. Other genetic and clinical factors may also influence a patient's metabolism and response to pravastatin.; TT:Patients with the TT genotype may have decreased plasma concentrations of pravastatin as compared to patients with the CC or CT genotype, although this does not appear to influence risk for statin-related myopathy. Other genetic and clinical factors may also influence a patient's metabolism and response to pravastatin.",827827131; 827827144; 827827157; 827827440; 769169405; 769170865; 827811014; 827826991,"Allele C is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin as compared to allele T.; Allele C is not associated with the lipid-lowering efficacy of pravastatin when exposed to pravastatin in healthy individuals.; Genotype CC is associated with increased mean peak concentration in plasma and area under the plasma concentration when exposed to pravastatin in men as compared to genotypes CT + TT.; Genotype CT is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to genotype TT.; Allele C is associated with increased risk of composite adverse events when treated with atorvastatin, hmg coa reductase inhibitors and simvastatin in people with Hypercholesterolemia as compared to allele T.; Allele C is associated with decreased metabolism of pravastatin in people with no disease as compared to allele T.; Genotypes CT + TT are not associated with the response of total cholesterol, LDL, HDL, triglycerides or CRP to pravastatin when treated with pravastatin in men with as compared to genotype CC.; Allele C is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to allele T.",16678544; 16678544; 17015053; 17622941; 19833260; 12811365; 21851379; 15116054,8,pravastatin,,White
981204372,rs1045642,ABCB1 (PA267),2A,Other,981204373; 981204374; 981204375,AA:Patients with AA genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of digoxin.; AG:Patients with AG genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of digoxin.; GG:Patients with GG genotype may have increased metabolism and decreased serum concentration of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact the metabolism of digoxin.,769170859; 827807733; 827925284,Genotype AA is associated with decreased metabolism of digoxin as compared to genotype GG.; Allele A is associated with increased serum concentrations of digoxin as compared to allele G.; Genotype GG is associated with increased metabolism of digoxin as compared to genotype AA.,10716719; 18334914; 12189368,3,digoxin,,
981204641,rs1799971,OPRM1 (PA31945),2B,Toxicity/ADR,981204642; 981204643; 981204644,"AA:Patients with the AA genotype may have a decreased , but not absent, severity of intoxication and a decreased response when exposed to ethanol as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's ethanol response.; AG:Patients with the AG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's ethanol response.; GG:Patients with the GG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's ethanol response.",769171518; 827806034,"Allele G is associated with increased subjective feelings of intoxication, stimulation, sedation, and happiness when exposed to ethanol as compared to allele A.; Genotypes AG + GG are associated with increased severity of intoxication when exposed to ethanol and naltrexone in healthy individuals as compared to genotype AA.",15608594; 21900886,2,ethanol,,
655387798,rs1902023,UGT2B15 (PA37188),2B,Other,655387799; 655387800; 655387801,AA:Subjects with the AA genotype who are treated with oxazepam may have a decreased oxazepam oral clearance as compared to subjects with the CC genotype which the study reports resulted in no differences in pharmacodynamic measures. Other genetic and clinical factors may also influence the oral clearance of oxazepam.; AC:Subjects with the AC genotype who are treated with oxazepam may have a decreased oxazepam oral clearance as compared to subjects with the CC genotype which the study reports resulted in no differences in pharmacodynamic measures. Other genetic and clinical factors may also influence the oral clearance of oxazepam.; CC:Subjects with the CC genotype who are treated with oxazepam may have an increased oxazepam oral clearance as compared to subjects with the AA and AC genotype which the study reports resulted in no differences in pharmacodynamic measures. Other genetic and clinical factors may also influence the oral clearance of oxazepam.,655387783; 655387790,Genotype AA is associated with decreased S-oxazepam glucuronidation in human liver microsomes when exposed to oxazepam as compared to genotype CC.; Genotype AA is associated with decreased oxazepam oral clearance when exposed to oxazepam as compared to genotype CC.,15044558; 19916996,2,oxazepam,,
637879879,rs339097,CALU (PA26047),2B,Dosage,637879880; 637879881; 637879882,AA:Patients with the AA genotype who are treated with warfarin may require a lower maintenance dose as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.; AG:Patients with the AG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.; GG:Patients with the GG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.,608431797; 637879873; 637879876; 827864550,Allele G is associated with increased dose of warfarin.; Allele G is associated with increased dose of warfarin.; Allele G is associated with increased dose of warfarin.; Genotypes GG + AG are associated with increased dose of warfarin as compared to genotype AA.,20200517; 20200517; 20200517; 21228733,4,warfarin,,Black or African American
655384684,rs2231142,ABCG2 (PA390),2B,Efficacy,655384688; 655384687; 655384686,GG:Patients with the GG genotype who are treated with rosuvastatin may be less likely to reach target LDL levels as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.; GT:Patients with the GT genotype who are treated with rosuvastatin may be more likely to reach target LDL levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.; TT:Patients with the TT genotype may have increased response to rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.,655388369; 655388082; 655388379; 655388373,"Genotype GG is associated with decreased AUC of rosuvastatin in people with no disease as compared to genotypes TT + GT.; Allele T is associated with increased reduction in low-density lipoprotein cholesterol (LDL-C) level, in a gene-dose-dependent manner, when treated with rosuvastatin in people with Hypercholesterolemia as compared to allele G.; Allele T is associated with increased likelihood of achievement of target LDL when treated with rosuvastatin in people with Myocardial Infarction as compared to allele G.; Genotype TT is associated with increased AUC of rosuvastatin in people with no disease as compared to genotypes GG + GT.",16784736; 20130569; 20207952; 19474787,4,rosuvastatin,,
655385241,rs1799971,OPRM1 (PA31945),2B,Efficacy,655385244; 655385243; 655385242,AA:Patients with the AA genotype who are treated with naloxone may have lower cortisol response as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence the response to naloxone.; AG:Patients with the AG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype.; GG:Patients with the GG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to naloxone.,747714537; 747435525; 747661534,Allele G is associated with increased cortisol response when treated with naloxone as compared to genotype AA.; Genotypes GG + AG are associated with increased cortisol response when treated with naloxone as compared to genotype AA.; Genotypes GG + AG are associated with increased peak cortisol response when treated with naloxone as compared to genotype AA.,11751037; 18004207; 12627468,3,naloxone,,
981201549,rs2298383,ADORA2A (PA24584),2B,Toxicity/ADR,981201550; 981201551; 981201552,CC:Patients with the CC genotype may have increased anxiety when exposed to caffeine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patients response to caffeine.; CT:Patients with the CT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.; TT:Patients with the TT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.,769278134; 827700157,Genotype CC is associated with increased anxiety when exposed to caffeine in people with no disease as compared to genotype TT.; Genotype CC is associated with increased anxiety when exposed to caffeine as compared to genotypes CT + TT.,18305461; 20520601,2,caffeine,,
